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Abstract 
 
Integrin-linked Kinase (ILK) is an integrin-associated protein kinase, which regulates 
growth factor-signalling pathways and cell-ECM adhesion events. Abrogated ILK 
expression or activity has been implicated in contributing to oncogenic transformation. 
We examined the role played by ILK in growth factor-stimulated and integrin signalling 
events in five human oesophageal squamous cell carcinoma cell lines (HOSCCs), 
known to overexpress the EGF receptor. Western blot analysis revealed the presence of 
ILK (59kDa) in all the moderately differentiated HOSCC lines. ILK1 was confirmed as 
being the predominant isoform. Densitometrically analysed Western blots showed that, 
per unit of protein, ILK is expressed uniformly across the cell lines under standard 
culture conditions. Following EGF (10 ng/ml) and TGFβ1 (1 ng/ml) treatment, ILK 
expression increased in all five HOSCCs. Indirect immunofluorescence microscopy 
showed the majority of ILK to localise at a cytoplasmic/nuclear level, with a proportion 
of ILK localising at the membrane, which resembled the distribution pattern of the β3 
integrin subunit. This membranal distribution most likely follows that of the adhesion 
plaques although lesser, and variable, amounts were also identified throughout the 
cytoplasm. The functionality of the ILK1 kinase domain was demonstrated using 
myelin basic protein (MBP)-based kinase assays. EGF and TGFβ1 treatment produced 
an increase in ILK activity in the WHCO3 cell line of 3.5 fold, but a decrease in activity 
in the other cell lines, which are suggested to involve the actions of PTEN. The 
identification of nuclear ILK was surprising, and the mechanism for nuclear ILK 
localisation was suggested to involve a caveolae-associated protein, caveolin-1. Cell 
adhesion assays revealed that KP-392-mediated inhibition of ILK resulted in a 
nonsignificant reduction in cell adhesion to collagen and fibronectin. These data provide 
distinctive evidence for the influence of growth factors on ILK expression, but a duality 
in the effect on ILK activity. This apparent dichotomy is noteworthy and may be of 
particular relevance in HOSCC. It is further suggested that KP-392-induced ILK 
inhibition destabilises the αβ integrin heterodimer and that PI3K acts upstream of ILK-
mediated cell adhesion events in HOSCCs. This suggests that ILK mediates integrin 
associated processes in human oesophageal SCC cell lines. 
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Chapter 1 
The Importance of ILK in Cell Signalling 
 
1.1 Cell Adhesion in Tissue Maintenance 
In virtually every multicellular organism, cell adhesion exists as a fundamental 
mechanism that provides a framework which allows for the communication between 
cells and their surrounding tissues. The information that cells receive from adhesion 
contacts must be integrated to regulate diverse processes such as protein synthesis and 
cell growth, motility, cell architecture and polarity, differentiation, and programmed cell 
death. The signalling pathways that regulate these processes are not isolated from one 
another but are interconnected to form complex signalling networks (Martin, 2003). 
From a cell biology perspective, disturbances in these regulatory mechanisms of cell 
adhesion are crucial to the progression of cancer. While covering the entire scope of the 
intricacies of cancer is a near impossibility, this literature review attempts to clarify 
these regulatory mechanisms, which play a pivotal role with regards to cancer 
progression. 
 
Before an understanding of the process of cell adhesion can be developed, one must 
appreciate that although cancer invasion and metastasis are intricate processes, the 
initial steps of metastasis involve the detachment of neoplastic cells from the primary 
tumour and eventual establishment at distant tissue sites (Kurschat and Mauch, 2000). 
This metastatic cascade stems from the dysregulation of cell-cell and cell-extracellular 
matrix interactions (Nair et al., 2005). 
 
Multiprotein complexes which consist of cell adhesion molecules (CAMs), extracellular 
matrix (ECM) proteins and cytoplasmic plaque proteins serve primarily to mediate 
adhesion of cells either to the extracellular matrix (ECM), or to other cells. This 
determines the overall structure of tissues (Hynes, 1999; Grashoff et al., 2004; Wu, 
2004; Nair et al., 2005). CAMs function in a dynamic and highly regulated fashion and 
are necessary in orchestrating the three-dimensional structure of tissues (Edelman and 
Crossin, 1991; Gumbiner, 1996). As is discussed above there are three general classes 
of proteins which make up the multiprotein complexes that form the functional units of 
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cell adhesion, these are i) the cell adhesion molecules/adhesion receptors, ii) the 
extracellular matrix (ECM) proteins, and iii) the cytoplasmic plaque/peripheral 
membrane proteins (Jawhari et al., 1997; Grashoff et al., 2004; Nair et al., 2005). 
 
Cell adhesion falls into two principle categories i) cell-cell adhesion where physical 
bonds are formed between adjacent cells, and ii) cell-matrix adhesion where these same 
physical bonds bind cells to adhesive proteins in extracellular matrices (Ruoslahti and 
Öbrink, 1996; Watt, 2002; Reddig and Juliano, 2005; Su et al., 2005; Vespa et al., 
2005). The cell adhesion receptors are transmembrane glycoproteins that mediate 
binding interactions at the extracellular (EC) surface and determine the specificity of 
cell-cell and cell-ECM recognition. They include members of the integrin, cadherin, 
immunoglobulin, selectin, and proteoglycan superfamilies (Albelda and Buck, 1990; 
Gumbiner, 1996; Malik and Parsons, 1996; Hynes, 1999; Stewart et al., 2004; Nair et 
al., 2005). The five primary adhesion molecules will now be discussed in greater detail, 
but emphasis will be placed on the cadherin and integrin families since these receptors 
are the major regulators of epithelial cell adhesion. Epithelial cells have a particular 
morphology, which is maintained by a characteristic organisation of the cytoskeleton as 
well as the adhesion molecules (Braga, 2000; Perez-Moreno et al., 2003). 
 
The nervous system and immune system consists of many molecules with one or more 
Ig domains (Hynes, 1999; Nair et al., 2005). It is in these areas that the immunoglobulin 
superfamily (Ig-SF) adhesion receptors dominate. The Ig-SF receptors are characterised 
by the presence of varying numbers of Ig-related domains (Hynes, 1999; Peggs and 
Allison, 2005). These domains consist of two β sheets held together by homophilic self-
association, as is the case with the cadherins (Ruoslahti and Öbrink, 1999; and 
discussed below). However, although Ig-SF members are involved in homophilic 
associations certain Ig-SF members interact utilising heterophilic associations, such is 
the case with integrins (e.g. NCAM) or with ECM proteins (e.g. DCC-netrins) (Hynes, 
1999). The immunoglobulin superfamily has also been correlated with tumour 
progression in certain instances. For example, melanomas are known to express a 
diverse range of cell adhesion molecules. These include neural cell adhesion molecules 
such as L1 (a ligand of α5β3, NCAM and CD57) (Johnson, 1999). 
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The selectins are the second well-studied group of cell adhesion receptors. They will be 
considered briefly, as they are not expressed in epithelia and are thus not pertinent to 
this study. Although the selectins are not extensively expressed they do have crucial 
roles in cells of the vertebrate circulation (endothelium and blood cells) (Hynes, 1999). 
They are carbohydrate-specific receptors, which utilise heterophilic interactions for 
functioning (Rosen, 2004). For example, P selectin binds to its counter-receptor, a 
heavily glycosylated protein (PSGL-1). The C-type lectin domain, which mediates the 
association, recognises specific carbohydrate groupings in the counter-receptor/ligand 
(Hynes, 1999; Middleton et al., 2002). The selectins are not isolated molecules and are 
known to be crucial in the adhesion of leukocytes to endothelium, by cooperating with 
integrins and Ig-SF receptors (Lasky, 1995; Hynes, 1999; Witz, 2006). 
 
So far we have examined two sets of adhesion molecules, both of which play pivotal 
roles in the maintenance of tissue architecture. However, when considering cell-cell and 
cell-ECM interactions, the remaining two adhesion receptors are crucial (Hynes, 1999). 
The structure and functioning of the cadherin and integrin class of adhesion receptors 
has been comprehensively studied and they are known to be vital in the regulation of 
many cellular processes (O’Toole et al., 1994; Gumbiner, 1996; Wijnhoven et al., 2000; 
Perez-Moreno et al., 2003; Su et al., 2005). Not only are they important with regards to 
normal cellular functioning, but they also play a pivotal role during the metastatic 
process in many cancers (Felding-Habermann et al., 2001). This occurs when the 
intricate processes of cell adhesion go awry in cells where mutations, changes in 
expression or localisation, and functional alterations of these molecules have been 
observed (Somasiri et al., 2000; Wijnhoven et al., 2000).  
 
The cadherin family that mediates Ca2+- dependent cell-cell adhesion, are 
transmembrane glycoproteins, that play crucial roles in both developmental and disease 
processes (Hinck et al., 1994; Ramburan and Govender, 2002; Christofori, 2003; Foty 
and Steinberg, 2004; Nair et al., 2005). Cadherins are genetically distinct from the 
integrin and immunoglobulin superfamily, and in the presence of Ca2+, bind cells tightly 
by homophilic interactions (Shiozaki et al., 1996; Goodwin and Yap, 2004). There are 
three common cadherins, which are named according to their tissue distribution; these 
include E- (epithelial), N- (neuronal) and P- (placental) cadherins (Gumbiner, 1996; 
Wijnhoven et al., 2000; Christofori, 2003; Goodwin and Yap, 2004; Chan, 2006). Of 
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these, E-cadherin is probably the best studied and most relevant to this particular study. 
E-cadherin forms the key functional component of adherens junctions between 
epithelial cells (Jamora and Fuchs, 2002). During the induction and maintenance of 
polarised and differentiated epithelium during embryonic development, the normal 
expression of E-cadherin is especially important (Wijnhoven et al., 2000; Perez-Moreno 
et al., 2003). For example, absence of E-cadherin in epithelia results in cells being 
incapable of maintaining a tight association (Gumbiner, 1996). Furthermore, the many 
other cell adhesion and cell junction proteins that occur in epithelial cells are by 
themselves unable to support intercellular adhesion (Gumbiner, 1996).  
 
In the maintenance of cell-cell adhesions, cadherins associate with cytoplasmic proteins 
such as α-catenin and β-catenin (Goodwin and Yap, 2004). The cytoplasmic domain of 
E-cadherin complexes with β-catenin or plakoglobin (also called γ-catenin). 
Plakoglobin and β-catenin also interact with α-catenin, which is thought to directly or 
indirectly link the complex composed of cadherin, β-catenin and α-catenin to the actin 
cytoskeleton (Caca et al., 1999; Kaibuchi et al., 1999; Braga, 2000; Jamora and Fuchs, 
2002). Indeed, deficiency of α-catenin in mice results in deficits of epidermal 
intercellular tightness and numerical reduction of adherens junctions (Vasioukhin et al., 
2001). Although cell-cell adhesions are generally static processes, dynamic 
rearragements of cell-cell interactions can occur during various cellular processes. For 
example, epithelial cell scattering, dispersal of cancer cells and early embryonic cell 
migration all require perturbation of cell-cell contacts (Kaibuchi et al., 1999). 
 
β-Catenin is known to have a dual function in cells influencing both cell adhesion as 
well as intracellular signalling via the canonical Wnt/Lef pathway (Korswagen et al., 
2000; Young et al., 2003; Bienz, 2004; Brembeck et al., 2006). Thus the association of 
E-cadherin with β-catenin may allow for E-cadherin-mediated signal transduction 
events. For instance, cadherin-mediated cell-cell adhesion can affect the Wnt signalling 
pathway (Polakis, 2000). β-catenin (as well as γ-catenin) is usually sequestered by 
cadherins in the cadherin-catenin complex. Overexpression of the tyrosine kinases Src 
and Fer and activation of the transmembrane tyrosine kinases epidermal growth factor 
receptor (EGFR) and c-Met all downregulate E-cadherin-mediated adhesion, and are 
responsible for the tyrosine phosphorylation of β-catenin (Lilien et al., 2002; Lilien and 
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Balsamo, 2005). Upon loss of E-cadherin function, non-sequestered, free β-catenin is 
usually phosphorylated by glycogen synthase kinase 3β (GSK3β) and subsequently 
degraded by the ubiquitin-proteasome pathway (Chan, 2006). Cadherins themselves 
lack enzymatic activity, and other than functioning as structural cell adhesion 
components, the cadherins obviously have further roles to play in cellular signalling and 
tumour growth (Nair et al., 2005; Chan, 2006). 
 
Cadherins are important with respect to tumour biology, as aberrant levels of cadherins 
correlates with growth, invasion and metastasis (Hinck et al., 1994; Nieman et al., 
1999; Wijnhoven et al., 2000; Peinado et al., 2004; Chan, 2006). For example, human 
invasive carcinomas and carcinomas in situ have been reported to show aberrant levels 
of E-cadherin expression in comparison to their related normal tissue (Jawhari et al., 
1997; Valizadeh et al., 1997; Bailey et al., 1998; Wijnhoven et al., 2000). Further 
studies have demonstrated that patients with prostate cancer have reduced expression 
levels of E-cadherin (Davies et al., 2000), while other research on prostate cancer cells, 
which had a fibroblast-like morphology, were shown to be invasive having lost E-
cadherin expression (Wijnhoven et al., 2000). Similarly, >85 % of all breast carcinomas 
display reduced E-cadherin expression (Berx et al., 2001; Cowin et al., 2005). 
Decreased E-cadherin expression has also been observed in gastric carcinoma in a 
number of different studies (Chan, 2006). In fact most carcinomas demonstrate reduced 
E-cadherin expression, which is directly associated with induction of an epithelial to 
mesenchymal transition (EMT). EMT is frequently observed during carcinoma invasion 
(Thiery, 2002; Peinado et al., 2004). 
 
The adhesion receptors that have been discussed thus far have been examined 
individually for the sake of clarity. However, it must be remembered that a large degree 
of ‘crosstalk’ occurs between adhesion molecules. These associations are not yet fully 
understood, but the next section of this discussion will attempt to clarify somewhat 
briefly what is probably the most fundamental interaction in epithelial cells. It is the 
crosstalk that exists between the cadherins and the integrin class of receptors, which 
requires further scrutiny. 
 
Considerable crosstalk is thought to exist between the integrin and cadherin class of 
adhesion receptors (von Schlippe et al., 2000; Kawano et al., 2001), suggesting that the 
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processes of cell-cell and cell-ECM adhesion are more closely intertwined than 
originally thought. Evidence of this crosstalk between these adhesion receptors includes 
experiments involving integrin-blocking antibodies, which were shown to induce the 
formation of multicellular spheroids in breast carcinoma cell lines expressing E-
cadherin (von Schlippe et al., 2000). Similarly, a breast cancer cell line has been shown 
to upregulate the migratory activity mediated by αv integrins following the introduction 
of a dominant negative E-cadherin construct.  
 
The integrins are capable of mediating both cell-cell and cell-ECM interactions (Qian et 
al., 1994; Zutter et al., 1998; Dedhar et al., 1999; Lim et al., 2001; Cabodi et al., 2004; 
Brockbank et al., 2005) where this broad activity makes them an extremely versatile 
receptor. The integrins however are more widely known for their ability to regulate cell-
matrix interactions (Plantefaber and Hynes, 1989; O’Toole et al., 1994; Zhang et al., 
1996; Humphries et al., 2004). The integrins will be discussed in this regard since 
several malignant carcinomas show dysregulated integrin expression (Qian et al., 1994; 
Danen et al., 1998; Zutter et al., 1998; Miller and Veale, 2001; Evans et al., 2003; 
Brockbank et al., 2005). It is for this reason that the integrin receptors form a critical 
aspect of this study. The integrin class of receptors therefore warrants a more detailed 
examination. 
 
1.2 Role of Integrins in ECM Attachment and Signal Transduction 
 
1.2.1 Cell Attachment 
Although this study places more emphasis on the functional aspects of the integrin 
receptors, it is necessary to examine their structure briefly to fully understand how they 
are able to regulate the adhesion process as well as signalling cascades. Integrins consist 
of αβ heterodimers and each αβ combination has its own binding specificity and 
signalling properties (Giancotti and Ruoslahti, 1999; Liu et al., 2000; Zamir and Geiger, 
2001; Watt, 2002; Mould and Humphries, 2004; Stewart et al., 2004). The integrin 
heterodimer bears a receptor site towards the amino terminal of the extracellular domain 
(Gui et al., 1997; Travis et al., 2003). The carboxyl end is maintained within the cell 
and provides a link to the cytoskeleton via cytosolic proteins such as talin, vinculin and 
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actin (Otey et al., 1993; Martel et al., 2000; Brakebusch and Fässler, 2003; Reddig and 
Juliano, 2005; Boulter et al., 2006). Connection of integrins to the actin cytoskeleton 
allows for the correct localisation of these receptors as well as influencing their role in 
cell spreading, migration and matrix assembly (Schwartz, 2001; Aplin et al., 2002; 
Brakebusch and Fässler, 2003; DeMali et al., 2003; Wu, 2004). 
 
Integrins mediate adhesive interactions to the ECM that in turn play fundamental roles 
in regulating cell survival, migration, proliferation, differentiation and tumour 
progression. The secretion and organisation of the ECM by cells provides structural 
support for these processes (Pankov et al., 2000; Whittard and Akiyama, 2001; Travis et 
al., 2003; Ffrench-Constant and Colognato, 2004). Cells adhere to the ECM either 
directly to the interstitial matrix, or through adhesion to the basement membrane, which 
covers the surfaces of virtually all epithelial cells; surround the surfaces of muscle fibres 
and ensheath nerves (Gumbiner, 1996). A constituent of the basement membrane, the 
basal lamina, is found adjacent to cells and is composed of glycoproteins (e.g. 
fibronectin and laminin), proteoglycans, and collagens (Mosher et al., 1992) that are 
secreted and assembled into an organised, and unique three dimensional networks 
(Taverna et al., 1998; Badylak, 2002). 
 
Collagen is the most abundant protein within the ECM with well over 20 distinct types 
having been identified (Badylak, 2002). Type I collagen is the primary structural 
collagen in mammalian tissues, and is a well-characterised, ubiquitous ECM protein 
(Vanderrest and Garrone, 1991). Collagen type IV, although expressed in much lower 
quantities, is an important ligand for endothelial cells, and is expressed in the basement 
membranes of all epithelial structures (Badylak, 2002). Type VI collagen serves as a 
‘connector’ of functional proteins and glycosaminoglycans to larger structural proteins 
such as collagen I, giving the ECM a gel-like consistency (Badylak, 2002). This 
apparent diversity of collagens is responsible for the distinctive biological activity of 
ECM scaffolds (Badylak, 2002). 
 
Two other important components of the ECM are the fibronectin and laminin proteins, 
which are expressed in large quantities, although these quantities are lower than 
collagen (Badylak, 2002). Fibronectin exhibits many desirable properties, including 
ligands for adhesion of many cell types (Schwarzbauer, 1991). Fibronectin is found in 
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the ECM of both submucosal and basement membrane structures (McPherson and 
Badylak, 1998; Badylak, 2002). Laminin is a complex adhesion protein found in the 
ECM, which has a prominent role in the formation and maintenance of epithelial 
structures (Ponce et al., 1999). 
 
As key receptors for cellular attachment to the ECM, the integrin group is capable of 
binding more than one cellular ligand and, more often than not, individual ligands are 
recognised by more than one integrin receptor (Hynes, 1992; Jones and Walker, 1999; 
Thorne et al., 2000). For example the αvβ3 integrin, a vitronectin receptor, shows strong 
affinity for fibronectin, collagen, tenascin C, thrombospondin and fibrinogen (Boudreau 
and Jones, 1999; Watt, 2002). Particular ECM components that are capable of binding 
to more than one integrin include fibronectin which, in addition to the α5β1 receptor, 
also binds at least seven other integrin heterodimers. Similarly, laminin binds α3β1, α6β1 
and α6β4 integrins with high affinity. This apparent redundancy suggests that, in 
addition to mediating attachment to a particular ECM ligand, different integrins perform 
specific signalling functions (Juliano and Haskill, 1993; Boudreau and Jones, 1999). 
 
The association of cells with the ECM initiates the assembly of specific cell-matrix 
adhesion sites and, by attaching to various ECM proteins, allows cells to proliferate and 
grow (Ruoslahti, 1996; Kumar, 1998; Brakebusch and Fässler, 2003). The ECM 
provides structural support for cell adhesion, migration, and tissue organisation, as well 
as external regulation of cellular functions (Pankov et al., 2000). For example, 
promotion or suppression of growth by the ECM is associated with either stimulation or 
inhibition of cell cycle mediators including cyclins and early response genes (Boudreau 
and Jones, 1999). A vital purpose of the integrins is to maintain a tight regulation of the 
interactions occurring between cells and the ECM components (Hynes, 1992; Hynes 
and Lander; 1992; Giancotti and Ruoslahti, 1999; Ffrench-Constant and Colognato, 
2004). Although the physical attachment provided by integrins is an essential and 
necessary function, it does not even begin to describe the versatility and uniqueness of 
this class of receptors. 
 
Among the superfamilies of cell adhesion molecules, the integrins are quite likely the 
most extensively studied group of adhesion receptors and arguably the most important 
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(Qian et al., 1994; Zutter et al., 1998; Dedhar et al., 1999; Lim et al., 2001). The 
integrin adhesion receptors are known to play pivotal roles in many biological processes 
and malignant transformation (Zutter et al., 1998; Brassard et al., 1999; Keely et al., 
1999; Schwartz, 2001; DeMali et al., 2003; Mould and Humphries, 2004). Individual 
members of these families may serve as adhesion ligands for members of the same or 
other families. They may trigger events, which regulate the expression and function of 
other receptors and proteolytic enzymes, or they may act coordinately to mediate the 
same processes such as differentiation and/or cell proliferation (Brodt, 1996a). 
 
By creating an ‘integrated’ link between the outside and inside of the cell (Boudreau 
and Jones, 1999), the integrins are perfectly located for executing the vast number of 
signalling processes required by the cell (Hynes, 1992; Akiyama et al., 1994; Giancotti 
and Ruoslahti, 1999; Liu et al., 2000; Yu et al., 2000; Cabodi et al., 2004; Boulter et al., 
2006). What now follows is a comprehensive look into the ways in which integrins 
respond to the ECM. 
 
1.2.2 Signal Transduction by Integrin Receptors 
The signal transduction events mediated by integrins have continued to be defined over 
the past five years. Integrins serve as integrators of the ECM and cytoskeleton and these 
connections have far-reaching effects in the cell. Integrins control many aspects of 
cellular function (Boudreau and Jones, 1999; Giancotti and Ruoslahti, 1999; Coppolino 
and Dedhar, 2000; DeMali et al., 2003; Reddig and Juliano, 2005), and therefore the 
signal transduction cascades mediated by integrins require detailed scrutiny. 
 
Specialised cells are surrounded by a multitude of ECM proteins and express an array of 
tissue-specific integrin receptors (Juliano and Haskill, 1993; Boudreau and Jones, 1999; 
Ffrench-Constant and Colognato, 2004). This receptor diversity effectively generates 
unique intracellular signals that give rise to tissue-specific phenotypes (Boudreau and 
Jones, 1999). Most, if not all of the signalling molecules involved in ECM-integrin 
interactions appear to be rather ubiquitous mediators of signal transduction (Boudreau 
and Jones, 1999). For example, Miyamoto et al. (1995) showed that at least 20 different 
proteins, including RhoGTPases, Raf, Ras, focal adhesion kinase (FAK), and 
microtubule associated protein serine/threonine kinases (MAPKs) such as extracellular-
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signal-regulated kinases (ERKs), can be recruited to the ECM ligand/integrin-binding 
site. 
 
Bi-directional signalling capabilities by the integrin receptors make it possible to 
mediate signal transduction events between ECM and intracellular compartments in 
either direction (Parsons, 1996; Coppolino and Dedhar, 2000; Liu et al., 2000; Danen 
and Yamada, 2001; Mould and Humphries, 2004). Thus, the extracellular binding 
activity of integrins is regulated from the inside of the cell (inside-out signalling), and 
regulates integrin ligand-binding affinity and cell adhesion (Liu et al., 2000; Deryugina 
et al., 2002; Vellon et al., 2006). A particularly good example of this kind of signalling 
involves the regulation of integrin activity in cells circulating in the blood. The αIIbβ3 
integrin in platelets and the β2 integrins of white blood cells are expressed at the cell 
surface, but in an arrangement that does not bind ligand (Ruoslahti and Öbrink, 1996). 
Cells are allowed to respond quickly to a change in environment by the activation of 
ligand binding. In a similar scenario, leukocytes attach to blood vessel walls through β2 
integrins that have been activated by inflammatory signals (Ruoslahti and Öbrink, 
1996). On the other hand, the binding of the ECM elicits signals that are transmitted 
into the cell (outside-in signalling). ECM binding results in cytoskeletal re-organisation, 
gene expression and cellular differentiation and various processes pivotal to 
carcinogenesis, such as altered tyrosine phosphorylation pathways of key signalling 
proteins, including FAK and ILK (Akiyama et al., 1990; Kornberg et al., 1991; 
Giancotti and Ruoslahti, 1999; Liu et al., 2000; Schwartz, 2001; Deryugina et al., 2002; 
Attwell et al., 2003; Ffrench-Constant and Colognato, 2004; Pinkse et al., 2005). 
 
It is also interesting to note that an integrin associated protein ILK, also displays 
‘inside-out signalling’ and its activation leads to decreased adhesion to the ECM 
(Boudreau and Jones, 1999; Brakebusch and Fässler, 2003). Another example of 
‘inside-out’ signalling includes talin, which in addition to linking integrins to the actin 
cytoskeleton, also regulates integrin activation (Brakebusch and Fässler, 2003). Talin is 
capable of binding to most β cytoplasmic domains and overexpression of talin is 
capable of activating integrins (Ginsberg et al., 2005). In addition, knocking down talin 
expression with small interfering RNAs blocks β1 and β3 activation (Tadokoro et al., 
2003).  
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As outlined above, there are numerous protein molecules that are able to bind to the 
ECM/integrin binding site. The ‘outside-in’ signalling pathways of Rac/cell division 
cyclin 42 (Cdc42)/Ras homolog member A (RhoA), FAK/Shc and MAPK (Figures 1a 
and 1b, pg 15) however are arguably the most fundamental integrin signalling 
pathways, as they influence various facets of cell behaviour and function, including cell 
proliferation and differentiation (Giancotti and Ruoslahti, 1999; Barberis et al., 2000). It 
is for these reasons that these molecules are considered important and hence will be the 
focus of the following sections. Although these pathways will be considered separately 
to aid understanding, it must be remembered that there is a great deal of interdigitation 
between these signal transduction pathways, making it possible for particular pathways 
to elicit a variety of responses. 
 
1.2.3 Integrin Signalling Influences Cell Migration and Cell Spreading 
The importance of integrin signalling is highlighted by its impact upon organisation of 
the cytoskeleton (Brakebusch and Fässler, 2003; DeMali et al., 2003). With regards to 
cytoskeletal organisation and cell migration, regulation of the Rho family GTPases is 
important (Graness et al., 2005). This can generally be characterised by two phases. 
Firstly, early adhesion is associated with pathways that stimulate protrusion, whereas 
mature adhesions are associated with the development of tension (DeMali et al., 2003). 
Early phase leads to Rac and Cdc42 activation and to actin polymerisation. The later 
phase leads to RhoA activation, increased contractility and the transmission of tension 
to the sites of integrin ligation (Ridley, 2001; DeMali et al., 2003; Humphries et al., 
2004). When cells attach and spread on an ECM, cells extend filopodia and 
lamellipodia, structures regulated by Cdc42 and Rac, respectively. Integrin-mediated 
adhesion activates Cdc42 and Rac (Price et al., 1998; Kramer et al., 2005), and Rac 
activation requires an intact β integrin subunit.  
 
Rho family GTPases are active when GTP-bound, and inactive when bound to GDP. 
Activation is catalysed by guanine nucleotide exchange factors (GEFs) and inactivation 
is promoted by GTPase-activating proteins (GAPs) that stimulate the intrinsic GTPase 
activity of the Rho proteins (DeMali et al., 2003; Kramer et al., 2005). An example of a 
GEF activated downstream from integrin engagement is Vav2, which is widely 
distributed (DeMali et al., 2003). Although evidence suggests that Vav2 is activated 
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downstream of growth factors and not from integrins (Lui and Burridge, 2000; Liu et 
al., 2000; Moores et al., 2000), a dominant-negative form of Vav2 blocks 
lamellipodium formation and spreading on fibronectin, which is consistent with Vav2 
having a role in Rac activation following integrin engagement (Marignani and 
Carpenter, 2001). 
 
Integrin engagement leads to transient depression of RhoA activity and it is has been 
proposed that reduced RhoA promotes lamellipodial extension during cell migration 
(Arthur et al., 2001; Kramer et al., 2005). The reduction in RhoA activity requires Src, 
FAK and p190RhoGAP. A role for paxillin phosphorylation in mediating RhoA 
reduction has also been suggested. This role includes the phosphorylation of paxillin, 
initiated by integrin adhesion, generates a binding site for p120RasGAP, thereby 
displacing it from its binding partner p190RhoGAP. When p190RhoGAP is freed from 
p120RasGTP, it becomes activated and hence contributes to the decrease in RhoA 
activity (Tsubouchi et al., 2002). However, it has been demonstrated that a decrease in 
RhoA exists even when cells are in suspension that bind soluble-peptide integrin ligands 
(Arthur et al., 2000), a situation in which paxillin does not become phosphorylated 
(DeMali et al., 2003). Nevertheless, paxillin may still contribute to the depression of 
RhoA activity when cells attach to fibronectin (DeMali et al., 2003). 
 
Integrins have been demonstrated to have differing impacts upon RhoA. In this regard, 
differing integrins result in different RhoA responses. It has been demonstrated that 
while α6β4 results in stimulation of RhoA activity, β1 clustering induces depression of 
RhoA (O’Connor et al., 2000). Furthermore, engagement of αvβ3 integrin on astrocytes 
by Thy-1 was shown to stimulate assembly of focal adhesions and stress fibres, which is 
consistent with RhoA activation (Leyton et al., 2001). Thus it is apparent that integrins 
are directly involved in Rac/Cdc42- and RhoA-dependent responses, which have 
essential consequences with regards to cell spreading and migration. 
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1.3 Adhesion-Based Signalling 
The coordinated cellular response to ECM attachment through integrins induces a 
multitude of changes in cell behaviour including alterations in cell proliferation, 
migration and adhesion (Bill et al., 2004). The “outside-in” and “inside-out” signal 
transduction pathways that are elicited by integrin receptors are intricately related. 
Moreover, the interconnection between signal pathways implies that a large degree of 
cross-modulation occurs during cell signalling. There are many signalling components 
that are crucial in ensuring proper regulation of integrin-mediated signalling cascades. 
However, I believe that FAK, MAPK and PTEN are key players in adhesion-based 
signalling events. Thus, the pathways elicited by these signalling molecules warrant 
further investigation. 
 
1.3.1 Consequences of FAK Signalling 
Integrins lack enzymatic activity and their cytoplasmic tails are generally short 
(Giancotti and Ruoslahti, 1999; Liu et al., 2000), suggesting that in order for integrins 
to be able to transduce signals, they need to associate with adaptor proteins, that connect 
integrins to the cytoskeleton, cytoplasmic kinases, and transmembrane growth factor 
receptors (Giancotti and Ruoslahti, 1999; Cabodi et al., 2004). FAK and Shc (SH2 
homology/collagen homology proteins) are the major tyrosine kinase-dependent 
pathways that are activated by the integrins. Both pathways include a Src family kinase 
as their central component (Mauro et al., 1999; Barberis et al., 2000; Schwartz, 2001; 
Planas-Silva et al., 2006) and include Src, Fyn and the Yes (Frame et al., 2002; Cabodi 
et al., 2004). We now have a scenario where two distinct signalling pathways share a 
common element, suggesting that both pathways are involved in regulating similar 
events. As we develop these pathways further, an understanding of this situation will 
ensue. 
 
Focal adhesions are specialised adhesion sites formed at the cell surface (Malik and 
Parsons, 1996; Wozniak et al., 2004), and are the principal sites of integrin signalling 
(Ruoslahti and Öbrink, 1996). Focal adhesions arise as a result of ligation of ECM 
proteins by integrin receptors, which cause cross-linking or clustering of integrins (Katz 
et al., 2000; Carragher and Frame, 2004). These sites are involved in physical 
attachment of cells to external surfaces, which is essential for cell migration and tissue 
 14
formation, as well for activation of adhesion-mediated signalling events (Katz et al., 
2000). They are comprised of protein kinases, such as FAK and ILK, in addition to non-
catalytic proteins such as integrins, talin, vinculin, paxillin and zyxin (Horwitz et al., 
1986; Turner and Burridge, 1991; Grashoff et al., 2004). They also contain EGF 
receptors (Boudreau and Jones, 1999). 
 
Ligand binding controls the localisation of β1- and β3-containing integrins into focal 
adhesions (Akiyama et al., 1994; Gumbiner, 1996), which allow for intrinsic signals 
facilitating focal adhesion localisation (Akiyama et al., 1994). Both FAK and ILK have 
been reported to bind the β integrin subunit (Liu et al., 2000). ILK phosphorylation of 
the β1 integrin cytoplasmic domain is further involved in the dynamic regulation of 
localisation of β1 to focal adhesions (Dedhar et al., 1999). All β1 and αv integrins are 
able to promote the focal adhesion assembly and FAK activation (Giancotti, 1997; 
Kumar, 1998), as are growth factors and cytokines. These integrins are therefore 
capable of initiating integrin adhesion-dependent signalling pathways. Incorporation of 
the integrins into focal adhesions is prevented by the α subunits of the heterodimers. 
This inhibition is relieved by the ligand binding, and allows the β subunit cytoplasmic 
tail signals to recruit the integrin dimer into the focal adhesion (Gumbiner, 1996). 
 
FAK is a 120 kDa non-receptor tyrosine kinase (Boudreau and Jones, 1999) that co-
localises with integrins and occurs at cell-substratum contact sites (Martin, 2003; 
Wozniak et al, 2004; Crowe and Ohannessian, 2004). FAK is incapable of 
phosphorylating other substrates directly and requires autophosphorylation (integrin-
dependent) (Barberis et al., 2000; Zamir and Geiger, 2001; Sawai et al., 2005), which 
allows it to interact with docking or adaptor proteins, including paxillin, tensin and 
Grb2/SOS (Son of Sevenless) (Barberis et al., 2000). These adaptor proteins, in turn, 
are able to activate downstream signalling mediators previously implicated in growth 
control, including Src, Ras and Raf (see Figures 1a and 1b). Regulation of the 
phosphorylation state and tyrosine kinase activity of FAK occurs through binding of 
cells to the ECM (Boudreau and Jones, 1999; Mudhopadhyay et al., 2005; Sawai et al., 
2005), as well as by tyrosine phosphatases (Giancotti and Ruoslahti, 1999) such as 
phosphatase and tensin homolog (PTEN). The relevance of PTEN to FAK signalling 
will be discussed later. 
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a) The activation of FAK by the integrin receptors enables FAK to bind to the SH2 domain of Src leading to subsequent Src activation. Src in turn activates 
p103CAS, which recruits Crk and Nck. Crk phosphorylates JNK, which subsequently activates c-Jun. c-fos then complexes with c-jun to form the AP-1 
complex, which serves to regulate cell cycle progression. In a distinct pathway the activation of Src by FAK leads to the regulation of other focal adhesion 
proteins such as paxillin and tensin, which influence cytoskeletal organisation and cell spreading. b) A second FAK signalling pathway involves the indirect 
activation of Shc via Fyn. Fyn phosphorylates Shc, which is recruited to the membrane via caveolin-1. Shc combines with the Grb-2-SOS complex and 
initiates the MAPK signalling cascade, which influences cell proliferation and differentiation. 
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Figure 1: Focal Adhesion Kinase (FAK) Signalling Pathways. 
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In response to adhesion receptor activation and integrin clustering, tyrosine 
phosphorylation of FAK occurs within the focal adhesion complex (Chen et al., 1996; 
Liu et al., 2000; Schaller, 2004; Benlimame et al., 2005; Planas-Silva et al., 2006), 
thereby binding to Src or Fyn (protein tyrosine kinases) (Schaller et al., 1992; Juliano 
and Haskill, 1993; Kumar, 1998). Once activated, FAK associates with the SH2 domain 
(Src homology domain) of Src. The Src kinase in turn, phosphorylates paxillin and 
tensin and p130CAS, a docking protein that recruits adapter proteins, including Crk and 
Nck (see Figure 1a and Barberis et al., 2000; Schwartz, 2001; Martin, 2003; Schaller, 
2004; Planas-Silva et al., 2006). Src itself is capable of regulating FAK as 
transformation of FAK deficient fibroblasts with the v-Src oncogene promotes cellular 
motility equal to that of FAK re-expression (Crowe and Ohannessian, 2004; Wozniak et 
al., 2004). 
 
In this pathway the MAPK c-Jun NH2-terminal kinase (JNK) is activated via Crk, and 
this serves to regulate progression through the cell cycle (Giancotti and Ruoslahti, 
1999). Alternatively, Crk is also able to interact with p130CAS which has crucial 
influences on cell transformation, morphology and migration (Wozniak et al., 2004). 
The Crk-p130CAS complex results in activation of the small GTPase, Rac, which is 
mentioned above, has crucial consequences with regards to cell migration (DeMali et 
al., 2003; Wozniak et al., 2004). 
 
We have now reached a point where the pathways of FAK and MAPK coincide, which 
once again demonstrates the complexity of these signalling cascades. To continue, 
activated JNK enters the nucleus and phosphorylates the transcription factor c-Jun, 
which combines with c-Fos, to form the activating protein (AP-1) transcription factor 
complex. AP-1 is then able to regulate genes that are important for cell proliferation 
such as cyclins (see Figure 1a and Martin, 2003; Wozniak et al., 2004). 
 
In a separate pathway, integrins recruit Shc via a series of sequential steps. Caveolin-1, 
a membrane adaptor protein, serves to couple, through its SH3 domain, the integrin α 
subunit to the Src family kinase Fyn (Wary et al., 1996; Barberis et al., 2000). Fyn then 
phosphorylates Shc and combines with the Grb-2-mSOS complex (Coppolino and 
Dedhar, 2000). Grb-2 serves to link FAK to the Ras pathway (see Figure 1b), and the 
phosphoinositide 3-OH kinase (PI3K) (Ruoslahti and Öbrink, 1996; Sanders et al., 
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2000; Crowe and Ohannessian, 2004; Mukhopadhyay et al., 2005). PI3K is involved in 
the regulation of ILK, and is discussed later. 
 
The consequences of FAK and Shc signalling are widespread and include amplification 
of various cellular responses. For instance, Shc signalling augments hepatocyte growth 
factor (HGF)-induced proliferation and migration in human lung adenocarcinoma 
(Pelicci et al., 1992; Pelicci et al., 1995 cited in Mauro et al., 1999). Src overexpression 
and enhanced activity has also been linked to the progression and metastasis of different 
types of cancer (Sawai et al., 2005).  
 
FAK activation via integrins plays a central role in initiating a host of signals that are 
involved in the regulation of growth (Mukhopadhyay et al., 2005). For example, 
introduction of constitutively activated FAK leads to cell transformation, anchorage-
independent growth and the suppression of apoptosis (Ilic et al., 1998; Sawai et al., 
2005). FAK overexpression has been correlated with aggressive breast and colonic 
cancer as well as sarcoma and hepatocellular carcinoma (Weiner et al., 1993; Owens et 
al., 1995; Fujii et al., 2004; Lark et al., 2005; Schmitz et al., 2005). In melanoma cells, 
increased FAK expression is associated with increased cell motility (Mukhopadhyay et 
al., 2005; Hess and Hendrix, 2006). Both FAK and Shc contribute to the activation of 
the Ras-extracellular regulated kinase MAPK cascade when Shc-linked integrins bind to 
the ECM (see Figure 1a and Moro et al., 1998; Giancotti and Ruoslahti, 1999). 
 
1.3.2 MAPK Signalling Cascades 
Activation of the MAPK signalling pathway provides a common route leading to 
transcriptional regulation of genes that are crucial for cell growth and differentiation 
(Juliano and Haskill, 1993; Giancotti and Ruoslahti, 1999; Hynes, 1999). Sequential 
activation following transient activation of Ras GTP-binding proteins via receptor 
tyrosine kinases include MAPK/ERK kinase, MAPKK (also known as MEK) and 
ERK1 (p44)/ERK2 (p42) (Boudreau and Jones, 1999; Martin, 2003). The activation of 
the MAPK signalling cascade occurs in response to several stimuli including integrin 
engagement, activation of c-Src as well as ligand-induced activation (Carragher and 
Frame, 2004). 
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The phosphorylation of ERK1 and ERK2 results in their translocation to the nucleus, 
where they phosphorylate and activate a number of transcription factors associated with 
early response genes (see Figure 1b and Boudreau and Jones, 1999; Giancotti and 
Ruoslahti, 1999). MAPK activation could also occur through adhesion of cells to ECM 
proteins including fibronectin, vitronectin, collagen, tenascin and laminin, via ligation 
of α5β1, αvβ3, α2β1, αvβ6 and α6β4 (Boudreau and Jones, 1999). 
 
MAPK signalling is able to elicit a host of responses that are crucial for normal cellular 
functioning. For example, upregulation of the α1β1 collagen/laminin receptor in PC12 
cells is a direct result of MAPK-dependent differentiation. An elongated morphology is 
often associated with differentiation of this cell type (Boudreau and Jones, 1999). 
Similarly, in erythroleukaemia cells, MAPK-dependent differentiation and growth arrest 
are accompanied by upregulation of the platelet αIIbβ3, the expression of which is 
impaired by inhibiting MAPK. Furthermore, MAPK is capable of influencing cell cycle 
progression for αvβ3 and a subset of β1 integrins (Coppolino and Dedhar, 2000). In this 
report, Shc was shown to associate with the integrin α subunit, which promoted the 
MAPK pathway as well as passage through the G1 phase of the cell cycle (Coppolino 
and Dedhar, 2000). 
 
It is thought that Shc is responsible for the initial high-level activation of ERK, upon 
cell adhesion. FAK, which is activated more slowly, may be responsible for sustaining 
ERK activation (Schlaepfer and Hunter, 1998; Pozzi et al., 1998; Crowe and 
Ohannessian, 2004). FAK on the other hand, is able to limit adhesion to the ECM, 
which permits cells to take up a position or shape that accommodates migration and 
proliferation (Boudreau and Jones, 1999). This position is accomplished by cytoskeletal 
changes and ECM-directed morphology that co-ordinate cell receptors and intracellular 
signalling molecules, thereby permitting upstream effectors, including FAK, Ras and 
Raf to couple with their downstream targets, including MAPKs (Carragher and Frame, 
2004). In situations where limited growth factor concentrations exist in cells, the need 
for integrins to activate ERK becomes necessary (Mainiero et al., 1997; Giancotti and 
Ruoslahti, 1999). In this setting, proliferation is likely to require co-stimulation of ERK 
through integrins and growth factor receptors (Martin, 2003).  
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The signalling complexes that are assembled by integrins are able to activate multiple 
signalling pathways, which serve as a class of “master regulators” of cell function. Thus 
it is obvious that both MAPK and FAK signalling are central to integrin signalling 
(Ruoslahti and Öbrink, 1996). ILK is another protein kinase influencing many aspects 
of integrin function such as fibronectin matrix assembly, cell cycle progression, cell 
adhesion processes as well as neurite outgrowth, and leukocyte recruitment (Attwell et 
al., 2000; D’Amico et al., 2000; Yoganathan et al., 2000; Tan et al., 2001; Friedrich et 
al., 2002; Attwell et al., 2003; Pinkse et al., 2005). 
 
To ensure the correct biological functioning of cellular events, tight regulation is 
required over signalling pathways involving kinases such as MAPK and FAK. Protein 
kinases provide the stimuli for these signal transduction pathways, while protein 
phosphatases provide the necessary inhibitory regulation. One such lipid phosphatase, 
PTEN (phosphatase and tensin homologue deleted on chromosome ten) supplies the 
necessary negative regulation of these pathways and thus has particular pertinence to 
this study. While the following section will examine PTEN signalling in its role in 
regulating cell survival and growth pathways, Chapter 3 will examine the importance of 
PTEN signalling to ILK regulation. 
 
1.3.3 PTEN Signalling Cascades 
In the development of the majority of human cancers, it is widely established that 
inactivation of tumour suppressor proteins is required (Simpson and Parsons, 2001; 
Leslie et al., 2004). The tumour suppressor PTEN has been shown to play an essential 
role in the regulation of cellular adhesion, migration, growth and apoptosis (Marino et 
al., 2002; Suli et al., 2003; Kerr et al., 2006). The pertinence of PTEN stems from its 
ability to negatively regulate various signalling cascades that are critical in tumour 
progression. Indeed, PTEN directly exerts its effects on the MAPK, FAK and PKB 
signalling pathways (Gu et al., 1998; Cantley and Neel, 1999; Maehama et al., 2001; 
Waite and Eng, 2002; Yang et al., 2003). The roles of PTEN to these crucial signalling 
pathways will now be investigated.  
 
Although PI3K is capable of activating numerous signalling pathways downstream of 
PI3K, the PKB pathway has attracted much attention due to its role in cell survival 
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(Cantley and Neel, 1999; Cristofano and Pandolfi, 2000; Krasilnikov, 2000; Vara et al., 
2004; Walker et al., 2004). However, it is likely that the roles of PKB extend beyond 
that of cell survival since PKB targets substrates such as GSK3β, mammalian target of 
rapamycin (mTOR), insulin receptor substrate-1 (IRS-1), cyclin-dependent kinase 
inhibitors p21CIP1/WAF1 and p27KIP1, which are involved in cell cycle progression and 
growth (Blume-Jensen and Hunter, 2001; Gringas et al., 2001; Vara et al., 2004). 
However, during cancer progression, the ability of cells to evade cell death is a critical 
event and the PI3K/PKB pathway provides such a mechanism (Al-Khouri et al., 2005).  
 
The PI3K/PKB signalling pathway is perhaps the most relevant signalling pathway that 
involves PTEN function (Backman et al., 2002; Sulis et al., 2003). In this model, it has 
been demonstrated that PTEN dephosphorylates phosphatidyl inositol triphosphate 
(PIP3), which suggests a mechanism for how PTEN controls PI3K and PKB activity 
(Leslie et al., 2000; Downes et al., 2001; Li et al., 2001; Bayascas et al., 2005) (Figure 
2, pg 23). In quiescent cells, PIP3 levels are usually low but are rapidly increased upon 
stimulation by growth factors, through activation of PI3K. The accumulation of PIP3 at 
the membrane allows for the recruitment of proteins which contain pleckstrin homology 
(PH) domains, such as PKB, which then bind to PIP3 (Cristofano and Pandolfi, 2000). 
Activated PKB then exerts anti-apoptotic stimuli by preventing release of cytochrome C 
from mitochondria and inactivating Forkhead transcription factors (FKHR), which are 
known to induce the expression of genes that are critical for apoptosis (Cristofano and 
Pandolfi, 2000). PKB also phosphorylates and inactivates the proapoptotic factors Bcl-2 
(protein originally identified in B-cell lymphoma), the Bcl-2-associated death promoter 
(BAD) and caspase-9 (Datta et al., 1999, Cristofano and Pandolfi, 2000). In this context 
the function of PTEN is to keep the levels of PIP3 low. The loss of PTEN function 
results in an increased concentration of PIP3 and in PKB hyperactivation, leading to 
protection from pro-apoptotic stimuli (Stambolic et al., 1998). 
 
It is well established that the PI3K/PKB pathway are linked to human cancers via 
defects in PTEN. For example, in pancreatic cancer where PI3K was inhibited, PKB is 
constitutively activated (Stoll et al., 2006). Normally, PKB activity is low in the 
absence of growth factor stimulation. However, PTEN-deficient tumour cell lines 
exhibit high basal levels of PKB phosphorylation (Cantley and Neel, 1999). This is 
especially true in Alzheimer’s disease where it has been reported that increased PKB 
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levels exist when PTEN levels are low (Pei et al., 2003; Rickle et al., 2004). However, 
PKB levels were relatively low in a glioblastoma tumour sample carrying a mutation in 
the extreme C-terminus of PTEN compared to tumours with a phosphatase-inactivating 
mutation (Downes et al., 2001). This suggested that deregulation of PKB is not a 
universal feature of tumours that carry PTEN mutations. Conversely, it has been shown 
that PTEN-null fibroblasts are resistant to multiple pro apoptotic stimuli. Reconstitution 
of wild-type PTEN restores normal PKB regulation and sensitivity to these stimuli 
(Stambolic et al., 1998). These data suggest that perturbations of the PI3K/PTEN/PKB 
signal transduction pathway may contribute to a large fraction of human cancers. 
 
Even though the current knowledge regarding PI3K/PTEN/PKB is relatively well 
understood, many issues remain unresolved with regards to PTEN regulation of the 
PI3K/PKB pathway. For example, PTEN expression prevents basal activation of PKB 
(i.e. activation of PTEN in the absence of growth factor stimulation), yet in PTEN+ 
cells, growth factors remain able to activate PKB via a PI3K-dependent pathway. This 
suggests that PTEN is inactivated upon growth factor stimulation or that PTEN is 
activated by growth factor depletion. 
 
Although the effects of PTEN on PI3K/PKB signalling is almost certainly the most 
important signal transduction pathway influenced by PTEN, the effects of PTEN are 
also observed on the MAPK and FAK signalling cascades. Indeed, PTEN has been 
implicated in inhibitory regulation of these signalling cascades. It is interesting to note 
that in the PTEN-mediated regulation of FAK, PTEN is capable of regulating MAPK 
signalling. This is achieved via the PTEN-mediated dephosphorylation of FAK (Tamura 
et al., 1998; Zheng et al., 2003). For example, it has been reported that reintroduction of 
PTEN into the glioblastoma cell line U-87MG leads to direct dephosphorylation of 
FAK, thus inhibiting integrin-mediated cell spreading and migration (Tamura et al., 
1998). Moreover, it has been demonstrated that PTEN is able to bind and 
dephosphorylate Shc, thus inhibiting the recruitment of the Grb2 adaptor and the 
subsequent activation of the MAP kinase cascade (Gu et al., 1998; Tamura et al., 1998). 
Thus, by regulating FAK and Shc phosphorylation in response to integrin ligation, 
PTEN is capable of modulating various aspects of cell adhesion and migration 
(Cristofano and Pandolfi, 2000). Furthermore, PTEN is also capable of regulating focal 
adhesion structure, cell spreading and motility, by controlling FAK activity (Tamura et 
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al., 1998; Cantley and Neel, 1999). The inactivation of FAK via PTEN demonstrates its 
ability as a tumour suppressor by inhibiting cell invasion and metastasis (Zheng et al., 
2003). Thus, PTEN-mediated FAK regulation demonstrates that PTEN influences 
integrin-mediated signal transduction pathways. 
 
The regulation of Shc via PTEN represents one mechanism for PTEN-mediated 
regulation of MAPK signalling. However, the involvement of PTEN on MAPK 
signalling can also occur through regulation of the Ras protein. The role of PTEN in 
regulating MAPK signalling was revealed in a study, which found that reconstitution of 
PTEN in a cell line devoid of this protein due to mutation markedly inhibited the 
Ras/ERK signal transduction pathway in response to stimulation by fibronectin or 
growth factors (Gu et al., 1998). Obviously, PTEN regulation of MAPK has crucial 
consequences with regards to cell growth and differentiation. This indicates that 
downregulation of the Ras/MAPK pathway is an important function of the PTEN 
tumour suppressor in its cell biological functions, which supports the function of PTEN 
as a tumour suppressor. 
 
What has been discussed thus far clearly indicates that PTEN plays crucial roles within 
numerous signalling transduction pathways. While involvement of PTEN in MAPK and 
FAK signalling has important cellular consequences, the primary interest of PTEN to 
this study was its role in ILK activity. The details of PTEN function with regards to ILK 
activity will be discussed in greater in chapter 3 where the effects of growth factors on 
ILK activity are considered.  
 
1.4 ILK Signal Transduction Pathways 
 
1.4.1 ILK Signalling and Support 
Several instances have clearly demonstrated protein kinases as playing key roles in 
signal transduction pathways and cancer, where aberrant kinase activities correlate with 
pathological increases in cell proliferation and resistance to apoptosis (Yoganathan et 
al., 2000; Aplin et al., 2002; Graness et al., 2005; Pinkse et al., 2005). The participation 
of cellular kinases in signal transduction pathways allows cells to respond functionally 
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PTEN negatively regulates PKB-mediated cell survival. Binding of GFs, to RTKs activates PI3K. Activated PI3K phosphorylates PIP2 to produce PIP3, which 
recruits PKB to the plasma membrane where it is phosphorylated and activated by PDK1. PTEN prevents PKB-mediated cell survival by dephosphorylating 
PIP3. PKB also regulates protein translation and glucose metabolism. Bad − Bcl-2 associated death promoter, FKHR − forkhead transcription factors, GFs − 
growth factors, GSK3β − glycogen synthase 3β, PI3K − phosphoinositide 3-OH kinase, PIP2 − phosphatidylinositol (4,5) biphosphate, PIP3 − 
phosphatidylinositol (3,4,5) triphosphate, PDK1 − protein dependent kinase 1, PKB − protein kinase B, PTEN − phosphatase and tensin homolog, RTK − 
receptor tyrosine kinase, TOR − target of rapamycin. 
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Figure 2: PTEN Signalling Pathways. 
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to external messages or to extracellular stresses (Persad et al., 2000; Yoganathan et al., 
2000; Tu et al., 2001). ILK is a protein kinase that is critically involved in adhesion of 
cells to the ECM and signal transduction (Wu, 2001; Attwell et al., 2003; Xie et al., 
2004; Boulter et al., 2006). The kinase activity of ILK can be modulated by the 
interaction of cells with components of the ECM, or by integrin clustering and growth 
factors (Delcommenne et al., 1998; Janji et al., 2000; Persad et al., 2000; Yoganathan et 
al., 2000; Attwell et al., 2003). ILK was identified in the search for proteins capable of 
interacting with the cytoplasmic domain of the integrin β1 subunit. This was achieved 
using a yeast two-hybrid screen with the integrin β1 cytoplasmic domain as bait 
(Hannigan et al., 1996; Dedhar et al., 1999). The focus of this study examines the 
expression and kinase activity of ILK. ILK has attracted much interest of late due to its 
prime location in cells for regulating integrin-mediated processes. 
 
Extensive biochemical analysis has revealed that the structure of ILK comprises three 
identifiable features (Persad and Dedhar, 2003; Oloumi et al., 2004). The N-terminus 
consists of four non-catalytic ankyrin (ANK) repeats, which help target the molecule to 
focal adhesion complexes and link it to the growth factor signalling pathways via the 
adaptor protein PINCH (particularly interesting new calponin homology domain-
containing protein) (Tu et al., 1999; Somasiri.et al., 2000; Kaneko et al., 2004; Boulter 
et al., 2006). This is followed by a pleckstrin homology (PH)-like motif that binds a 
lipid product of phosphatidylinositol 3-kinase (PI3K) and participates in the regulation 
of the kinase activity (Li et al., 1999; Dedhar, 2000; Persad and Dedhar, 2003; Kaneko 
et al., 2004). This motif overlaps with the extreme N-terminus of the kinase catalytic 
domain. The C-terminal catalytic domain contains a protein kinase catalytic site as well 
as a binding site for β integrin cytoplasmic domains, which is located in the extreme C-
terminus of the kinase domain (Dedhar, 2000; Grashoff et al., 2004). 
 
ILK was originally identified as a binding partner to β1 integrins (Stevens et al., 2004), 
and evidence has demonstrated that ILK is important as a molecular scaffolder at cell-
ECM adhesion sites. Furthermore, ILK participates in various signalling pathways 
involved in controlling cell survival, differentiation, proliferation and gene expression 
in mammalian cells (Wu, 2001; Attwell et al., 2003; Erdödi et al., 2003; Wu, 2004; 
Graness et al., 2005).  
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The regulation of ILK activation occurs either through an interaction of cells with 
components of the ECM or by integrin clustering (Cordes and van Beuningen, 2003; 
Duxbury et al., 2005). ILK has a somewhat unusual kinase catalytic domain, in that it 
requires both PIP3 binding, as well as autophosphorylation for ILK activation (Dedhar 
et al., 1999; Lynch et al., 1999; Dedhar, 2000). ILK has, however, been shown to 
directly phosphorylate proteins such as PKB, glycogen synthase kinase 3 (GSK3), 
myosin light chain (MLC), and ILK-binding protein affixin (see Figure 2 pg 22 and 
Yamaji et al., 2001; Wu, 2001; Aoyagi et al., 2005; Pinkse et al., 2005; Yau et al., 
2005). All these downstream targets of ILK will be discussed in due course. However, it 
is first necessary to examine the association between ILK and the actin cytoskeleton.  
 
1.4.2 ILK Acts as a Molecular Scaffold 
Since the discovery of ILK by Hannigan et al. (1996), much has been revealed about 
this fascinating protein kinase. ILK plays a versatile role in just about every aspect of 
cellular functioning. It has already been mentioned that integrins are involved in 
physical attachment of cells to cell-matrix adhesion sites, which is crucial for cellular 
processes such as cell migration and tissue formation, as well as for activation of 
adhesion-mediated signalling events (Katz et al., 2000; Cordes and van Beuningen, 
2003; Cordes, 2004). By binding various adaptor proteins either directly or indirectly; 
ILK is linked to the actin cytoskeleton and is the primary regulatory kinase during these 
processes (Li et al., 1999; Janji et al., 2000; Somasiri et al., 2000; Grashoff et al., 
2004). 
 
Although the integrins provide the actual attachment to the ECM, they do not possess 
any catalytic activity of their own, and instead it is ILK which regulates their activation. 
This was shown in genetic model systems such as Drosophila where null mutations of 
ILK resulted in defects similar to those of integrin function loss (Zervas et al., 2001). 
Furthermore, when these mutations were examined in more detail it was revealed that 
actin filaments were detached from the membranes at the muscle attachment sites 
(Zervas et al., 2001). Thus, it became apparent that ILK was capable of acting as a 
bridge between the integrin receptors and the actin cytoskeleton. From these studies it 
was revealed that ILK was involved in cellular processes such as cell adhesion, cell 
survival, migration and angiogenesis (Yoganathan et al., 2000; Cordes and van 
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Beuningen, 2003; Dai et al., 2003; Fukuda et al., 2003; Cho et al., 2005). Moreover, it 
was demonstrated by these studies that ILK also played an important role in focal 
adhesion formation and actin reorganisation (Yamaji et al., 2002; Vouret-Craviari et al., 
2004). 
 
Adaptor proteins such as PINCH, calponin homology (CH) domain-containing ILK-
binding protein (CH-ILKBP), paxillin, actopaxin and affixin are the primary proteins, 
which link ILK to the actin filaments. CH-ILKBP, paxillin, actopaxin and affixin all 
show a degree of sequence homology making it possible to bind to ILK (Wu, 2001; 
Attwell et al., 2003; Wu, 2004). CH-ILKBP is an actin-binding focal adhesion protein 
containing two calponin-homology (CH) domains. CH-ILKBP localises to focal 
adhesions (FAs) in response to cell-matrix attachment, but not cell-cell adhesions, 
which is also the case for ILK (Tu et al., 2001). As ILK is the only FA protein that is 
known to bind CH-ILKBP, ILK probably plays a crucial role in recruiting CH-ILKBP 
to FAs (Tu et al., 2001). CH-ILKBP is closely related structurally to rat actopaxin, a 
paxillin- and actin-binding protein (Wu, 2001). The C-terminal domain of ILK and the 
CH2 domain of CH-ILKBP mediate the interactions between ILK and CH-ILKBP (Wu, 
2001; Fukuda et al., 2003; Wu, 2004; Boulter et al., 2006). 
 
Although not directly associated with actin, the focal adhesion protein PINCH, 
comprising five LIM domains (a common protein-protein interaction motif that was 
originally discovered in the products of the lin-11, isl-1, and mec-3 genes) (Li et al., 
1999; Velyvis et al., 2001; Fukuda et al., 2003; Boulter et al., 2006), is able to bind ILK 
with high affinity. The ILK-PINCH binding is mediated by the N-terminal ankyrin 
repeat domain of ILK and the second Zn finger located within the N-terminal-most LIM 
domain (LIM1) of PINCH (Wu, 2001, Fukuda et al., 2003; Persad and Dedhar, 2003; 
Wu, 2004, Figure 3, pg 33). The importance of the ILK-PINCH to the integrin-actin 
network is strengthened by reports that demonstrate that overexpression of dominant 
negative forms of either PINCH or ILK that disrupt the PINCH/ILK interaction impairs 
fibronectin matrix assembly, cell spreading and migration (Guo et al., 2001; Yang et al., 
2005). As a result of these interactions a stable PINCH-ILK-CH-ILKBP tertiary 
complex in cells is formed (Wu, 2001). The formation of this complex facilitates the 
localisation of PINCH, ILK and CH-ILKBP to cell-ECM contact sites, at which they 
provide a crucial physical connection between transmembrane receptors such as 
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integrins and the actin filaments (Tu et al., 2001; Wu, 2001; Grashoff et al., 2004; Wu, 
2005). 
 
Paxillin is a multidomain adaptor protein that contains five leucine-aspartate repeat 
(LD) motifs at its N-terminus (Nikolopoulos and Turner, 2002). Paxillin has not been 
detected as part of the multicomponent (PINCH-ILK-CH-ILKBP) complex, despite its 
ability to interact with both ILK and CH-ILKBP through the LD1 motif (Wu and 
Dedhar, 2001; Persad and Dedhar, 2003). Paxillin however, binds actopaxin, which is 
localised to focal adhesions and binds actin and ILK (Nikolopoulos and Turner, 2002). 
Thus, although paxillin is not a part of the tertiary complex of ILK, it still does provide 
an indirect link to the actin cytoskeleton by binding to actopaxin. Interestingly, a 
reduction in cell adhesion/spreading on collagen has been demonstrated when a paxillin 
binding-defective actopaxin mutant in HeLa cells was ectopically expressed. This 
suggests an important role for actopaxin-paxillin interactions in integrin-dependent 
remodelling of the actin cytoskeleton (Nikolopoulos and Turner, 2001). Actopaxin was 
identified in a screen for actin-binding proteins and named parvin, defining a family of 
proteins with three members (α, β, γ) (Olski et al., 2001; Nikolopoulos and Turner, 
2001). The interactions between ILK and an actopaxin family member (human 
actopaxin-paxillin-α-parvin-CH-ILKBP) (Nikolopoulos and Turner, 2002) provide 
evidence for these interactions in focal adhesion targeting of ILK and, a role for ILK in 
integrin-mediated signal transduction events. 
 
It is thought that an additional connection, between integrins and the actin cytoskeleton, 
could be provided by the affixin-β-parvin complex (Wu and Dedhar, 2001). Affixin-β-
parvin contains a tandem CH domain-containing protein and belongs to a novel family 
of FA proteins, together with other homologous proteins such as the actopaxin-CH-
ILKBP-α-parvin complex and γ-parvin (Yamaji et al., 2002). Affixin is involved in the 
development of focal adhesions and actin stress fibres and is known to bind to ILK. It 
has been reported that the initial spreading of cells is inhibited by overexpression of an 
affixin fragment containing the ILK-binding CH2 domain (Yamaji et al., 2001). 
Extensive effort has gone into finding a direct interaction between affixin-β-parvin and 
actin. However, this interaction has not been detected in vitro (Yamaji et al., 2001). 
Recently, Yamaji et al. (2002) have demonstrated signalling in platelets by integrin-
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ILK-affixin, thus suggesting that affixin does play an important role in linking the 
cytoskeleton to the integrin receptors. Thus, ILK is capable of mediating the link 
between the integrin receptors and the actin cytoskeleton through numerous actin-
binding proteins, all of which bind ILK (Persad and Dedhar, 2003). 
 
It is apparent that ILK is suitably placed to modulate the physical strength of the 
connections at the cell matrix contact sites. It is apparent that ILK provides a molecular 
scaffold at the cell-ECM adhesion sites (Wu and Dedhar, 2001), which requires the 
correct subcellular localisation of ILK, and an intact paxillin-actopaxin-ILK protein 
complex, which are likely to impact significantly on normal ILK signalling 
(Nikolopoulos and Turner, 2001; Persad and Dedhar, 2003; Wu, 2005). Besides the 
complexes mentioned above, there are likely protein complexes containing talin, 
filamin, or α-actinin, that can also physically link the ECM and transmembrane 
receptors to the intracellular actin cytoskeleton (Tu et al., 2001) to bring about specific 
cellular responses. 
 
1.4.3 Intracellular signalling by ILK 
ILK is suitably placed to mediate a host of cellular functions by influencing intracellular 
processes such as actin organisation and, extracellular processes, including cell motility 
and adhesion. By creating muliprotein complexes that connect ILK to the actin 
cytoskeleton, ILK provides a physical connection between the integrin receptors and the 
actin cytoskeleton, and elicits the signals that provide the communication network 
between the extracellular and intracellular compartments of cells (Pinkse et al., 2005; 
Vespa et al., 2005). 
 
Numerous signalling pathways have been acknowledged to involve ILK, and 
examination of these would require in depth discussion and detail. For the sake of 
brevity, we will confine this discussion to two important signalling pathways involving 
ILK. These include the outcomes of ILK signalling on the actin cytoskeleton, as well as 
the Wnt signalling pathway, which is important in the regulation of many genes 
controlling proliferation, the cell cycle and anchorage independent growth (Wu and 
Dedhar, 2001). 
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The signals that are elicited as a consequence of the integrin-ILK-actin scaffold are able 
to influence actin organisation, which are mediated by affixin-β-parvin and actopaxin-
CH-ILKBP-α-parvin (Wu, 2005). These signals relay changes in cell spreading and 
adhesion (Nikolopoulos and Turner, 2002; Yamaji et al., 2002; Attwell et al., 2003; 
Wu, 2004). ILK is involved in the regulation of cell migration, cell motility, and 
contractibility by directly phosphorylating proteins such as MLC (Deng et al., 2001), 
affixin (Wu and Dedhar, 2001; Yamaji et al., 2001; Attwell et al., 2003), as well as the 
Rho family members (Graness et al., 2005). It is thought that this occurs in the early 
stages of cell spreading where the phosphorylation of affixin modulates the interaction 
of the affixin-ILK-actin complex (Wu and Dedhar, 2001; Yamaji et al., 2001). Affixin 
and ILK are known to colocalise at FAs and, when affixin is overexpressed in CHO 
cells, the COOH-terminal half of affixin disrupts preformed FAs and actin stress fibres 
(SFs), suggesting affixin to be one of the downstream targets of ILK (Yamaji et al., 
2001).  
 
ILK is also an essential component connecting the clustering of integrins to the 
activation of the Rho proteins, Cdc42 and Rac. ILK-deficient fibroblasts are not only 
deficient in spreading and adhesion, but also show alterations in the expression of actin 
fibres compared to wild type cells. In contrast to these findings, overexpression of wild-
type and mutated ILK in U2OS osteosarcoma cells hardly affected actin organisation. 
Furthermore, mutated ILK was correlated with increased RhoA signalling (Khyrul et 
al., 2004). A principal effector of RhoA is Rho-associated kinase (ROCK), which is 
capable of modulating the actin cytoskeleton through pathways involving myosin kinase 
(Riento and Ridley, 2003). It has been demonstrated that ILK contributes to the 
regulation of cytoskeletal organisation, morphology and cell migration through a 
ROCK-mediated pathway. In this study, the wild-type ILK-dependent effects on 
spreading, morphology and motility were reversed by inhibition of RhoA signalling or 
its downstream effector ROCK (Khyrul et al., 2004). It is obvious that ILK plays a 
major role in the modulation of the actin cytoskeleton by regulating crucial signalling 
molecules. 
 
It has been mentioned above that affixin and CH-ILBP are both able to bind ILK and, 
furthermore this binding occurs via similar domains demonstrating that affixin and CH-
ILKBP share sequence homology (Attwell et al., 2003). For this reason, although it has 
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not yet been demonstrated, it is likely that ILK is able to phosphorylate CH-ILKBP (Wu 
and Dedhar, 2001). On the other hand it is also likely that certain functions of ILK do 
not require ILK kinase activity. For example, it has been suggested that in Drosophila, 
during the regulation of integrin-actin cytoskeleton interactions, no kinase activity by 
ILK is required (Zervas et al., 2001). 
 
To understand ILK signalling pathways, specifically the way in which ILK transduces 
signals, overexpression studies are often performed. The characteristics of ILK 
overexpression in normal epithelial cells include the loss of cell-cell adhesion, due to 
inhibition in the level of E-cadherin expression (Novak et al., 1998; Tan et al., 2001;  
Oloumi et al., 2004), nuclear translocation of β-catenin, as well as β-catenin 
stabilisation (Dedhar, 2000; Somasiri et al., 2001; Oloumi et al., 2004). 
 
The responses that are elicited by ILK are numerous and their impacts upon cellular 
functioning widespread. The Wnt (cell-fate determining protein) signalling pathway is 
one such crucial pathway that is important in the development of vertebrates as well as 
invertebrates, and is also involved in the development of several human cancers (Morin 
et al., 1997; Rubinfeld et al., 1997; Seidensticker and Behrens, 2000). Understanding 
the role of ILK in this pathway is of particular interest, as ILK is able to regulate 
proteins in the Wnt signalling pathway (D’Amico et al., 2000) by inhibiting or 
stimulating key components of this cascade. Central to Wnt signalling is the control of 
β-catenin stability, which is regulated by glycogen synthase kinase-3β (GSK3β) 
(D’Amico et al., 2000). Regulation of β-catenin and GSK3β are the primary ways in 
which ILK directs Wnt signalling (Persad et al., 2000; Tan et al., 2001; Attwell et al., 
2003; Persad and Dedhar, 2003, Figure 3). 
 
β-catenin is an imperative molecule in the Wnt pathway, which forms complexes with 
transcription factors, such as TCF (T cell factor)/Lef-1 (leukocyte enhancing factor). 
These TCF/Lef-1-β-catenin complexes are often constitutively observed in tumour cell 
lines and tissue samples (Seidensticker and Behrens, 2000). ILK is able to induce this 
complex association via phosphorylation of β-catenin (Novak et al., 1998; Persad et al., 
2001). The phosphorylation of β-catenin leads to an increase in the levels of β-catenin 
and a relocation of β-catenin to the nucleus as well as higher levels of activity for AP-1 
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by modulating c-Jun DNA-binding activity (D’Amico et al., 2000; Yoganathan et al., 
2000). The increase in β-catenin is a direct result of inhibited GSK3β via ILK 
phosphorylation. Inhibited GSK3β is responsible for the degradation of β-catenin, 
whereas the relocalisation is a consequence of an unusual elevation of the transcription 
factor partner of β-catenin, Lef-1, which stimulates activity of the Lef-1-β-catenin 
complex (Dedhar et al., 1999; Persad et al., 2000; Wang et al., 2001; Attwell et al., 
2003; Persad and Dedhar, 2003). Activation of the transcriptional complex of TCF/lef-
1-β-catenin, leads to downregulation of E-cadherin expression as well as the stimulation 
of cell cycle control genes including c-myc and cyclin D1 (Novak et al., 1998; 
Seidensticker and Behrens, 2000; Oloumi et al., 2004). 
 
The regulation of GSK3β by ILK can be either direct or indirect. Research has shown 
that ILK overexpression is capable of inhibiting GSK3β activity either by direct 
phosphorylation or indirectly, via PKB phosphorylation, which also inhibits GSK3β 
(Dedhar et al., 1999; Persad et al., 2000; Yoganathan et al., 2000; Persad and Dedhar, 
2003). The phosphorylation of PKB by ILK is also an essential step for the complete 
activation of PKB (Dedhar et al., 1999). Survival pathways and glucose metabolism are 
regulated by PKB as well as several transcription factors, including E2F transcription 
factor 2 (E2F) and cyclic AMP (cAMP)-responsive element binding protein (CREB) 
(Yoganathan et al., 2000; Prolov and Dysan, 2004, Figure 3). PKB is discussed in depth 
later when anchorage independent growth is considered. 
 
The aforementioned signalling pathways affected by ILK are able to control the 
activities of key signalling pathways, which result in either the activation or repression 
of genes encoding proteins involved in the regulation of cell survival, cell cycle, cell 
adhesion and ECM modification (Wu and Dedhar, 2001). It is thus redundant that ILK 
is central to many of the cellular aspects of signal transduction pathways. As well as 
being involved in activation and inhibition of certain molecules, ILK also plays a 
fundamental role in the control of cell cycle progression. This control is mediated 
primarily by cyclins whose expression is limited to specific points in the cell cycle 
(Youssef et al., 1997). Changes in expression of these proteins are able to alter rates of 
cell proliferation and, as discussed above, ILK is capable of regulating their expression 
levels. Associated with the induction of cyclins by ILK overexpression, is anchorage 
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independent growth (D’Amico et al., 2000). Cell proliferation is usually increased in 
many malignant cancers (McCormick, 1999; Giannis, 2000; Andl et al., 2003), and 
together with anchorage-independent growth, contributes to the metastatic cascade. 
 
1.5 The Relationship between Cell Proliferation and Anchorage 
Dependent Growth 
 
1.5.1 Cell Proliferation 
Understanding the cell division process is essential as progression through the cell cycle 
increases rapidly during the metastatic process. ILK has the potential to be directly 
involved in influencing the rate of cell division. Cell division is a tightly controlled 
process regulated by the cyclin/Cdk (cyclin dependent kinase) family of protein kinase 
complexes (Garrett and Fattaey, 1999; Danen and Yamada, 2001; Bhadriraju and 
Hansen, 2004; Boonstra and Moes, 2005). Progression through the cell cycle is 
dependent on the presence of both growth factors and on cell attachment (Hulleman et 
al., 1999; Walker and Assoian, 2005). Several checkpoints contribute to cell cycle 
regulation (Amon, 1999; Donaldson and Blow, 1999; Roy and Thompson, 2006) and 
this fidelity is abrogated in transformed cells resulting in increased cell proliferation 
(Hartwell and Kastan, 1994). Ras-ERK (extracellular signal regulated kinase) activation 
is a consequence of ligation of α1β1, α5β1 and αvβ3 integrins linked to Shc signalling 
pathways. This in turn promotes progression through the G1 phase of the cell cycle 
(Wary et al., 1996; Bill et al., 2004). 
 
ILK influences cell cycle control directly by stimulating many molecules involved in its 
regulation. Studies have reported that ILK overexpression increases the expression of 
cyclin A, cyclin D1 and Cdk4 proteins (Radeva et al., 1997). Hyperphosphorylation of 
the retinoblastoma protein (Rb) was also shown, caused by elevated activities of both
ILK is activated via the lipid product of PI3K, PIP3. ILK is inactivated by the lipid phosphatase PTEN, which dephosphorylates PIP3. Once activate, ILK is 
able to phosphorylated PKB and GSK3β. Phosphorylation of PKB contributes to its activation, which suppresses apoptosis and anoikis. Phosphorylation of 
GSK3β leads to its inhibition, which stabilises β-catenin and stimulates AP-1 activity. β-catenin and CREB activation via ILK and GSK3β lead to 
upregulation of cyclin D1, whereas AP-1 activates MMPs expression, thereby controlling cell migration. ILK also phosphorylates MLC, thus regulating 
smooth muscle contraction and possible cell motility in muscle cells. AP-1 − activating protein-1, CREB − cAMP responsive element binding protein, GSK3β 
− glycogen synthase 3β, ILK – integrin linked kinase, Lef-1 − leukocyte enhancing factor-1, MLC – myosin light chain, MMP – matrix mettaloproteinase, 
PI3K − phosphoinositide 3-OH kinase, PIP3 − phosphatidylinositol (3,4,5) triphosphate, PKB – protein kinase B, PTEN – phosphatase and tensin homolog. 
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Figure 3: Signalling Pathways Activated by ILK. 
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cyclin D1-Cdk4 and cyclin E-Cdk2 kinases. Important regulatory cascades involved in 
G1-S phase transition include the MAPK and PI3K signalling pathways (Boonstra and 
Moes, 2005). Activation of ILK via PI3K, leads to GSK3β inhibition, which results in 
the activation of the transcription factor AP-1 (Persad and Dedhar, 2003). This together 
with β-catenin/TCF, and the transcription factor CREB, may be responsible for ILK-
mediated upregulation of cyclin D1 expression (D’Amico et al., 2000; Cordes and van 
Beuningen, 2003). All these responses lead to progression through G1 and into the S 
phase of the cell cycle. 
 
The p16-cyclin D1-Cdk4-Rb pathway is central to the regulation of the G1-S phase 
transition and alterations or mutations in this pathway are encountered in most human 
cancers, the most prominent being cyclin D1 (Bill et al., 2004; Roy and Thompson, 
2006). Cyclin D1 is responsible for the phosphorylation of various substrates including 
the Rb protein. The partial phosphorylation of Rb results in liberation of transcription 
factors, predominantly the ones belonging to the E2F family, which in turn activate 
various genes responsible for the progression through S phase (Dysan, 1998; Pankov et 
al., 2004; Walker and Assoian, 2005). Cyclin D1 has been implicated in the 
pathogenesis of various cancers. For example, induction of cyclin D1 in breast cancer 
cell lines shortens G1 and results in an increase in the number of cells progressing 
through G1 (Musgrove et al., 1994). In addition overexpression of cyclin D1 is 
correlated with progression of oral tongue and colorectal carcinoma (Wu et al., 2005; 
Wang et al., 2006). 
 
Integrins have been established to have direct implications with regards to cell cycle 
control and cyclin D1. Studies have shown that induction of cyclin D1 requires 
sustained ERK activity. It has been reported that in fibroblasts cell adhesion to 
fibronectin and activation of α5β1 is necessary for the prolonged ERK activity (Roovers 
and Assoian, 2003). While this is suggested to occur upstream of Ras other sites have 
been proposed to occur downstream of Ras, either between Ras and Raf (Lin et al., 
1997), or Raf and MEK (Renshaw et al., 1997). Dissecting the roles of the α2 
cytoplasmic domain of the α2β1 integrins revealed that distinct residues within the α2 
cytoplasmic tail are required for cell cycle progression in response to insulin leading to 
sustained ERK activity (Kiekotka et al., 2001; Damsky and Ilic, 2002). In another 
 35
study, integrin-mediated adhesion regulated secretion of macrophage migration 
inhibitory factor (MIF), which, together with growth factor receptors, sustained ERK 
activity, induced cyclin D1 and stimulated S phase entry (Liao et al., 2003). Integrin are 
thus capable of sustaining ERK activity, which occurs via numerous signalling 
pathways including FAK, Src and p130CAS (Crk associated substrate) (Barberis et al., 
2000; Walker and Assoian, 2005). 
 
Adhesion to the ECM is also required for progression of cells through the G and into the 
S phase of the cell cycle (Hulleman et al., 1999; Bhadriraju and Hansen, 2004). When 
this adhesion is lost, cells arrest in the G1 phase of the cell cycle and undergo apoptosis 
(Danen and Yamada, 2001).  However, ILK, which is capable of causing reduction in 
cell adhesion to ECM, as well as anchorage independent growth, is a specific correlate 
of tumour growth in vivo, may be involved directly in by-passing this apoptotic 
pathway. 
 
1.5.2 Anchorage Independence 
In normal cells, anchorage adhesion constraints exist in order to prevent unsuitable 
localisation of cells (Frisch and Francis, 1994; Valentijn et al., 2004). These survival 
restraints are breached in transformed cells, and these cells posses the ability to survive 
and grow in inappropriate environments in vivo (Wang, 2004; Redding and Juliano, 
2005). It could be reasoned that transformation requires matrix-independent survival 
(Frisch and Francis, 1994). Upon detachment from the substratum normal fibroblasts 
undergo growth arrest while normal epithelial cells undergo apoptosis, a phenomenon 
known as ‘anoikis’ (Grossman, 2002; Wang, 2004). Without apoptosis, detached cells 
could possibly reattach to inappropriately localised matrices, and resume growth (Frisch 
and Francis, 1994). However, apoptosis occurring in normal detached cells would 
abrogate this escape mechanism. The ability of cancer cells to proliferate in the absence 
of adhesion to ECM proteins is termed anchorage independence of growth (Schwartz, 
1997). Tumour cells are generally resistant to anoikis and can proliferate in the absence 
of anchorage to the ECM (Giancotti and Ruoslahti, 1999). 
 
The mechanism for the induction of apoptosis in response to cell detachment from the 
substratum is not clear but both the mitochondria and death-receptor –mediated 
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activation of apoptotic caspases are likely to be involved (Grossman, 2002; Valentijn et 
al., 2004). In order to maintain appropriate cell numbers, as well as tissue organisation 
in certain cell types such as lymphocytes and neurons, programmed cell death 
(apoptosis) is vitally important (Frisch and Francis, 1994; Wang, 2004). Lack of matrix 
attachment could stringently restrict inappropriate growth by inducing apoptosis 
(Attwell et al., 2000).  
 
The incorrect localisation, as occurs in metastasis, is a characteristic that distinguishes 
malignant from benign tumours (Schwartz, 1997). For some time anchorage 
independent cell proliferation has been considered as a hallmark of malignant 
transformation (Attwell et al., 2000; Wang, 2004). The migratory, invasive and anoikis-
resistant capability of cancer cells provides them with the metastatic potential 
(Schwartz, 1997; Wang, 2004). This may explain their propensity to leave their original 
site and metastasise.  
 
In order for adherent cells to survive, they must anchor to an appropriate ECM 
molecule, and this anchorage occurs via the integrin molecules (Valentijn et al., 2004; 
Wang, 2004). The requirement for a specific integrin as the mediator of the attachment 
may provide a safety factor, as it would facilitate the destruction of cells that have 
attached at an inappropriate tissue location (Giancotti and Ruoslahti, 1999).  
Initiation of apoptosis requires caspase activation in most cells which ultimately 
permeabilises the outer mitochondrial membrane (OMM) (Martinou and Green, 2001). 
This releases a host of factors into the cytosol, whose combined effect is caspase 
activation (Valentijn et al., 2004). Cytochrome C acts as a cofactor for the recruitment 
of caspase-9 in to the apoptotic protease activation factor 1 (APAF-1), resulting in its 
cleavage and activation. OMM permeabilisation initiates the whole caspase cascade, 
culminating in cell death (Valentijn et al., 2004). In this regard, members of the Bcl-2 
family contribute to OMM permeabilisation (Cory and Adams, 2002), which is 
necessary for cell death. 
 
There are a wide variety of stimuli that promote the apoptotic pathway. What will be 
discussed next are some of the important pathways known to be involved in regulating 
anchorage-independent growth. These include the integrins, cadherins, 
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PI3K/PKB/GSK3β signalling as well as the importance of growth factor signalling. 
Furthermore, the relevance of ILK to apoptosis will be considered. 
 
Interestingly, SCC cells remain anchorage-dependent and generally fail to survive in the 
absence of cell-ECM adhesions (Kramer et al., 2005). Understanding why SCCs require 
integrin signalling to proliferate has obvious importance, since it is difficult to explain 
the extensive intratumoural growth that occurs in vivo, where the cells do not have 
access to integrin engagement and FAK activation (Kramer et al., 2005). Activated 
integrins signal through a vast array of signalling cascades that are activated by tyrosine 
kinase growth factor receptors (Damsky and Ilic, 2002; Juliano, 2002). The activation of 
FAK, which, as mentioned above, is vital to many cellular processes (Kramer et al., 
2005) may impinge upon survival pathways. Indeed, FAK is capable of activating the 
PI3K signalling pathway, which has important consequences in cell survival (Sawai et 
al., 2005). 
 
The ECM is able to control anoikis in an integrin-specific manner. For example, the 
α5β1 integrin binds to fibronectin and induces the expression of the anti-apoptotic 
protein Bcl-2 protecting cells from apoptosis (Zhang et al., 1995). Other integrins, 
including another fibronectin receptor αvβ1, do not provide this survival effect, whereas 
the αvβ3 integrin provides endothelial and melanoma cell survival (Stromblad et al., 
1996; Giancotti and Ruoslahti, 1999). A study by Janes and Watt (2004) recently 
discovered a function of the αvβ5 integrin in promoting anoikis in H357 SCC cells. 
These authors demonstrate that when the αvβ5 integrin is replaced with αvβ6 integrin, 
anoikis is prevented. Thus it is implied that overexpression of αvβ6 may confer a 
survival advantage in SCCs. Other potential survival pathways include activation of Shc 
by the α1β1, α5β1 and αvβ3 integrins (Giancotti and Ruoslahti, 1999). Adhesion 
mediated Shc-linked integrins promote cell survival and progression through the G1 
phase of the cell cycle in response to mitogenic growth factors, whereas adhesion 
mediated by other integrins result in exit from the cell cycle and, in certain cases, cell 
death (Pozzi et al., 1998). 
 
It has been proposed that cadherins and catenins are capable of regulating cell death and 
growth. Cell-cell contact can sometimes inhibit growth (contact inhibition of growth) 
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especially in normal cells (Kramer et al., 2005), and this has been linked to alterations 
in cyclin-dependent kinases (cdks). Previous work has implicated E-cadherin-mediated 
cell-cell adhesion in protecting head and neck SCCs from anoikis (Kantak and Kramer, 
1998). There is considerable evidence that cell-cell contacts promote cell survival in the 
absence of cell-ECM attachment. The ability of E-cadherin to induce survival signals 
may depend on their association with other signalling pathways, since cadherins 
themselves lack enzymatic activity (Kramer et al., 2005). In fact, E-cadherin has been 
demonstrated to interact with the PI3K signalling pathway in adherens junctions 
(Arregui et al., 2000). 
 
The PI3K/PKB signalling pathway plays a pivotal role in anchorage-independent 
growth. PI3K is activated in response to different mechanisms including growth factor 
receptors and integrin/ECM-mediated signalling (Wang, 2004). To ascertain the 
relevance of PI3K to anchorage-independent growth, studies revealed that the colony-
forming ability of v-Ros-transformed CEF cells was inhibited upon treatment with the 
PI3K inhibitor LY294002 (Wang, 2004). Conversely, an activated PI3K was able to 
rescue the colony-forming activity of two transformation-defective mutants of v-Ros (a 
protein tyrosine kinase derived from an avian sarcoma retrovirus) (Nguyen et al., 2002; 
Wang, 2004). 
 
How PI3K signalling promotes anchorage-independent growth involves the expression 
of various cyclins and cyclin-dependent kinases (cdks) (Wang, 2004). Indeed, cyclin A-
associated Cdk activity was augmented in the v-Ros-expressing CEF, which was further 
found to be PI3K-dependent, since it was blocked by the PI3K inhibitor (Uttamsingh et 
al., 2003). In another study it was shown that EGF and TGFβ1 synergistically protect 
RIE cells from anoikis, which was also blocked by PI3K inhibitors (Wang, 2004). Thus, 
it is apparent that PI3K signalling is capable of blocking the apoptotic pathway and 
enhancing the anchorage-independent cell cycle progression at the same time.  
Growth factors are also known to participate in regulating the process of anchorage-
independence, since activation of MAPK and PKB was prolonged in the EGF- and 
TGFβ1-treated cells grown under nonadhering conditions. This leads to the 
phosphorylation and inactivation of pro-apoptotic proteins such as GSK3β and 
forkhead-related transcription factor (FKHRL1) as well as decreased levels of cyclin 
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inhibitor p27KIP1 and p16TNK4a (Wang, 2004). It has previously been shown that 
inhibition of EGF signalling upregulates another proapoptotic factor, Bim. 
Downregulation of EGF occurs in MCF10A epithelial cells after prolonged removal 
from ECM (Reginato et al., 2003). It was found that small interfering RNA against Bim 
significantly reduced apoptosis over this time period suggesting that Bim may 
contribute to anoikis in some cells (Frisch, 1999). 
 
Suppression of apoptosis and anoikis is one of the consequences of constitutive ILK 
activation in mammalian cells (Attwell et al., 2000; Persad et al., 2000). Both of these 
effects involve ILK-mediated activation of PKB/Akt and suppression of caspase 3 
activation (refer to Figure 2 and Wu and Dedhar, 2001; Pinkse et al., 2005). PKB is a 
serine/threonine kinase (Persad et al., 2000; Yoganathan et al., 2000), which is activated 
in response to PI3K (Yoganathan et al., 2000; Vara et al., 2004; Yau et al., 2005). PKB 
also regulates several transcription factors including E2F, CREB, and the forkhead 
family member Daf-16 (Scheid and Woodgett, 2000). Furthermore, PKB is capable of 
directly or indirectly phosphorylating and inactivating pro-apoptotic proteins such as 
caspase-9, Bad and FKHRL1 (Tang et al., 1999; Pap and Cooper, 2002; Rossig et al., 
2002). It also appears that the nuclear factor of kappa light chain gene enhancer in B-
cells (NF-κB) family of transcription factors is a target of PKB, as shown in the Jurkat 
T cell line (Sizemore et al., 1999). The induction of NF-κB would have serious 
implications on T cell growth and survival (Kane et al., 1999; Yoganathan et al., 2000). 
It remains to be established however, whether ILK also modulates NF-κB activity 
through PKB (Yoganathan et al., 2000). 
 
What has been discovered is that mammary gland tumours arise in ILK transgenic mice, 
and the tumour tissues exhibit many of the hallmarks of ILK overexpression in tissue 
culture cells (Wu and Dedhar, 2001). These include phosphorylation of PKB/Akt and 
GSK3β but also downregulation of E-cadherin expression and phosphorylation and 
activation of extracellular signal-regulated kinase (ERK) (White et al., 2001; Wu and 
Dedhar, 2001). As outlined above, PKB, GSK3β and E-cadherin are all possible 
mediators of apoptosis. Since ILK is implicated in the regulation of these molecules, 
emphasises how important ILK is to apoptotic events. 
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1.6 Aberrant ILK/Integrin Expression in Tumour Progression and 
Metastasis 
Most cancer deaths result from the invasion of surrounding tissues and widespread 
metastasis to vital organs. Adhesion and detachment of tumour cells to one another and 
to heterologous cells may play a decisive role in metastatic spread at several levels 
(Qian et al., 1994). Cell adhesion events can therefore be considered as critical in 
tumour metastasis (Danen et al., 1998; Wang, 2004) and cell-matrix alterations are an 
essential prerequisite step in the metastatic cascade (Hart and Saini, 1992). 
 
The metastatic process has traditionally been viewed as consisting of the following 
steps: (1) detachment of individual cells from the primary lesion, (2) invasion of local 
stroma, (3) entry of single cells or aggregates of tumour cells into blood vessels directly 
or via the lymphatic channels (intravasation), (4) arrest in the vasculature followed by 
extravasation, and (5) invasion into the parenchyma of the target organ site with the 
resulting establishment of secondary lesions (Qian et al., 1994; Brodt, 1996b; Kurschat 
and Mauch, 2000). Numerous studies have confirmed that the steps involved in 
metastasis entail changes in the adhesive properties of the tumour cells (Stroeken et al., 
1998; Zutter et al., 1998). The cellular effects mediated by integrin expression in 
tumour invasion may only be empirically related to cell-matrix adhesion. Loss of 
integrin expression may predispose cells to tumour progression by the loss of regulatory 
control over growth and differentiation (Gui et al., 1997). 
 
During the multi-step process of malignant transformation, cancer progression, and 
tumour cell invasion, malignant cells encounter and interact with components of the 
extracellular matrix at several crucial steps (Giancotti and Mainiero, 1994; Zutter et al., 
1998). It was shown by Dedhar and Saulnier (1990), that treatment of human osteogenic 
sarcoma (HOS) cell lines with N-methyl-N’-nitro-N-Nitrosoguanidine (MNNG), a 
potent carcinogen, altered integrin expression. The MNNG treated cells exhibited 
greater invasiveness in an in vitro model. In this example, transformation was 
associated with morphologic alterations and increased invasiveness, suggesting that 
changes in integrin receptors might contribute to changes in cell phenotype associated 
with malignant transformation (Zutter et al., 1998). A report on colonic tumours showed 
that changes in the level of expression or activity of integrin receptors are thought to be 
involved in its progression (Pouliot et al., 2000). Furthermore, colonic tumours 
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generally exhibit altered ECM composition in their basement membranes. Thus, 
changes in their microenvironment and in the adhesive properties of colonic tumours 
are thought to contribute to the progression of the disease (Pouliot et al., 2000). 
 
Altered expression levels of integrin receptors have been associated with malignant 
spread of many cancers. For example, reduced α3 integrin subunit expression has been 
found in breast, colorectal, and pancreatic carcinomas (Zutter et al., 1998). Furthermore, 
expression of the β4 integrin subunit was decreased in many breast, prostate, and basal 
cell carcinomas, but expression was increased in other subtypes of carcinoma including 
squamous cell carcinoma (Zutter et al., 1998). In squamous cell carcinoma of the 
larynx, it has been demonstrated that α5β1 is upregulated (Charalabopoulos et al., 2005). 
With regards to malignant melanoma, upregulation of the αv, α2 and α3 integrin 
subunits was reported, whereas the α6 integrin subunit was shown to be decreased 
(Kuphal et al., 2005). Studies in mammary epithelial cells showed that loss of 
expression of the laminin and collagen receptor, α2β1, is correlated with a transformed 
phenotype (Taverna et al., 1998).  
 
In many instances, increased expression of other integrins correlates with tumour 
progression in many metastatic tumours such as increased α3β1 integrin. Several other 
carcinomas of the lung, colon, bladder, head, and neck show increased levels of α6 
integrin, whereas αvβ3 is upregulated in breast cancer (Taverna et al., 1998; Felding-
Habermann et al., 2001). In squamous cell carcinomas it has been revealed that 
considerable variation in integrin expression, both between tumours and in different 
regions of the same tumour occurs (Watt, 2002). The integrin most heavily implicated 
in epithelial carcinogenesis is α6β4 (Mercurio and Rabinovitz, 2001). Overexpression of 
α6β4 has been reported in human oral cancer (van Waes et al., 1991). Within a given 
tumour, α6β4 overexpression occurs in the suprabasal layers with focal loss of α6β4 at 
the tumour margin (Downer et al., 1993). Moreover, the α6β4 integrin is implicated in 
promoting the migration, invasion, and survival of carcinoma cells (Chung and 
Mercurio, 2004). These data suggest that ECM molecules and their receptors can act 
either as suppressors, or promoters, of tumour progression. 
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The stimulation of intracellular signalling processes is caused by integrin engagement 
involving molecules such as focal-adhesion kinase (FAK), Shc, Cas and the mitogen-
activated protein (MAP) kinase cascade (refer to Figure 1a and 1b, pg 15). The 
regulation of these signals, that are transmitted to the MAP kinase signalling pathway, 
are controlled by cell adhesion, which results in the alteration of the activation of MAP 
kinase kinase (MEK) or Raf (Schwartz, 1997). What remains unclear however, are the 
events proximal to the integrin receptor initiating such signals (Dedhar et al., 1999). 
ILK participates in fundamental cellular processes such as cell-ECM interactions and 
intracellular signal transduction pathways. By regulating relatively modest changes, 
such as alterations in expression or activity, ILK might contribute to the pathogenesis of 
cancers that involve alterations in cell proliferation and cell-ECM interactions (Attwell 
et al., 2003; Ito et al., 2003). 
 
Studies have suggested that ILK is overexpressed in several human tumours, including 
Ewing’s sarcoma, primitive neuroectodermal tumour and medullablastoma (Chung et 
al., 1998; Dedhar et al., 1999; Wu, 1999). Furthermore, ILK has been shown to induce 
an invasive phenotype in brain tumour cell lines (Troussard et al., 2000). ILK 
expression has also shown to be upregulated by constitutively active ErbB-2 (Xie et al., 
1998), a member of the EGF receptor family that has been implicated in 
tumourigenesis. Furthermore, overexpression of ILK in epithelial cells induces tumour 
formation in vivo (Wu et al., 1998). Recently, it has been reported that ILK correlates 
with invasion and metastasis in gastric carcinoma as well as laryngeal squamous cell 
carcinomas (Ito et al., 2003; Wu et al., 2006), and expression of ILK is associated with 
the tumourigenesis and progression of prostate cancer (Graff et al., 2001). Further 
studies have revealed that increased ILK expression is correlated with sorter survival in 
non-small cell lung cancer (Takanami, 2005), and is able to promote the invasive 
behaviour of ovarian carcinoma (Ahmed et al., 2004; Rosano et al., 2006). 
 
ILK function and expression are of vital importance with regard to many cellular 
aspects of malignant transformation and acts as a receptor-proximal effector in the 
crossmodulation between growth factor response and integrin signalling (Sheppard, 
2005). Growth factor overexpression is known to be involved in many highly invasive 
squamous carcinomas (Yomamoto et al., 1986; Veale and Thornley, 1989; Mariotti et 
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al., 2001). Their connection with integrins and particularly ILK is vital to the 
understanding of cell-ECM adhesion in the multistep development of carcinogenesis. 
 
1.7 ILK/Integrin Link to Growth Factor Signalling 
The similarities that exist between integrin-mediated signalling and growth factor 
receptor-mediated signalling suggest the possibility of crosstalk between these 
signalling pathways (Coppolino and Dedhar, 2000; Janji et al., 2000; Persad and 
Dedhar, 2003; Grashoff et al., 2004; Sheppard, 2005). Indeed, only under appropriate 
cell attachment conditions are the receptors for insulin, platelet-derived growth factor 
(PDGF), EGF, and vascular epithelial growth factor (VEGF) optimally activated by 
their ligands (Giancotti and Ruoslahti, 1999). An example of this relationship comes 
from a study by Chung et al. (2004) who clearly demonstrated that VEGF expression 
depends on the α6β4 integrin since it functions in concert with hypoxia to activate 
hypoxia inducible factor-1 (HIF-1) and stimulate VEGF transcription. It is well 
established that growth factors are capable of activating the Ras-Raf-MEK-Erk signal 
transduction pathway. Sustained Erk activity is essential for the proliferation of 
fibroblasts, which is activated by integrin-mediated cell adhesion to ECM (Danen and 
Yamada, 2001). Furthermore, growth factors are known to be associated with the 
metastatic process and are capable of influencing cell motility (Tong et al., 2000).  
 
Numerous reports have confirmed that there is an interaction between the integrin and 
growth factor receptors (Delcommenne et al., 1998; Dedhar et al., 1999; Janji et al., 
2000; Persad and Dedhar, 2003). Coppolino and Dedhar (2000) showed involvement of 
the α5β1 and β1 integrins with growth factors, where it was demonstrated that α5β1 
mediates fibronectin-induced epithelial proliferation through activation of the EGF 
receptors. Further evidence for the association of growth factors and integrins has been 
shown by the α5β3 integrin receptor, which immunoprecipitated in complexes with the 
PDGF and VEGF receptors. In addition, it has been reported that the αvβ1, αvβ5 and 
αvβ6 integrins are capable of directly associating with the latency peptide of TGFβ. 
While the significance of the binding αvβ1 and αvβ5 is not known, it has clearly been 
shown that αvβ6 binding induces the activation of latent complexes of TGFβ (Crawford 
et al., 1998). The functional importance of this pathway is proposed to influence 
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fibrosis of multiple epithelial organs (Sheppard, 2005). The aggregation of the growth 
factor receptor results in their partial activation and enables crosstalk between integrins 
and growth factor receptors (Coppolino and Dedhar, 2000). 
 
Growth factor involvement has been shown to be a central component during the 
progression of many cancers. For example, EGF and TGF’s, which are probably the 
most well defined growth factors, are involved in highly malignant and invasive breast 
cancer (Welch et al., 1990; Klijn et al., 1992; Wang et al., 1998; Tong et al., 2000), as 
well as other highly invasive squamous carcinoma cells (Tennenbaum et al., 1996 cited 
in Mariotti et al., 2001). These include malignancies of the bladder, breast and lung 
(Sainsbury et al., 1985; Ozanne et al., 1986 cited in Mayer et al., 2000). Furthermore, 
EGFR and PDGFR expression are highest during the early stages of cervical cancer 
progression (Mayer et al., 2000). Mariotti et al. (2001) have demonstrated the necessity 
of EGFR activation and β4 integrin tail phosphorylation in epithelial cell migration and 
invasion. This occurs by EGFR association with α6β4 and the induction of 
phosphorylation of the β4 cytoplasmic domain through the Src family kinase Fyn 
(Mariotti et al., 2001).  
 
From these data it becomes obvious that integrins play an important role in growth 
factor modulation. Growth factors have been shown to affect the expression of the 
integrin receptors (Lai et al., 2000; Pouliot et al., 2000; Yu et al., 2000; Lim et al., 
2001), but the interaction between these two classes of receptors is not direct. As ILK is 
known to influence both the integrin class of receptors and the growth factor receptors it 
is a prime candidate for mediating the link between integrins and growth factors 
(Delcommenne et al., 1998; Janji et al., 2000; Atwell et al., 2003; Pinkse et al., 2005). 
 
ILK serves not only as a molecular scaffold at the cell-ECM adhesion sites, but due to 
its interactions with integrins, it is capable of providing a link between integrin-
mediated signalling and the growth factor signalling pathways, as well as being 
favourably positioned to directly regulate metastatic processes. The four non-catalytic 
ankyrin repeats of ILK help target ILK to focal adhesion complexes and link it to 
growth factor receptor tyrosine kinase signalling via the adaptor protein PINCH/Unc 97 
(Li et al., 1999; Somasiri et al., 2000). 
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It has already been noted that PINCH binding to ILK is crucial for ILK focal adhesion 
localisation. This occurs through the N-terminal ANK repeat domain of ILK binding to 
PINCH. What has not been mentioned is the fact that the ILK-PINCH interaction 
connects ILK to Nck-2, a SH2-SH3-containing adaptor protein (Wu, 1999). The fourth 
LIM domain of PINCH interacts with Nck-2 and, it is thought that Nck-2 plays a unique 
role in connecting the growth factor signalling pathway with the PINCH-ILK complex 
and thus the integrin signalling pathway (Fukuda et al., 2003; Wu, 2004). Both Nck-2 
and PINCH are recruited to activate EGFR and PDGF receptors via the SH2 domain of 
Nck-2 (Figure 4 and Dedhar et al., 1999). Unlike ILK, PINCH does not contain a 
catalytic domain, and thus the primary role of PINCH is to mediate these types of 
intermolecular interactions (Wu, 1999; Fukuda et al., 2003; Grashoff et al., 2004; 
Boulter et al., 2006). Downstream signalling pathways involved in apoptosis, and the 
promotion of cell survival through PKB and GSK3β appear to be coupled to growth 
factors and integrins via ILK (Delcommenne et al., 1998; Troussard et al., 2000; Cordes 
and van Beuningen, 2003; Kaneko et al., 2004; Watanabe et al., 2005). TGF-β1 and 
EGF play an important role in controlling the proliferation, survival, morphology, and 
motility of epithelial cells (Pouliot et al., 2000).  
 
In colon cancer cells, the control of the in vitro proliferation by EGF receptor 
stimulation exerts profound effects on cellular morphology (Pouliot et al., 2000). 
Integrins have been reported to form complexes with EGF (and other growth factors) 
receptors to modulate their functions (Miyamoto et al., 1995; Pouliot et al., 2000). 
Moro et al. (1998) have shown that integrins are capable of inducing EGF receptor 
tyrosine phosphorylation in the absence of EGF receptor ligands, leading to activation 
of a typical EGF receptor pathway that involved Shc phosphorylation and MAP kinase 
activation. The consequence of MAPK activation is the induction of transcription of 
proteases, such as urokinase-type plasminogen activator (uPA), which could affect cell 
motility and invasion, and transcription of proteins that induce angiogenesis, such as 
VEGF (McCormick, 1999; Byzova et al., 2000; Watanabe et al., 2005). Furthermore, 
integrin-dependent EGF receptor activation is important in anchorage-dependent cell 
survival (Moro et al., 1998). Thus, there is considerable crosstalk between the integrin 
and growth factor receptors, which is likely to be important in the development and 
progression of tumours (Pouliot et al., 2000; Danen and Yamada, 2001). 
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1.8 Relevance of ILK to Human Oesophageal SCCs 
The alterations in the adhesive events that are necessary in the processes of invasion and 
metastasis are regulated primarily by integrins (Stroeken et al., 1998; Zutter et al., 
1998). Loss of cell-ECM adhesion allows for the migration of cells and the 
establishment of secondary tumours at sites distant from the primary tumour. The 
importance of cell adhesion molecules in oesophageal carcinoma has been investigated 
extensively. A study by Zhao et al. (2003) addressing the expression of E-cadherin, α-, 
β-, and γ-catenin in oesophageal SCCs revealed a reduction in all these molecules which 
correlated closely with tumour grade. Considering integrin expression, Miller and Veale 
(2001) demonstrated that the αv integrin subunit is strongly expressed in HOSCCs. 
Downregulation of α2 and β1 integrins were also reported, implying that cell adhesion 
may be decreased and migration promoted in HOSCCs. Another study showed that the 
β1 integrin was correlated with lymph node metastasis in HOSCC (Takayama et al., 
2003). These studies highlight the importance of CAMs such as cadherins and integrins 
to the development and progression of HOSCC. 
 
Since ILK is closely associated with the integrin receptors it is highly probable that this 
protein kinase has a crucial influence on HOSCCs. The importance of ILK in tumour 
development and metastasis has been established in many other carcinomas. 
Upregulation of activity and expression have been shown in advanced prostate cancers 
(Persad et al., 2000; Graff et al., 2001), colonic polyposis, gastric, non-small cell lung 
cancer and colorectal cancers (Marotta et al., 2001; Ito et al., 2003; Takanami, 2005). 
 
Even though the importance of ILK in oesophageal carcinoma has not yet been 
documented, its role as a diagnostic marker of tumours with primitive neural 
differentiation has been shown previously (Chung et al., 1998). What is of particular 
interest to us is the role of ILK in cell-ECM adhesion, with the possibility of ILK being 
a potential adhesion marker in carcinoma of the oesophagus.  
 
The coupling of ILK to the growth factor receptors or components of growth factor signalling, such as IRS-1 are mediated by the adaptor proteins, PINCH and 
Nck-2. PINCH mediates interactions with the SH3 domain of Nck-2 that associates with growth factors via its SH2 domain. The ILK-PINCH complex also 
ensures the correct localisation of ILK at focal adhesion plaques. This is accomplished via the interaction between the LIM1 domain of PINCH and the ANK1 
repeat of ILK. The kinase domain of ILK is capable of phosphorylating PKB and GSK3β, which impinges cellular events such as cell survival, differentiation 
and cell proliferation. GFRs – growth factor receptors, GSK3β - glycogen synthase 3β,  ILK – integrin linked kinase, IR – insulin receptor, PINCH – 
particularly interesting new calponon homology domain containing protein and PI3K – phosphoinositide 3-OH kinase, PKB – protein kinase B. 
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Figure 4: The Link between ILK and Growth Factor Receptor Signalling. 
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Oesophageal carcinoma remains largely prevalent amongst the black population in 
South Africa, predominantly in rural regions of the Transkei and Soweto (Kneebone and 
Mannell, 1985; Isaacson, 2005). It also shows high incidence in areas such as France, 
China, Japan, northern Iran, India, Thailand, and South America regions (Kneebone and 
Mannell, 1985; Launoy et al., 1997; Saidi et al., 2000; Lehrbach et al., 2003; Kazemi-
Noureini et al., 2004; Zhang et al., 2004). The exposure of oesophageal cells to 
exogenous agents such as food, alcohol, smoke and endogenous causes (e.g. genetic) as 
well as inflammation of oesophagus tissue, together with racial and cultural habits have 
been accounted for high incidence in these geographical regions (Kazemi-Noureini et 
al., 2004). Late presentation, together with the propensity of the disease to metastasise 
(Quint et al., 1995) makes surgical resection difficult. The development of oesophageal 
carcinoma is a multistep, progressive process. An early indicator of this process is an 
increased proliferation of oesophageal epithelial cells morphologically including basal 
cell hyperplasia, dysplasia, carcinoma in situ and advanced HOSCC (Lehrbach et al., 
2003).  
 
Patients with oesophageal carcinoma have a very poor survival rate, with contributing 
factors being the delay in diagnosis, as well as patients being unaware of cancer being 
the cause of their symptoms (Mufti et al., 1997; Rothwell et al., 1997), and are 
intensified by the inaccuracy of clinical staging (Adelstein et al., 1997). In South Africa 
the 50 % mortality period are 3.6 months for males and 4.2 months for females (Walker 
et al., 1984). Over the years the prognosis has not changed significantly and remains as 
one of the most lethal of all cancers (Gore, 1997; Friess et al., 1999; Isaacson, 2005). 
 
1.9 Aims 
Since ILK has far-reaching effects in both normal and pathological conditions, and is 
overexpressed in numerous malignancies (Dedhar et al., 1999; Marotta et al., 2000) the 
aims of this investigation were: 
i) Firstly, to examine the distribution of ILK in human OSCCs. This would 
potentially suggest the functional role of ILK. 
ii) Secondly, to discern the effects of growth factors on both ILK expression 
and activity, and to establish the link, if any, between ILK and growth factor 
signalling pathways in HOSCCs, and finally, 
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iii) To examine the role of ILK activity in cell-ECM adhesion in moderately 
differentiated oesophageal squamous cell carcinoma cell lines, with a view 
to providing insight as to whether ILK is directly involved in integrin 
mediated processes. 
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Chapter 2 
Identification and Localisation of ILK in Human Oesophageal 
SCCs 
 
2.1 Introduction 
Epithelial cells require that the integrin-mediated interactions of cells are tightly 
regulated, as it is these processes that are vital in the maintenance of tissue structure and 
differentiation (Gumbiner, 1996; Zhang et al., 2002; Khyrul et al., 2004; Quélo et al., 
2004; Wu, 2004). When considering cell-ECM adhesion, the integrin class of adhesion 
receptors, which consist of α and β subunits are particularly important. Notably, they 
are directly linked to the processes of invasion and metastasis of tumours (Stroeken et 
al., 1998; Zutter et al., 1998; Takanami et al., 2005). Closely associated with the 
integrin receptors is ILK, which, by being in close proximity to the β integrins, is able 
to interact with and regulate integrin activity (Zhang et al., 2002; Grashoff et al., 2004; 
Khyrul et al., 2004; Quélo et al., 2004; Chun et al., 2005; Takanami et al., 2005). As a 
consequence ILK is thought to directly regulate the processes of cell-ECM adhesion 
(Dai et al., 2003; Pinkse et al., 2005; Boulter et al., 2006).  
 
The presence of ILK has been identified in numerous normal tissues including kidney, 
lung, prostate, colon, brain, stomach and liver (Li et al., 1999; Janji et al., 2000; Persad 
et al., 2000; Kaneko et al., 2004; Hannigan et al., 2005; Takanami et al., 2005). 
Myocardiac cells and skeletal muscle fibres show highest expression levels of ILK 
(Chung et al., 1998) where it directs processes such as cell survival, cell differentiation, 
and cell cycle progression (Radeva et al., 1997; Delcommenne et al., 1998; D’Amico et 
al., 2000; Wu and Dedhar, 2001; Atwell et al., 2003; Quélo et al., 2004; Wu, 2004). 
ILK is also thought to play a central role in invasion processes since its overexpression 
has been reported to increase invasiveness in rat intestinal epithelial cells (Novak et al., 
1998; Takanami, 2005). When considering ILK expression in tumours, this widespread 
protein kinase is consistently overexpressed in tumours such as Ewing’s sarcoma, 
primitive neuroectodermal tumour and medullablastoma and is thus considered a 
marker of tumours with neural differentiation (Chung et al., 1998; Li et al., 1999; Wu, 
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1999). On the other hand, small round sarcomas have been found to be negative for ILK 
expression (Chung et al., 1998). Furthermore, ILK overexpression and activity has also 
been noted in tumours of the breast, prostate, brain and colon (Li et al., 1999; Persad et 
al., 2000; Troussard et al., 2000; Tan et al., 2001; Yoganathan et al., 2002; Aoyagi et 
al., 2005). 
 
It is particularly noteworthy that only one previous study has considered ILK expression 
in oesophagus (Janji et al., 2000). Furthermore, since this study was conducted on 
normal cat oesophagus, it does not demonstrate the functional role of ILK in human 
oesophageal carcinoma. This, together with the fact that ILK mediates integrin-growth 
factor signalling events in both normal (Boudreau and Jones, 1999; Wu and Dedhar, 
2001) and malignant phenotypes (Chung et al., 1998; Yoganathan et al., 2000), has 
prompted this investigation into examining ILK expression in human oesophageal SCC 
cell lines. The determination of ILK expression will allow further our understanding of 
the possible role/s played by ILK during invasion and metastasis.  
 
ILK is found in focal adhesion sites (Hannigan et al., 1996; Mulrooney et al., 2000; 
Nikolopoulos and Turner, 2001; Chun et al., 2005) and fibrillar adhesion (Guo et al., 
2001) thus placing ILK in a suitable location for the regulation of the β integrin subunits 
(Coppolino and Dedhar, 2000; Nikolopoulos and Turner, 2002; Quélo et al., 2004). A 
prime example of this role, is the demonstration that ILK overexpression in epithelial 
cells causes suppression of integrin-mediated adhesion (Radeva et al., 1997; Coppolino 
& Dedhar, 2000; Hannigan et al., 2001).  
 
To fully appreciate the intricacies of ILK function in mammalian cells, and particularly 
in carcinoma of the oesophagus, it must be pointed out that two isoforms of ILK exist, 
namely, ILK1 and ILK2 (Janji et al., 2000). Both isoforms share characteristics such as 
sequence identity and protein cross-reactivity (Janji et al., 2000). However, a major 
difference between these isoforms is that the ILK1 gene contains a unique BamHI 
restriction site and the ILK2 gene a unique HincII restriction site, which are important 
with regards to identification. Although extremely similar in most respects, ILK2 is not 
as widely expressed as ILK1, with ILK2 being found in only certain malignancies (Janji 
et al., 2000). 
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An important facet to ILK signalling that requires further consideration, are growth 
factor receptors. Growth factor receptors are able to directly impinge upon both the 
integrin and ILK signalling pathways. The effects of two important growth factors, 
namely, EGF and TGFβ1, may have important implications when considering ILK 
function in SCC. EGF, which serves to relay signals from the external environment to 
the internal cytoplasm (Mayer et al., 2000), affects a host of cellular responses, 
including cell growth, apoptosis, cell cycle progression, and cellular differentiation 
(Ozanne et al., 1986; Rosenfeld et al., 1987; Frish and Ruoslahti, 1997; Giancotti, 1997; 
Yu et al., 2000; Dikic et al., 2003). This indicates that EGF is a potent effector of key 
signalling molecules during normal signalling cascades. Moreover, in tumour cells, 
EGF expression is crucial during the progression of cancer, including metastatic spread 
and inhibition of apoptosis (Wells, 1999; Andl et al., 2003). Increased EGFR levels 
have also been noted in a host of epithelial malignancies, including breast, bladder, lung 
and more pertinently cells of squamous origin (Sainsbury et al., 1985; Ozanne et al., 
1986 cited in Yu et al., 2000; Wang et al., 1998; Andl et al., 2003). It has been 
demonstrated by Mayer et al. (2000) that unregulated expression of EGF receptors is 
one of the early steps during the development of cervical carcinogenesis. This has also 
been suggested to be the case for oesophageal SCCs (Andl et al., 2003). 
 
The significance of TGFβ1 is highlighted by the fact that a loss of response to TGFβ1 is 
exhibited by numerous malignancies including colon, gastric, endometrial, ovarian, and 
cervix, which is in term associated with malignant conversion and progression (Akhurst 
and Derynck, 2001; Teicher, 2001). In addition, the ability of TGFβ1 to act as both a 
tumour suppressor and as a major stimulator of tumour progression, invasion and 
metastasis further emphasises the importance of this signalling cytokine in oesophageal 
carcinoma (Akhurst and Derynck, 2001). Interestingly, however, TGFβ1 is generally 
regarded as an inhibitor of epithelial cell growth (Gotzmann et al., 2001; Hu and 
Zuckerman, 2001; Kim et al., 2004). Carcinoma of the oesophagus particularly, 
demonstrates reduced TGFβ1 expression, which is correlated with depth of invasion, 
lymph node metastasis and poor prognosis (Fukai et al., 2003). 
 
ILK is thought to act as a mediator between growth factor receptors, such as EGF and 
TGFβ1, and integrin signalling pathways (Delcommenne et al., 1998) (see Chapter 1, 
Figure 2). It is known that increased numbers of EGF receptors are present on the 
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membranes of the human oesophageal carcinoma cell lines examined in this study 
(Veale and Thornley, 1989; Andl et al., 2003). Thus it must be borne in mind that when 
examining ILK expression in oesophageal SCCs, the effects of growth factor receptors 
may well be a major contributing factor to the way in which ILK transduces cellular 
signals.  
 
This study examines and compares the expression of ILK in five cell lines derived from 
moderately differentiated human squamous cell carcinomas of the oesophagus. To 
achieve this end, it was first necessary to determine if ILK was expressed in the 
oesophageal SCCs examined and secondly, whether exogenous growth factors effected 
the expression of ILK in this group of cell lines. 
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2.2 Methods and Materials 
 
2.2.1 Cell Lines 
Five South African moderately differentiated human oesophageal squamous cell 
carcinoma cell lines WHCO1, WHCO3, WHCO5, WHCO6 (Veale and Thornley, 1989) 
and SNO (Bey et al., 1976) were obtained from the Cell Biology Laboratory, School of 
Molecular and Cell Biology, University of the Witwatersrand. Medium was removed 
and cells washed twice with pre-warmed (37 °C) phosphate buffered saline (PBS, 
Appendix 1.1.1). Cells were harvested using 0.05 % (w/v) trypsin and 0.01 % (w/v) 
EDTA (Appendix 1.1.2). Cell lines were cultured in 10 cm Nunc™ tissue culture dishes 
with Dulbecco’s Modified Eagles Medium (DMEM)/Hams F12 (3:1), supplemented 
with 10 % Foetal Calf (or bovine) Serum (FCS or FBS). Cultures were maintained in a 
humid, 37 °C incubator, 5 % carbon dioxide (CO2) atmosphere. 
 
Where the experiment required, cell lines were grown to 80 % confluency and treated 
with 10 ng/ml EGF and 1 ng/ml TGFβ1 for a period of 0.5, 1, 3, 6 and 24 hours 
respectively. Cells were cultured in DMEM/Hams F12 (3:1), supplemented with 10 % 
FBS and maintained in a humid, 37 °C incubator with a 5 % CO2 atmosphere. 
 
2.2.2 Total RNA Extraction 
Cells were grown to 80 % confluence in sterile 10cm Nunc™ tissue culture dishes. Cells 
were washed 3 times with cold (4 °C) sterile PBS. 1 ml of TRIzol® reagent 
(GibcoBRL) was added to the dish. TRIzol® reagent is able to maintain RNA integrity 
while disrupting cells and dissolving cell components. All glassware and apparatus that 
were used during the RNA extractions were sterilised in order to further the 
preservation of RNA integrity. Cells were scraped and pipetted into fresh eppendorf 
tubes and centrifuged at 12000 rpm for 10 minutes in a Sorvall® MC 12 V centrifuge at 
4 °C. This was followed by incubation for 5 minutes at room temperature. Chloroform 
(200 µl) was added and the tubes shaken for 15 seconds. Samples were once again 
incubated for 3 minutes at room temperature, followed by centrifugation at 12000 rpm 
for 5 minutes and the aqueous phase being transferred to a sterile eppendorf tube. 
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Isopropyl alcohol (500 µl) was added and the samples incubated for 10 minutes at room 
temperature. This was followed by centrifugation at 12000 rpm for 10 minutes. The 
supernatant was decanted and the RNA pellet washed with 1 ml EtOH (75 %). The 
samples were centrifuged at 7500 rpm in a Sorvall® MC 12 V centrifuge for 5 minutes. 
After centrifugation, the supernatant was decanted and the RNA pellet resuspended in 
40 µl dH2O and incubated at 60 °C for 10 minutes. Eppendorf tubes containing RNA of 
interest were stored at −70 °C. 
 
2.2.3 ILK Amplification by Reverse Transcription Polymerase Chain 
Reaction (RT-PCR) 
 
2.2.3.1 Reverse Transcription 
A two-step RT-PCR was carried out − this protocol has been shown to be more efficient 
in fragment amplification as opposed to the one-step RT-PCR method (Kawasaki and 
Wang, 1989; Hamaguchi, 1998). The first step, which utilised approximately 2 µg of 
total RNA, was the process of reverse transcription. To the RNA 2 µl of random 
hexamer primers (Roche, SA) was added, and incubated at 70 °C for 5 minutes. The 
reaction mixture was placed on ice for 5 minutes, which was followed by centrifugation 
at 6000 rpm in a TOMY-desktop centrifuge for 1 minute. Synthesis of cDNA was 
accomplished using a reverse transcription kit (Promega, USA) with the addition of RT 
buffer (5 µl), RNAsin (0.6 µl), dNTPs (2 µl), Moloney Murine Leukemia Virus 
(MMLV) reverse transcriptase (2 µl) and dH2O (12.4 µl) respectively. The reaction 
mixture was incubated at 37 °C for 1.5 hours. The reaction was stopped by placing the 
mixture at 90 °C for 5 minutes, placing on ice for 5 minutes and centrifuging at 6000 
rpm in a TOMY-desktop centrifuge for 2 minutes. To remove any bound DNA and 
protein, 25 µl of a phenol/chloroform (Appendix 1.2.1) mixture was added and 
centrifuged in a TOMY-desktop centrifuge for 2 minutes. The aqueous phase was 
removed and transferred to a sterile eppendorf tube. To precipitate cDNA products 100 
µl Ethanol (EtOH 100 %) and 3 µl sodium acetate (NaAc, 3 M, pH 5.2) (Appendix 
1.2.2) solutions were added and the samples precipitated overnight at −20 °C. The 
following day, the mixture was centrifuged at 12000 rpm in a Sorvall® MC 12 V 
 56
centrifuge for 30 minutes. The supernatant was decanted, and the cDNA pellet 
resuspended in 10 µl dH2O. cDNA products were stored at −70 °C. 
 
2.2.3.2 Polymerase Chain Reaction (PCR) 
The second step was standard PCR protocol. The ILK primers used were obtained from 
a previously published ILK cDNA sequence from Janji et al. (2000). These primers 
consisted of an antisense primer (30mer) corresponding to the published ILK nucleotide 
sequence 1359-1341 (Hannigan et al., 1996) with a XhoI restriction site (CTCGAG): 5’-
CTCGAGCTACTTGTCCTGCATCTTCTCAAG-3’. The upstream sense primer was a 
32mer corresponding to the ILK nucleotide sequence 1-21 with an EcoRI restriction site 
(GAATTC) and two additional nucleotides (GT) before the start codon ATG: 5’- 
GAATTCGTATGGACGACATTTTCACTCAGTGC-3’.  
 
The cDNA was amplified for 30 cycles on a Perkin Elmer GeneAmp PCR System. The 
cycling program included a 95 °C denaturation step, a 1 minute annealing step at 50 °C 
and a 2 minute extension step at 72 °C, followed by a final elongation at 72 °C for 10 
minutes. RT-PCR products were visualised on a 2 % agarose gel (Appendix 1.5.1) 
following ethidium bromide (EtBr, 10 µg/ml) staining. Minnie Agarose HE 33 gel units 
(Hoefer Scientific, USA) were used, which were filled with 1× Tris acetic acid 
ethylenediamine tetraacetic (EDTA) acid solution (TAE) (Appendix 1.5.3) diluted from 
a 20× TAE stock solution (Appendix 1.5.2). 
 
2.2.4 Antibodies 
ILK was specifically detected with a rabbit polyclonal antibody obtained from Sigma® 
Laboratories, USA. Polyclonal horseradish peroxidase (HRP)-bound anti-rabbit 
secondary antibody was used in Western blot experiments (Separations, SA). 
Monoclonal mouse anti-human β3 antibody (Chemicon, USA) and Fluoroscine 
isothiocyanate (FITC)-conjugated anti-rabbit (or anti-mouse for β3 detection) secondary 
antibody from Chappel, USA were used in the immunofluorescence experiments. 
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2.2.5 Triton X-100-based Extraction 
A Triton X-100 extraction protocol was performed which has been shown to preserve 
integrin integrity (Giancotti and Ruoslahti, 1990). This extraction protocol enriches both 
membrane and cytoplasmic associated proteins. Cell lines were grown to 80 % 
confluence in 10 cm Nunc™ tissue culture dishes. To isolate ILK, which is found 
associated with integrins at cell membranes a Triton X-100 extraction was performed on 
each of the various cell lines. The cultures were washed three times with sterile PBS at 
4 °C and scraped from the culture dishes with a rubber policeman in PBS containing 
phenyl-methyl-sulphonyl fluoride (PMSF)/Aprotinin (Trasylol® Bayer, SA) protease 
inhibitor stock solution (Appendix 1.3.2). The cell suspension was centrifuged at 6000 
rpm in a TOMY-desktop centrifuge for 1 minute. The PBS supernatant was removed 
and the cell pellet suspended in 400 µl of a Tris-based Triton-X100 (pH 8.5) extraction 
buffer (Appendix 1.3.3) and incubated for 1 hour on ice. Thereafter, samples were 
centrifuged at 12000 rpm in a Sorvall® MC 12 V centrifuge for 10 minutes at 4 °C and 
the supernatants decanted into a sterile eppendorf and stored at −70 °C. 
 
2.2.6 Protein Estimation 
Equivalent protein concentrations were determined using the commercial BioRad 
protein G assay kit II (catalogue number: 500-0002). However, reliable absorbance 
readings could not be obtained as the Triton X-100 detergent concentration present in 
the extraction buffer caused interference. It is mentioned in the BioRad protocol manual 
that a Triton X-100 concentration of 0.1 % is compatible with the BioRad solution. 
Subsequent dilutions of the buffer however, resulted in precipitation of proteins. Thus, 
the protein estimation was accomplished utilising the Bradford assay (Bradford, 1976) 
following the protocol from Bramhall et al. (1969). Whatman® glass fibre discs were 
first rinsed in dH2O for 20 minutes to remove any loose fibres, followed by 5 minute 
washes in 95 % alcohol, 100 % alcohol and acetone respectively, to dehydrate the discs, 
which were subsequently allowed to air dry. A standard curve was constructed using 
bovine serum albumin (BSA, Appendix 1.3.4). Following air drying, protein samples (1 
µl) from each respective cell line was spotted onto the glass fibre discs and again 
allowed to air dry for 5 minutes. To fix proteins to the glass fibre discs, the discs were 
placed in 2.5 % trichloroacetic acid (TCA, Appendix 1.3.5), for 30-40 minutes with 
gentle agitation. Thereafter the discs were immersed in Coomassie blue stain (Appendix 
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1.3.6) for 5 minutes to rinse off excess TCA. The discs were then stained in Coomassie 
blue for 1 hour and destained in an acetic acid:methanol:dH2O (10:12:100) solution for 
2 hours, until the background levels were completely removed. Destained dots were 
excised from the discs and placed in 5 ml of elution buffer (Appendix 1.3.7) in a 
darkroom overnight. The following day absorbance readings were measured using a 
Beckman DU®-64 Spectrophotometer (λ=595nm). The concentration of the total 
protein was calculated from the BSA standard curve (y=0.0634x−0.01, R2=0.9639, 
Appendix 2.1). The graphs were plotted using Microsoft® Excel. 
 
2.2.7 Antibody Binding Assays for Primary and Secondary Antibodies 
The functionality of the primary and secondary antibodies was tested using dot blots. To 
ensure that the primary ILK antibody was specific to ILK protein, the supplied ILK-
peptide (1 µl of a 50 mg/ml solution, Zymed® Lab. Inc.), which is a synthetic peptide 
derived from the C-terminus of human ILK, was spotted onto a piece of nitrocellulose 
Hybond™-C, and allowed to air dry for 10 minutes. The nitrocellulose was blocked in a 
casein-based blocking buffer (BLOTTO, Appendix 1.4.1) for 5 minutes. The 
nitrocellulose membrane was incubated in the polyclonal rabbit anti-ILK primary 
antibody (1:250) for 2 hours. To ensure binding of the primary ILK antibody to HRP-
bound secondary antibody, a second nitrocellulose blot was prepared containing 1 µl of 
preabsorbed ILK antibody blocked for 5 minutes. Both membranes were washed 6 
times with ice cold PBS at 5-minute intervals and incubated with HRP-bound anti-
rabbit secondary antibody (1:1500) for 1 hour. The nitrocellulose pieces were once 
again washed 6 times with PBS at 5-minute intervals. In conjunction with this, a third 
nitrocellulose blot was prepared that contained preabsorbed HRP-bound secondary 
antibody (1 µl). This blot was also washed 6× in PBS with 5-minute intervals and 
immersed in BLOTTO for 5 minutes. This reaction was performed to ensure reactivity 
of the secondary antibody with the Supersignal® West Pico Chemiluminescent Kit 
(Pierce, USA). Thereafter, all three blots were reacted with the Supersignal® West Pico 
Chemiluminescent Working Solution (Appendix 1.4.2) for 5 minutes. The membrane 
pieces were wrapped in polyethylene ‘saran wrap’. The reaction blots were exposed to 
hyperfilm™ MP autoradiography film (Amersham, UK) for 1.5 minutes. The film was 
placed in D19B developer (Appendix 1.4.3) for 5 minutes, washed in water briefly, 
placed in fixer (Appendix 1.4.4) for 5 minutes and washed once again. 
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2.2.8 Polypeptide Resolution and Western Blotting 
Samples were resolved on 10 % Sodium dodecyl Sulphate (SDS) polyacrylamide gels 
(Appendix 1.5.4) according to Laemmli, (1970) and, resolved at a constant current of 18 
milliamperes (mA) with electrophoresis running buffer pH 8.3 (Appendix 1.5.5), and 
visualised with Coomassie Blue protein stain (see Appendix 1.3.6). Equivalent protein 
concentrations (10 µg/ml) were made up to equal volumes with 1× lysis buffer 
(Appendix 1.5.6), boiled for 5 minutes and centrifuged briefly for 1 minute in a TOMY-
desktop centrifuge prior to loading. Samples from cell lines WHCO1, WHCO3, 
WHCO5, WHCO6 and SNO were resolved on polyacrylamide gels, and transferred to 
Nitrobind nitrocellulose transfer membrane (MSI, USA), in a BioRad Trans-Blot™ Cell 
at 400 mA for 3 hours (4 °C) in Western Blot Transfer Buffer (Appendix 1.4.5). After 
transfer was complete, the nitrocellulose membranes were rinsed twice with PBS (see 
Appendix 1.1.1), and stored overnight at 4 °C.  
 
Each membrane was blocked in BLOTTO (see Appendix 1.4.1) for 5 minutes to prevent 
non-specific antibody binding and washed 6 times in PBS. The blots were incubated in 
a rabbit anti-ILK primary antibody (1:250) for 2 hours. Washing was performed 6 times 
at 5-minute intervals with PBS to remove any residual antibody. Membranes were 
incubated with a HRP-bound secondary anti-rabbit antibody (1:1500) for 1 hour in the 
dark. Once again membranes were washed 6 times at 5-minute intervals with PBS 
before being exposed to the Supersignal® West Pico Working Solution (see Appendix 
1.4.2) from the West Pico Chemiluminescent Substrate Kit (Pierce, USA) for 5 minutes. 
Blots were sealed in polyethylene ‘saran wrap’ and exposed to hyperfilm™ MP 
autoradiography film (Amersham, UK) for 1.5 minutes. Film was developed in D19B 
developer (see Appendix 1.4.3) for 5 minutes, rinsed briefly in H2O before fixing (see 
Appendix 1.4.4) for 5 minutes. The experiment was repeated three times. 
 
2.2.9 Purification of ILK PCR Fragments and Restriction Digests 
ILK RT-PCR products were purified using a QIAGEN® QIAquick PCR Purification 
Kit (50) (Catalogue Number 28104, Germany). Buffer PB (5 volumes) was added to the 
PCR reaction mixture (1 volume) and adding the mixture to a QIAquick column. The 
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column was centrifuged for 1 minute at 12000 rpm in a Sorvall® MC 12 V centrifuge. 
The flow-through was discarded and 750 µl of buffer PE added to the column and 
centrifuged for 1 minute. The flow-through was once again discarded and the sample 
centrifuged for an additional minute. The column was placed in a sterile eppendorf tube, 
and 50 µl dH20 was added. The column was allowed to stand for 1 minute. The column 
was then centrifuged for 1 minute at 12000 rpm to elute the DNA. DNA was stored at 
−70 °C. 
 
Restriction digests were performed by firstly adding 10 µl of purified ILK product from 
each respective cell line into a sterile eppendorf tube. This was followed by the addition 
of buffer K (1.5 µl), dH20 (1.5 µl) and BamH1 (2 µl, 0.5 units/µg). Samples were 
incubated for 1.5 hours at 37 °C. Subsequent digestions were cleared of protein by the 
addition of 25 µl phenol/chloroform (see Appendix 1.2.1). Samples were centrifuged at 
6000 rpm in a TOMY-desktop centrifuge for 2 minutes and the aqueous phase removed 
and transferred to a sterile eppendorf tube. Chloroform (25 µl) was added and the 
solution centrifuged once again at 6000 rpm for 2 minutes. The aqueous phase was 
decanted into a sterile eppendorf tube. Both 0.7 M EtOH (100 µl) and 3 M NaAc pH 5.2 
(3 µl) (Appendix 1.2.2) were added to the aqueous phase and the samples allowed to 
precipitate DNA overnight at −20 °C. The following day the samples were centrifuged 
at 12000 rpm for 20 minutes in a Sorvall® MC 12 V centrifuge. The supernatant was 
decanted and the DNA pellet resuspended in 1.5 µl dH20. Products were visualised by 2 
% agarose gel electophoresis (see Appendix 1.5.1) following EtBr (10 µg/ml) staining. 
 
Digests were also performed with the HincII restriction enzyme. 10 µl of purified ILK 
product was used in the reaction from WHCO1, WHCO3, WHCO5, WHCO6 and SNO 
cell lines. Buffer M (1.5 µl) was pipetted into the reaction mixture followed by the 
addition of dH2O (1.5 µl) and HincII (1.5 µl, 0.1 units/µg). Samples were restricted for 
1.5 hours. Procedure was then carried out as per the BamH1 digestions above. 
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2.2.10 Co-immunoprecipitation of ILK and the β3 Integrin Subunit 
Cell lysates were preabsorbed with protein G sepharose beads overnight at 4 °C, and 
centrifuged at 3000 rpm. The supernatant was transferred to fresh eppendorf tubes and 
incubated with 10 µl monoclonal mouse anti-human integrin β3 antibody (Chemicon, 
USA) overnight at 4 °C. The following day protein G sepharose beads (100 µl) 
(Amersham, SA) were added to the immune complex for 4 hours. The protein G-ILK1-
β3 complex was centrifuged at 3000 rpm in a Sorvall® MC 12 V centrifuge for 2 
minutes. The supernatant was decanted, and 800 µl Tris.HCl buffer pH 8.0 added. 
Centrifugation was performed once again at 3000 rpm. This washing step was repeated 
twice more. The supernatant was decanted and an equal volume (10 µl) of double lysis 
buffer (Appendix 1.6.4) was added to the pellet. The suspension was boiled for 5 
minutes and centrifuged for 10 minutes at 12000 rpm in a Sorvall® MC 12 V 
centrifuge. The product was resolved on an 8 % SDS-PAGE gel (Appendix 1.5.4) and 
transferred to nitrocellulose for 3 hours as in Methods and Material Section 2.2.8. The 
blot was probed for ILK and the β3 integrin subunit using standard antibody 
concentrations. Blots were then exposed to the Supersignal® West Pico Working 
Solution (see Appendix 1.4.2) for 5 minutes, sealed in polyethylene ‘glad wrap’ and 
then exposed to hyperfilm™ MP autoradiography film (Amersham, UK) for 1.5 
minutes. Film was developed in D19B developer (see Appendix 1.4.3) for 5 minutes, 
rinsed briefly in H2O, before fixing (see Appendix 1.4.4) for 5 minutes. 
 
2.2.11 Indirect Immunofluorescence Microscopy 
The localisation of ILK and the β3 integrin subunit was performed utilising indirect 
immunofluorescence microscopy. The WHCO1, WHCO3, WHCO5, WHCO6 and SNO 
cell lines were grown to 80 % confluency and seeded onto sterile glass coverslips. 
Coverslips were washed five times in cold PBS, fixed with 4 % paraformaldehyde 
(Appendix 1.6.1) for 30 minutes and washed again with PBS. Coverslips were 
immersed in 0.25 % Triton X-100 (Appendix 1.6.2) for 10 minutes to permeabilise the 
cells, washed twice with PBS, dipped into dH2O, and allowed to dry partially. This 
allowed the DAKO® pen (Denmark) to adhere properly to the glass coverslips. Two 
circles or wells per coverslip were drawn with the DAKO® pen to create a fluid barrier. 
One well per coverslip was incubated with a polyclonal rabbit anti-ILK primary 
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antibody (1:250) for one hour or with a monoclonal mouse anti-β3 primary antibody 
(1:250). The other well was incubated in PBS (control). This was followed by a 
thorough washing in PBS as before. All circled areas were incubated with an anti-rabbit 
Fluorescine Isothiocyanate (FITC)-conjugated anti-rabbit antibody (1:250) for ILK and 
FITC-conjugated anti-mouse antibody (1:250) for the β3 integrin. Both wells were 
incubated for one hour in the dark. The coverslips were washed six times with sterile 
PBS and then mounted with Elvanol mounting agent (Appendix 1.6.3) onto sterilised 
glass slides. All incubations were carried out in a humidity chamber to prevent 
desiccation. Slides were viewed under a Zeiss LSM 410 confocal microscope (FITC 
excitation 490nm, emission 525nm). 
 
2.2.12 Nuclear Extraction 
Nuclear extractions were performed utilising the CelLytic™ NuCLEAR™ Extraction Kit 
(Sigma, USA). Cells were grown to 80 % confluency and washed twice with PBS and 
subsequently scraped into PBS. Cells were centrifuged for 5 minutes at 3000 rpm. The 
supernatant was decanted and the packed cell volume (PCV) was estimated. Thereafter, 
500 µl of a hypotonic 1× lysis buffer (5 µl 0.1 M DTT, 5 µl protease inhibitor cocktail) 
was added to the PCV. The cell pellet was gently resuspended while avoiding foam 
formation. Packed cells were incubated on ice for 17 minutes, which allowed the cells 
to swell. A 10 % Igepal CA-630 solution was added to a final concentration of 0.6 % 
(i.e. 30 µl per 500 µl hypotonic lysis buffer). The cells were subsequently vortexed 
vigorously for 10 seconds and immediately centrifuged for 30 seconds at 12000 rpm. 
The supernatants, which constituted the cytoplasmic fractions, were transferred to fresh 
eppendorf tubes. To 98 µl of the extraction buffer, 1 µl 0.1 M DTT solution and 1 µl 
protease inhibitor cocktail were added. The crude nuclei were resuspended in 80 µl of 
the above extraction buffer. Eppendorf tubes containing the crude nuclei were incubated 
on ice and placed on a shaker for 30 minutes. Thereafter, the subsequent nuclear 
extracts were centrifuged for 5 minutes at 30000 rpm. Supernatants were transferred to 
fresh chilled eppendorf tubes, snap-frozen and stored at −70 °C. 
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2.2.13 Densitometry 
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) was 
used for densitometric analysis to quantitatively determine the concentration level of 
ILK in the Western blots. Note: the densitometric analysis results are an average of 3 
separate repeated experiments. 
 
2.2.14 Image Capturing 
Images were captured on a Hewlard Packard Scanjet 4400c series scanner. 
Magnification, contrast and brightness of all images were standardised using Adobe 
Photoshop Version 7. 
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2.3 Results 
 
2.3.1 Human Oesophageal SCCs Express ILK 
Transcription of the ILK gene in the oesophageal SCC cell lines examined was 
elucidated by firstly extracting total RNA from the five oesophageal carcinoma cell 
lines. Since the TRIzol® reagent allows for rapid and efficient extraction of total RNA, 
intact RNA was successfully obtained for all cell lines (Figure 5a, lanes 2 and 3, blue 
arrow, WHCO1 and WHCO5 total RNA characteristic of all cell lines). Reverse 
transcription followed RNA extraction, which yielded representative cDNA across all 
cell lines (For precise determination of ILK mRNA expression levels real time PCR 
would have been necessary). The subsequent PCR analysis produced a strong ILK 
fragment of approximately 1360 bp for the WHCO1, WHCO3, WHCO5, WHCO6 and 
the SNO cell lines as indicated by the red arrow in Figure 5b, which corresponds to the 
size of ILK published by Janji et al. (2000). The β-catenin transcript was included in the 
experiment as a positive control and is marked in Figure 5b by the yellow arrow in lane 
4. The identification of ILK mRNA provides novel evidence of active transcription 
processes of the ilk gene in human carcinoma of the oesophagus (Figure 5c, green 
arrow). 
 
The identification of ILK mRNA in these cell lines lead to the next logical question of 
whether ILK mRNA was being translated to ILK protein. To answer this question the 
Triton X-100 protein fractions from both the pellet and the supernatant were resolved on 
SDS-PAGE. The polypeptide profiles from the protein fractions supernatant samples 
only showed a band at 59 kDa, which is corroborated by reports from Hannigan et al. 
(1996), Li et al. (1999), and Friedrich et al. (2002) (Figure 6a, lanes 3-7, blue arrow). In 
contrast, the pellet fractions demonstrated a banding pattern of proteins from 
approximately 45 kDa and lower (Figure 6b, lane 1, black arrow). The pellets comprise 
cytoskeletal constituents of the cell, which are insoluble in the Triton X-100 extraction 
buffer used. Since Triton X-100 is a non-ionic detergent, it is able to readily solubilise 
the hydrophilic lipid bi-layer present in cell membranes, but is unable to solubilise 
filamentous actin and intermediate filaments, which contain hydrophobic residues.  
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Before proceeding with Western blot analysis, dot blot techniques were performed to 
confirm antibody reactivity and binding and to ascertain optimal antibody 
concentrations for Western analysis. A synthetic ILK peptide (Zymed® Lab. Inc.), 
derived from the C-terminus of human ILK, was preabsorbed onto nitrocellulose. This 
peptide demonstrated strong reactivity, following incubation in the ILK antibody and 
HRP-bound secondary antibodies, with the Supersignal® West Pico Chemiluminescent 
substrate (Figure 6c). This dot blot was included as a positive control for the specificity 
of the rabbit anti-ILK primary antibody. The two other dot blots demonstrated that the 
rabbit anti-ILK primary antibody (1:250) was able to bind the HRP-bound anti-rabbit 
secondary antibody (Figure 6d) efficiently and that the HRP-bound secondary antibody 
(1:1500) was reacting with the Supersignal® West Pico Chemiluminescent substrate 
(Figure 6e). 
 
Subsequent Western blotting analysis revealed the presence of an ILK band, specifically 
recognised by anti-ILK antibody at an apparent molecular weight of 59 kDa. ILK 
expression was confirmed in the supernatant fraction for all cell lines (Figure 7a, 
indicated by red arrow). Densitometric analysis further revealed that for standardised 
loading concentrations of cytoplasmic extracts, ILK protein expression levels were 
relatively uniform across the WHCO3, WHCO5 and SNO cell lines (per µg of total 
cellular protein extracted). However, the WHCO1 cell line, which displayed highest 
ILK expression, had ILK levels approximately 1.85 fold higher in comparison to 
WHCO6 cells and approximately 1.30 fold higher than the WHCO3, WHCO5 and SNO 
cell lines. On the other hand, WHCO6 cells showed lowest expression levels of ILK 
approximately 0.68 fold lower than the WHCO3, WHCO5 and SNO cell lines (Figure 
7b). These experiments are representative of three separate repeats.  
 
With this in mind, the trend suggested that ILK protein expression levels in the 
WHCO3, WHCO5, and SNO cell lines are not appreciably different from each other, 
whereas the noticeable difference in ILK expression in WHCO1 and WHCO6 in 
comparison to the other cell lines may well be significant. Note, due to the multi-
repeats, which is essentially pseudoreplication this experiment did not lend itself to 
typical statistical analysis leading to a test of true significance. 
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As mentioned in the introduction to this chapter, two isoforms of ILK (ILK1 and ILK2) 
are known to exist and although they share similar characteristics with regards to 
structure and function, these ILK isoforms are predominantly expressed in certain 
tissues (Janji et al, 2000). Indeed, whereas ILK1 has been found in the majority of 
tissue types, ILK2 is only expressed in two highly metastatic melanoma and 
fibrosarcoma tumour cell lines and, has not been identified in normal adult tissues (Janji 
et al., 2000). In light of this, identifying isoform expression in carcinoma of the 
oesophagus was of interest. Restriction fragment analysis utilising the BamH1 and 
HincII restriction enzymes showed ILK to be digested by BamH1 producing two 
fragments of approximately 823 (Figure 8a, red arrow) and 536 bp (Figure 8a, green 
arrow) respectively. Digestion of the ILK fragment did not occur with the HincII 
restriction enzyme, where a single ILK band of 1359 bp was observed (Figure 8b, lanes 
2, 4, 6, 8, and 10, yellow arrow) confirming that these oesophageal SCC cell lines only 
express the ILK1 protein isoform. 
 
To summarise the data obtained thus far, this constitutes a clear demonstration that the 
transcriptional and translational activities of the ILK gene are intact in all cell lines 
tested. Furthermore, it has been shown that the ILK1 isoform is expressed in 
oesophageal SCCs, which although not surprising, supports the notion of ILK1 as being 
widely expressed in mammalian tissues. Since this study does not examine the ILK2 
isoform, the ILK1 isoform will be referred to as ILK during the remainder of this report. 
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Figure 5: RT-PCR Analysis of ILK Expression in HOSSCs Cultured In Vitro. 
a) WHCO1 and WHCO5 total RNA characteristic of all cell lines extracted with 
TRIzol® reagent. Lane 1 = molecular weight marker (1 kb), lane 2 = WHCO1 total 
RNA, lane 3 = WHCO5 total RNA (blue arrow). b) ILK PCR product at a molecular 
weight of approximately 1360 bp. Lane 1 = molecular weight marker (1 kb), lane 2 = 
ILK PCR product (lane 2, red arrow), lane 3 and 4 = β-catenin positive control (yellow 
arrow), lane 5 = Absence of ILK fragment, negative control. c) Full ILK transcript of 
the WHCO1, WHCO3, WHCO5, WHCO6 and SNO cell lines. Lane 1 = 1 kb marker, 
lanes 2-6 = 1360 bp ILK PCR fragment (green arrow). ILK total RNA and RT-PCR 
products were resolved on 2 % agarose gels following EtBr staining (10 µg/ml). Note: 
bands indicated by purple arrow are primer dimer. 
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Figure 6: SDS-PAGE Resolution of Triton X-100-Based Extracts.  
a) Triton X-100-based extracts of all human oesophageal SCC cell lines resolved on 10 
% SDS-PAGE. Lane 1 = molecular weight protein marker, lanes 3-7 = protein profiles 
of supernatant lysates. The ILK protein is approximately located in the area marked by 
the blue arrow. It was further revealed that ILK was a component of the supernatant 
fraction (b - indicated by the black arrow, lane 2). Lane 1 = pellet fraction separated by 
SDS-PAGE, lane 2 = supernatant separated by SDS-PAGE, lane 3 = low molecular 
weight marker. Dot blots revealed that the rabbit anti-ILK primary antibody (1:250) was 
specific for ILK (c) and able to bind rabbit HRP-bound secondary antibody (d). 
Furthermore, the rabbit HRP-bound secondary antibody (1:1500) was shown to react 
with the Supersignal® West Pico chemiluminescent substrate (e). Note: due to the 
sensitivity of the chemiluminescent substrate a very bright reaction occurred with the 
HRP-bound secondary antibody, which accounts for the scatter in (e). Note: the 
expression levels are representative as a percentage of maximum per 10 µg of protein 
from concentrated fractions (included to normalise for loading variation). 
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Figure 7: Western Blot and Densitometric Analysis of ILK Expression Levels.  
a) Western blots utilising a rabbit anti-ILK antibody (1:1500) performed on the 
supernatant extracts (10 µg) revealed ILK expression at approximately 59 kDa across 
all cell lines (indicated by orange arrow). Lane 1 – WHCO1, lane 2 – WHCO3, lane 3 – 
WHCO5, lane 4 – WHCO6 and lane 5 – SNO. Note: Western blotting procedures were 
only performed on the supernatant extracts, which were composed of soluble 
components of the cell, whereas the pellets consisted of insoluble cytoskeletal elements. 
b) Densitometric analysis revealed a relative uniform expression of ILK between the 
WHCO3, WHCO5 and SNO cell lines whereas the WHCO1 and WHCO6 cell lines 
showed dissimilar protein expression under standard culture conditions. The WHCO1 
cell line demonstrated the highest expression of ILK – 1.85 fold higher than ILK 
expression in the WHCO6 (lowest ILK expression) cell line and 1.3 fold higher than the 
WHCO3, WHCO5 and SNO cell lines. Note: the expression levels are representative as 
a percentage of maximum per 10 µg of protein from concentrated fractions (included to 
normalise for loading variation). Experiments were repeated three times. 
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Figure 8: Restriction Fragment Analysis of the Full ILK Transcript.  
a) Restriction digests using BamH1 (0.5 units/µg) producing two bands of 823 (red 
arrow) and 536 bp (green arrow) respectively. Lane 1 – 1 kb molecular weight marker, 
lanes 2, 4, 6, and 8 – BamHI digestions for WHCO1, WHCO3, WHCO5, and WHCO6 
respectively. Lanes 3, 5, 7 and 9 – ILK cDNA (blue arrow). b) HincII (0.1 units/µg) 
digestion shows one unrestricted band of 1359 bp (yellow arrow). Lane 1 – 1 kb 
molecular weight marker, lanes 2, 4, 6, 8 and 10 – ILK DNA following HincII 
restriction enzyme addition for WHCO1, WHCO3, WHCO5, WHCO6, and SNO cell 
lines respectively, lanes 3, 6, 9 and 11 – ILK product with no addition of restriction 
enzymes for the respective cell lines. Restricted ILK fragments were resolved on 2 % 
agarose gels following EtBr staining (10 µg/ml). 
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2.3.2 ILK and β3 Integrin Association 
Co-localisation between the β1 and β3 integrin subunits and ILK has been shown 
previously in platelets, kidney, mammary epithelial cells and prostate carcinoma cell 
lines (Hannigan et al., 1996; Dedhar et al., 1999; Janji et al., 2000; Zervas et al., 2001; 
Yamaji et al., 2002) but has not been reported in carcinoma of the oesophagus. Thus, 
the possibility of a similar interaction between ILK and the β3 integrin subunit was 
sought in oesophageal carcinoma cell lines. To ascertain if the association was 
occurring between the β3 integrins and ILK would give an indication of ILK integrin 
regulatory functions in oesophageal SCCs. Co-immunoprecipitation analysis was 
performed in order to confirm this interaction. Indeed, ILK and the β3 integrin subunit 
were shown to co-immunoprecipitate in all cell lines tested, indicating an ILK and β3 
integrin subunit association. A band of approximately 88 kDa for the β3 subunit and a 
band of 59 kDa for ILK were obtained following protein G sepharose 
immunoprecipitation and Western blotting (Figure 9, β3–purple arrow, ILK–orange 
arrow). As a reminder to the reader that the extract that was used for the co-
immunoprecipitation analysis was preabsorbed with protein G and therefore there 
cannot be non-specific protein G associated products (see Methods and Meterials). 
 
2.3.3 Cellular Localisation of ILK and Integrin β3
The majority of cells and tissues including intestinal, spleen, kidney and thymus cells 
show ILK to be predominantly located at focal adhesion sites (Hannigan et al., 1996; Li 
et al., 1999; Nikolopoulos and Turner, 2001; Zhang et al., 2002). At this position it 
associates principally with the β1 and β3 integrin subunits (Dedhar et al., 1999; 
Friedrich et al., 2002). This pattern of ILK localisation is consistent for a role of ILK in 
regulating cell-ECM adhesion. Since ILK localisation has not yet been determined in 
oesophageal carcinoma the questions that needed to be asked were: What ILK pattern of 
distribution exists in oesophageal SCCs, and is there a relationship between ILK and β3 
integrin subunit localisation in these cell lines?  
 
ILK and β3 integrin subunit visualisation was accomplished for each of the oesophageal 
SCC cell lines. The distribution of ILK is at a cytoplasmic and nuclear level (Figure 
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10a-e, red arrows) in oesophageal SCC cell lines with a smaller proportion being 
distributed at the membrane (Figure 10a-e, yellow arrows). The distribution of the β3 
integrin subunit was predominantly at the membrane. To define what was considered as 
a membrane distribution as opposed to a cytoplasmic distribution, the following criteria 
were used. A distinct intercellular distribution was considered as membrane associated 
while distribution across the cell with a more diffuse staining was considered as 
cytoplasmic associated. These data support the notion obtained by co-
immunoprecipitation that ILK and β3 integrin are indeed associated in HOSCCs. The 
two corresponding controls where firstly, primary ILK antibody was excluded from the 
experiment, and secondly, ILK was preabsorbed with the ILK peptide, which both 
indicated negligible staining, signifying that non-specific binding is extremely low 
(Figure 10f).  
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Figure 9: Co-immunoprecipitation Analysis Between β3 Integrin and ILK. 
Protein G sepharose co-immunoprecipitation between ILK and the β3 integrin in the 
SNO cell line, utilising a mouse anti-β3 antibody (10 µl) and Western blotting with 
mouse anti-β3 antibody (1:1500) and rabbit anti-ILK antibody (1:250), which was 
characteristic of all cell lines. Lane 1 − a band of 88 kDa for the β3 integrin subunit 
(purple arrow) and a 59 kDa ILK band (orange arrow) were obtained in all five cell 
lines, lane 2 − molecular weight marker. Note: Immunoprecipitation was also 
accomplished utilising Staphylococcus aureus cells. However, protein G sepharose is 
the active constituent of S.aureus cells and shows increased specificity towards 
antibodies. Furthermore, protein G sepharose beads are now the commercially accepted 
alternative for co-immunoprecipitation analysis and were thus the preferred choice. 
 74
 
a) WHCO1    b) WHCO3 
 
 
 
 
 
 
 
 
c) WHCO5    d) WHCO6 
 
 
 
 
 
 
 
 
e) SNO  f) WHCO1 
 
 
 
 
 
 
 
 
 
 75
g) Control 
 
 
 
 
 
 
 
 
 
Figure 10: Indirect Immunofluorescence of ILK in HOSCC Lines Cultured In 
Vitro.  
a-e) Immunofluorescence microscopy utilising a polyclonal rabbit anti-ILK antibody 
(1:250) or a monoclonal mouse anti-β3 antibody (1:250) and an rabbit anti-FITC-
conjugated anti-rabbit antibody (1:250) for ILK and a FITC-conjugated anti-mouse 
antibody (1:250) for the β3 integrin. ILK expressed by HOSCCs showing variable 
amounts of ILK distribution with majority of ILK being located at a 
nuclear/cytoplasmic region (red arrows). A smaller proportion of ILK was also localised 
at the plasma membrane as indicated by the yellow arrows f) Predominant β3 integrin 
subunit localisation occurring at the plasma membrane (blue arrows) in the WHCO1 
cell line, which was characteristic of all cell lines examined g) Negative control 
(excluding FITC-conjugated antibody) demonstrating negligible diffuse staining. Bar 
represents 10 µm. 
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2.3.4 Nuclear ILK Protein Levels 
To ensure that the nuclear localisation of ILK demonstrated was a true reflection of ILK 
distribution, we performed Western blotting analysis of nuclear extracts. Indeed, ILK 
was expressed at 59 kDa in nuclear fractions for the five cell lines (Figure 11a). 
Although it appeared from the confocal microscopy analysis that ILK was localised 
primarily in the nuclear/cytoplasmic region, Western analysis revealed that ILK levels 
in the membrane/cytoplasmic region were considerably higher than nuclear ILK protein 
levels per µg of total protein (densitometry). Furthermore, within the nuclear extracts, 
ILK levels were similar across the WHCO1, WHCO3, WHCO5 and WHCO6 cell lines. 
In contrast, the SNO cell line demonstrated a marked decrease in ILK expression, on 
average 3 fold lower by comparison to the other four cell lines (Figure 11b). 
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Figure 11: Nuclear ILK Protein Levels. 
a) Western blot analysis utilising a rabbit anti-ILK antibody (1:1500) revealed that ILK 
is expressed in nuclear extracts (10 µg) at a molecular weight of 59 kDa. Lane 1 – 
WHCO1, lane 2 – WHCO3, lane 3 – WHCO5, lane 4 – WHCO6 and lane 5 – SNO. b) 
Nuclear ILK concentration levels as analysed by densitometry. Expression levels were 
relatively uniform across the WHCO1, WHCO5, and WHCO6 cell lines. Lowest 
nuclear ILK concentration was observed in the SNO cell line, on average 3 fold lower 
than the WHCO1, WHCO3, WHCO5 and WHCO6 cell lines. Note: the expression 
levels are representative as a percentage of maximum per 10 µg of protein from 
concentrated fractions (included to normalise for loading variation). Experiments were 
repeated three times. 
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2.3.5 ILK Expression is Stimulated by EGF and TGFβ1 Growth Factors 
 
2.3.5.1 Effect of EGF on ILK Expression 
Overexpression of the EGFR is a common occurrence in squamous tumours and has 
been demonstrated in malignancies of the neck, lung, cervix, skin (Ozanne et al., 1986) 
and more pertinently, squamous carcinoma of the oesophagus (Ozanne et al., 1986; 
Veale and Thornley, 1989; Andl et al., 2003). With the knowledge that a link exists 
between the growth factor receptor activation and integrin receptors (Giancotti and 
Ruoslahti, 1999), and due to increased EGFR expression, specifically in theses SCCs, 
EGFR was an important molecule to consider when elucidating the role of ILK in 
HOSCCs. Thus it became necessary to explore EGF effects on ILK expression in these 
human oesophageal squamous carcinoma cell lines. 
 
To clarify the response of ILK expression to EGF, cells were exposed to EGF (10 
ng/ml) for a period of 0.5, 1, 3, 6 and 24 hours respectively (Figure 12a). It must be 
remembered that equivalent protein concentrations (10 µg) were loaded onto SDS-
PAGE gels prior to Western blotting. The data obtained, following densitometry, is 
indicative of a vast increase in the expression levels of ILK in oesophageal SCC cell 
lines following treatment with EGF. In interpreting the growth factor data, we 
considered a 1.2 fold increase (equivalent to 20 %), to be an appreciable increase in ILK 
expression levels. All subsequent fold increases are compared to an untreated control, 
unless otherwise stipulated. 
 
Exposure to EGF generally produced an increase in ILK expression in the five 
oesophageal carcinoma cell lines, although there was some variation in the increases 
observed. Similar ILK expression levels were observed in the WHCO1, WHCO5 and 
SNO cell lines, whereas the levels in the WHCO3 and WHCO6 cell lines each 
responded somewhat differently to EGF treatment (Figure 12b). 
 
In the WHCO1 cell line, highest ILK expression was noted after 1 hour EGF exposure 
where a increase of 1.8 fold was noted. These ILK levels were maintained through to 24 
hours where a 1.3 fold increase was observed. Similarly, the WHCO3 and WHCO5 cell 
lines produced similar trends in ILK expression following time dependent exposure to 
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EGF. In the WHCO3 cell line, an increase in ILK expression was noted after 0.5 hours 
of EGF exposure reaching a 3.3 fold increase by 3 hours (Figure 12b). Thereafter, ILK 
expression levels continued to increase, reaching a substantial increase of 4.5 fold after 
24 hours EGF treatment. Similarly, in the WHCO5 and WHCO6 cell lines, a large 
increase was observed following 0.5 hours EGF treatment of 3 and 2.7 fold 
respectively. Increased ILK expression levels remained constant and highest ILK 
expression was observed following 24 hours EGF exposure of 3.4 and 2.9 fold 
respectively (Figure 12b). 
 
Interestingly, in the WHCO3 and WHCO5 cell lines, EGF treatment caused ILK 
expression levels to fluctuate depending on the exposure period. This was apparent 
specifically at the 1 and 6 hour EGF exposures for both cell lines. In the WHCO5 cell 
line, ILK expression levels were considerably decreased in comparison to the 0.5 hour, 
1.3 fold higher than 1 hour exposure and 3 hours, 1.6 fold higher than 6 hour exposure 
treatment periods. A similar observation was made in the WHCO3 cell line, although 
the fluctuations were not as substantial. At the 0.5 hour time point, ILK levels were 1.1 
fold higher than the 1 hour exposure. A comparable fold increase was noted at the 3 
hour exposure period in comparison to the 6 hour EGF exposure. 
 
The WHCO6 cell line was also somewhat outstanding in the sense that ILK expression 
levels tended to fluctuate in the presence of EGF. ILK expression increased at 0.5 hours 
EGF treatment (1.4 fold), decreased at 1 hour (0.6 fold), but increased again at 6 hours 
(Figure 12b). It is to be noted that these data are the average of three separate 
experiments. 
 
In the WHCO6 cell line, ILK expression increased by 1.5 fold following EGF exposure 
for 0.5 hours. Thereafter, the results were somewhat unusual in that a large decrease in 
ILK expression of 1.9 fold occurred at 1 hour in comparison to the 0.5 hour treatment 
period. The more expected trend of increased ILK expression following EGF treatment 
re-emerged at 3 and 6 hours with an increase of 1.3 fold. By 24 hours an increase of 2.9 
fold had been achieved (Figure 12b) 
 
The SNO cell line was somewhat outstanding in that this cell line elicited greatest ILK 
expression of 2.2 fold following 0.5 hours EGF exposure. Thereafter, a less substantial 
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increase was noted at 1 hour of 1.5 fold, which was maintained through to 24 hours 
(Figure 12b). 
 
2.3.5.2 The Effect of TGFβ1 on ILK Expression 
The second growth factor considered in this study was TGFβ1, which has been shown 
to play both an inhibitory/stimulatory role in tumour progression (Akhurst and Derynck, 
2001; Vogelmann et al., 2005). Treatment with TGFβ1 produced an overall an increase 
in ILK expression (immunoblotting) not unlike the effect of EGF (Figure 13a). 
However variations were noted in the WHCO1 and SNO cell lines where fluctuations in 
ILK expression were observed (Figure 13a). After 0.5 hours ILK expression had 
increased by 2.5 fold for both cell lines. By 1 hour ILK expression decreased, but 
reached an increase of 1.5 (WHCO1) and 2 (SNO) fold by 3 hours. Although a 
reduction was observed at 6 hours in comparison to the 3 hour exposure period, ILK 
expression levels were still comparatively higher than the untreated control. By 24 
hours ILK expression levels had diminished and were 1.1 and 1.9 fold higher in the 
WHCO1 and SNO cell lines respectively (Figure 13b).  
 
The WHCO3, WHCO5 and WHCO6 cell lines demonstrated a similar trend in 
increasing ILK expression in response to TGFβ1 treatment. The WHCO3 cell line 
produced a substantial increase in ILK expression after exposure to TGFβ1 for 0.5 
hours of 4.3 fold. Treatment for 1 and 3 hours produced an even greater increase in ILK 
expression where a 7 fold increase was reached and maintained. Surprisingly, exposure 
to TGFβ1 for 6 hours did not produce a higher increase in ILK expression, even though 
ILK expression was still 5.6 fold higher than the untreated control. Although treatment 
for 24 hours elevated ILK levels they were comparatively lower than that seen over the 
0.5 – 6 hour exposure time course. With this said however, expression levels of ILK 
were still 4.4 fold higher than the untreated control (Figure 13b). 
 
Exposure to TGFβ1 for 0.5 hours in the WHCO5 and WHCO6 cell lines caused an 
increase in ILK expression of 2.5 and 2.4 fold respectively. TGFβ1 treatment for longer 
periods of time resulted in a further increase in ILK expression with increases of 2.8 and 
3.9 fold for the WHCO5 and WHCO6 cell lines after 3 hours TGFβ1 exposure. ILK 
expression reached peak levels at 6 hours of 5 fold for both cell lines. ILK expression 
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levels subsequently decreased following 24 hours TGFβ1 exposure as ILK levels were 
2.9 and 1.9 fold higher than the untreated control for the WHCO5 and WHCO6 cell 
lines respectively (Figure 13b). All data presented here are an average of three separate 
experiments. 
 
 82
a)  WHCO1 
 
 
          1         2         3         4          5                6          7 
 
 WHCO3 
 
 
         1          2           3         4           5             6          7 
 
 WHCO5 
 
 
          1         2          3         4           5              6          7 
 
WHCO6 
 
 
          1          2         3        4          5                  6           7  
 
SNO 
 
 
       1          2          3         4           5                6            7 
 
 
Please see next page for legend 
 
 
 
 
 
 
 
 
 83
b) 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 0.5 1 3 6 24
time (hours)
fo
ld
 in
cr
ea
se
WHCO1
WHCO3
WHCO5
WHCO6
SNO
 
 
 
 
 
 
 
 
 
 
Figure 12: ILK Expression Following EGF Exposure.  
a) Western blot analysis utilising a rabbit anti-ILK antibody (1:1500) of ILK expression 
following EGF (10 ng/ml) treatment for 0.5, 1, 3 and 6 hours respectively across all cell 
lines. Lane 1 – 0 hours EGF, lane 2 – 0.5 hours EGF, lane 3 – 1 hour EGF, lane 4 – 3 
hours EGF, lane 5 – 6 hours EGF. Lane 6 − 0 hours EGF and lane 7 − 24 hours EGF b) 
Densitometric analysis indicated by a fold increase in ILK expression levels following 
addition of EGF in the HOSCCs. An increased trend in ILK expression was apparent, 
although variations in expression were noted at certain instances. Note: the expression 
levels are representative as a percentage of maximum per 10 µg of protein from 
concentrated fractions (included to normalise for loading variation). Experiments were 
repeated three times. 
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Figure 13: ILK Expression Levels Following TGFβ1 Exposure.  
a) Western blot analysis utilising a rabbit anti-ILK antibody (1:1500) of ILK expression 
following TGFβ1 (1 ng/ml) treatment for 0.5, 1, 3 and 6 hours respectively across all 
cell lines. Lane 1 – 0 hours TGFβ1, lane 2 – 0.5 hours TGFβ1, lane 3 – 1 hour TGFβ1, 
lane 4 – 3 hours TGFβ1, lane 5 – 6 hours TGFβ1, lane 6 − 0 hours TGFβ1 and lane 7 − 
24 hours TGFβ1 b) Densitometric analysis of the expression levels (fold increase) of 
ILK in the HOSCCs demonstrated an increased trend in ILK expression, although 
variations in expression were noted at certain instances. Note: the expression levels are 
representative as a percentage of maximum per 10 µg of protein from concentrated 
fractions (included to normalise for loading variation). Experiments were repeated three 
times. 
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2.4 Discussion 
The intrinsic processes of cell-ECM adhesion are widely regarded as playing a pivotal 
role during both normal signalling and tumourigenesis. Cell-ECM adhesion is mediated 
primarily by integrins, and ILK is directly involved in regulating the integrins and thus 
cell-ECM adhesion. A major role of ILK is its ability to regulate cell-ECM adhesion by 
phosphorylation of the β integrin subunit (Dedhar, 1999; Attwell et al., 2000; 
Mulrooney et al., 2000; Pasquet et al., 2002). ILK is also capable of transducing signals 
throughout the cell that regulate gene expression, cell proliferation, and cell migration 
(Delcommenne et al., 1998; Li et al., 1999; D’Amico et al., 2000). Overexpression of 
ILK correlates with malignancy in several tumour types, including breast, prostate, 
brain and colon carcinomas (Persad et al., 2000; Yoganathan et al., 2002), indicating 
that ILK is also involved in tumourigenesis. Surprisingly, information regarding ILK 
expression by oesophageal SCCs is currently nonexistent in the literature and this 
prompted an investigation into ILK expression levels. The present study aimed to 
determine if similar levels of ILK were expressed in oesophageal squamous carcinoma 
cell lines derived from moderately differentiated tumours. It was also reasoned that 
determining ILK distribution would further our understanding of ILK function with 
regards to cell-ECM adhesion and signal transduction. 
 
Transcription of the ILK gene was confirmed by the amplification of the full ILK 
transcript (RT-PCR), which revealed an ILK product of approximately 1360 bp (see 
Figure 5b). This result is consistent with a previous study by Janji et al., (2000) who 
showed that ILK mRNA was expressed at a size of 1359 bp in human melanoma and 
fibrosarcoma cell lines. The present study also demonstrated that ILK mRNA is 
translated to ILK protein (59 kDa), where ILK protein expression (Western blotting) 
was demonstrated in all oesophageal SCC cell lines tested (see Figure 7a). It is 
important to note that ILK protein was identified from the supernatant protein fractions 
of a Triton X-100-based extraction (enriching both membrane and cytosolic proteins 
and shown to preserve integrin function), suggesting that ILK is membrane-associated 
in oesophageal carcinoma cells and indicates a role for ILK in integrin signalling and 
ECM adhesion processes. 
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The result of an expressed 59 kDa ILK protein concurs with previous studies, which 
have shown ILK to be of equivalent size (Hannigan et al., 1996; Dedhar et al., 1999; Li 
et al., 1999; Wu, 1999; Friedrich et al., 2002). Nikolopoulos & Turner, (2001) however, 
have reported the molecular mass of ILK as being 50 kDa. These authors suggested that 
this discrepancy in molecular size might signify different gene products of ILK, 
although the reason for these differing results is uncertain at present. This study 
revealed that, under standard culture conditions, ILK expression for three of the five cell 
lines is relatively similar (WHCO3, WHCO5 and SNO cell lines) whereas the WHCO1 
cell line exhibited higher ILK expression levels, while WHCO6 showed a lower ILK 
expression (densitometry–see Figure 7b). This may indicate dysregulated ILK 
expression in the latter cell lines although a comparison to normal epithelial 
oesophageal keratinocytes would be needed to draw further conclusions. The reader is 
reminded that all oesophageal lines are derived from tumours with similar pathological 
grading. Unfortunately, due to the difficulties in obtaining, and culturing, normal 
epithelial oesophageal keratinocytes, this comparison could not be made.  
 
The inconsistencies in ILK protein expression levels (even though samples were 
normalised for loading variations) lead us away from the possibility of ILK acting as a 
molecular marker for this pathological grade of oesophageal SCCs. However, it should 
be remembered that the laser densitometric technique utilised in determining expression 
levels is a semi-quantitative technique and it would perhaps be prudent for future work 
to verify these data utilising a more sensitive protocol such as a radio immunoassay 
(RIA). Furthermore, protein ILK expression do not necessarily reflect ILK mRNA 
expression levels, which would explain the differences in the intensities of the ILK 
mRNA and ILK protein bands observed in the WHCO1 and WHCO3 cell line (see 
Figures 5c and 7a). Real time PCR would have been necessary to precisely determine 
the levels of cellular ILK mRNA. 
 
While not being a marker, these differences in ILK expression within this single class of 
pathological grade may signify that the current system for pathologically grading SCC 
tumours is inconsistent. Although the data regarding ILK protein expression is 
disappointing, from a pathological grading perspective, this study still provides unique 
evidence that ILK mRNA and protein are expressed in oesophageal SCC cell lines. 
However, comparisons to other gastro intestinal cancers cannot be made since there is 
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currently no data available on the semi-/quantitative expression of ILK for any other 
cell line. 
 
The two known isoforms of ILK, ILK1 and ILK2, differ only in that they possess 
unique restriction sites, namely BamHI and HincII respectively. ILK2 has been found to 
be expressed in two metastatic cell lines but not in normal adult tissues (Janji et al., 
2000). ILK2, although only recently discovered, is known to have antigenic cross-
reactivity and functional attributes similar to ILK1 (Janji et al., 2000). Taken together, 
this evidence necessitated the determination of the isoform present. In these 
oesophageal SCCs, the ILK1 isoform was identified (following BamHI restriction), (see 
Figure 8a, 836 bp product-red arrow and 523 bp product-black arrow), corroborating 
evidence of ILK1 being the most abundant isoform expressed in metastatic tumours 
(Janji et al., 2000). 
 
Following the attachment of cells to ECM, allows for the localisation of ILK to focal 
adhesions (Wu & Dedhar, 2000; Nikolopoulos & Turner, 2001). This distribution 
pattern of ILK suggests roles for ILK in cell adhesion events; as overexpression of ILK 
results in inhibited adhesion to integrin substrates (Hannigan et al., 1996). Furthermore, 
this localisation controls cell migration processes; since inhibition of the PINCH-ILK 
interactions impairs coordinated changes in cell shape, which are required for cell 
migration to occur (Wu et al., 1998; Tu et al., 2001; Zhang et al., 2002). Thus ILK 
localisation regulated by PINCH (Velyvis et al., 2001) is responsible for placing ILK in 
the most suitable position for mediating specific adhesion and signalling functions. 
Furthermore, increased ILK expression has been shown to correlate with altered ILK 
localisation and possible altered function (Somasiri et al., 2000). In mesenchymal cells 
that overexpress ILK, Somasiri et al. (2000) demonstrated that ILK is localised to 
elongated “streaks” at the cell-substratum interface. Although these streaks resemble 
focal adhesions they differed considerably from control populations. 
 
Localisation of β3 integrin subunits requires regulation by ILK and therefore association 
between these molecules (Hannigan et al., 1996; Velyvis et al., 2001; Zervas et al., 
2001). The association shown between ILK and β3 integrins, most likely at focal 
adhesions, are indicative of an interaction between these two molecules. The physical 
interaction (direct/indirect) between ILK and the β3 integrin subunit was verified (by co-
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immunoprecipitation) for oesophageal SCCs, where a band of 88 kDa for the β3 integrin 
and a 59 kDa band for ILK were obtained (see Figure 9). Similar to other mammalian 
cell types, oesophageal SCC cell lines show that ILK is directly associated with the β 
integrin subunit, supporting evidence that ILK controls the expression and activity of 
the integrin receptors. 
 
As a result of the importance of ILK in signalling processes, and since the WHCO1 cell 
line seems to express ILK at higher levels in comparison to the other cell lines, it 
became necessary to investigate the localisation of ILK in these cell lines. Reports 
demonstrate clearly that localisation of ILK to focal adhesion plaques requires the LIM-
containing adaptor protein PINCH and ILKBP (Velyvis et al., 2001; Zhang et al., 
2002), as well as a functional interaction between paxillin and ILK (Nikolopoulos and 
Turner, 2001). In this thesis, immunofluorescence microscopy showed a prominent 
cytoplasmic/nuclear and membranal distribution for ILK (Figure 8a), implying that 
PINCH-ILK and ILK-paxillin interactions are stable and intact. A pericellular 
membranal distribution for the β3 integrin (see Figure 10f) for all cell lines was 
visualised. Miller and Veale, (2001) showed that the β1 integrin subunit also follows a 
pericellular distribution in these OSCC cell lines. Hence, it can be speculated that along 
with interacting with the β3 integrin subunit, an association may be occurring between 
ILK and the β1 subunit in human oesophageal SCCs. 
 
Localisation studies revealed that ILK was detected primarily in the 
cytoplasmic/nuclear region in the WHCO1, WHCO3, WHCO5, WHCO6 and SNO 
oesophageal carcinoma cell lines, with a much smaller proportion occurring at the 
membrane and focal adhesion contacts (see Figure 10). This nuclear localisation of ILK 
did not agree with the majority of previous studies, which report ILK as primarily 
having a focal adhesion distribution (Attwell et al., 2003; Chun et al., 2003). However, 
Western blotting confirmed our confocal microscopy results, identifying ILK 
localisation in the nucleus (see Figure 11a). Densitometric analysis further revealed that 
the nuclear levels of ILK expression were considerably higher in comparison to 
membrane/cytoplasmic expression levels of ILK (see Figure 11b). With the finding that 
the β3 integrin subunit localised exclusively at the membrane (ILK also exhibited 
membrane localisation) supports the notion of an association between ILK and the β3 
integrin subunit (see Figure 10f). 
 90
Epithelial tumours seem to exhibit a downregulation of integrin expression, which is 
thought to facilitate unregulated growth and invasion (Ziober et al., 1996; Meyer and 
Hart, 1998; Miller and Veale, 2001). Specifically, Miller and Veale, (2001) have shown 
that expression of the β1 integrin subunit is drastically reduced or lost in these particular 
oesophageal SCCs and since the distribution patterns of β1 and β3 have been shown to 
be similar, it is possible that ILK is the causative agent in β1, and possibly β3, reduction 
in carcinoma of the oesophagus. It will thus be of interest for future work to ascertain 
accurately β3 integrin subunit expression levels in these cell lines. 
 
We have thus far shown ILK protein and RNA expression in moderately differentiated 
oesophageal carcinoma cell lines, as well as showing localisation of ILK. The next 
logical step in developing an understanding of ILK in oesophageal SCCs was to explore 
the possibility of ILK as a mediator between growth factor expression and integrin 
signalling pathways. For this, the various cell lines were treated, with EGF and TGFβ1 
and the effects on ILK expression examined.  
 
Normal squamous epithelial cells express approximately 2 × 105 EGFR, with certain 
SCCs overexpressing EGFR up to 50 times higher in comparison to their normal 
counterparts (Veale and Thornley, 1989). This applies to a variety of epithelial 
malignancies (see introduction to this chapter and Mayer et al., 2000). Additionally, it 
has been reported that increased numbers of EGFR are required in the early steps of 
cervical carcinogenesis (Mayer et al., 2000) and also during the development and 
progression of colon cancer (Pouliot et al., 2000). Specifically, the oesophageal 
carcinoma cell lines used in the present study are known to overexpress the EGF 
receptors significantly higher than normal oesophageal keratinocytes. This applies 
particularly to the WHCO3 cell line (Veale and Thornley, 1989). While demonstrating 
increased EGFR expression, no relationship exists between the number of EGF 
receptors and biological response to EGF in these cell lines. For example, EGF inhibits 
the colony forming efficiency of SNO cells whereas the WHCO cell lines all differ in 
their responses to EGF (Veale and Thornley, 1989), highlighting the importance of EGF 
in growth and differentiation in SCCs. It was therefore of interest to assess EGF effects 
on ILK protein expression in oesophageal SCCs. Not only would this examination 
provide us with information on the responses of ILK expression to EGF, but would also 
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indicate a potential role for ILK as a mediator between the integrin and growth factor 
signalling pathways in oesophageal carcinoma. 
 
Exogenous TGFβ1 has been found to inhibit epithelial cell growth (Fukai et al., 2003; 
Kim et al., 2004). Loss of TGFβ1 growth inhibition is known to occur in oesophageal 
carcinoma since, emphasising the importance of understanding the role of TGFβ1 in the 
present study (Osawa et al., 2004; Edmiston et al., 2005). Understanding the role of 
TGFβ1 is clearly highlighted by the fact that the expression profiles of integrins are 
susceptible to regulation by TGFβ1, and integrin-mediated signalling also regulates 
TGFβ1 expression levels (Kumar et al., 1995 cited in Kim et al., 2004). Following the 
relationship identified between ILK and the β integrins in these HOSCCs, we reasoned 
that TGFβ1 may well impinge upon ILK signalling events.  
 
In HOSCCs examined here, the general response of ILK to both EGF and TGFβ1 
treatment was an increase in ILK expression levels over the duration of growth factor 
exposure (see Figures 12b and 13b). It is likely that this stimulation occurs via 
activation of the PI3K pathway, which has been shown to be activated in response to the 
application of these growth factors (Krasilnikov et al., 2000; Qui et al., 2004). The only 
other report of EGF and TGFβ1 influencing ILK expression, showed stimulation of ILK 
expression in a human melanoma cell line following exposure to EGF and TGFβ1 for 
24 and 48 hours (Janji et al., 2000). However, since several cell lines have been shown 
to respond rapidly to exogenous EGF and TGFβ1 (Mineo et al., 1999; Kim et al., 2000) 
the present study concentrated on shorter exposure times. 
 
Cell lines treated with 10 ng/ml EGF over a 0.5, 1, 3, 6 and 24 hours time course 
dramatically increased the expression of ILK in vitro between 1.5 to 3.3 fold for the 
WHCO1, WHCO5, WHCO6 and SNO cell lines (see Figure 12b). We expected a 
similar substantial increase in ILK expression in the WHCO3 cell line, since this line in 
particular expresses approximately 10.4 × 106 receptors per cell, up to 4 times more than 
the SNO cell line and 2.5 fold higher than the WHCO1 cell line (Veale and Thornley, 
1989). Indeed, the levels of ILK in this cell line were increased to the greatest extent up 
to 3.4 fold (6 hours EGF). Thus, it appears that the EGF signalling pathway dissociates 
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from ILK signalling, possibly through a substantial increase in PI3K levels. EGF feeds 
into the Ras-MAP kinase signalling pathway, controlling cellular growth and 
differentiation (Juliano and Haskill, 1993; Moro et al., 1998; Giancotti and Ruoslahti, 
1999; Mariotti et al., 2001; Andl et al., 2003). Furthermore, since Ras is able to 
stimulate PI3K, which is a positive regulator of ILK activity (Delcommenne et al., 
1998; Giancotti and Ruoslahti, 1999; Troussard et al., 2000; Mariotti et al., 2001), the 
activation of Ras via EGF may have further implications in the activation of ILK kinase 
activity. 
 
The noted variations in ILK expression among the cell lines suggest that a mechanism 
for recycling these growth factors occurs in response to exogenous application 
depending on the exposure time. In the instances where ILK expression decreased 
abruptly, the decrease could be attributable to a reduction in the number of receptors at 
the membrane as a result of receptor internalisation (Doré et al., 2001). It is widely 
accepted that, although EGFR localises primarily at the cell surface, they constantly 
shuttle and recycle through the cell (Wiley et al., 2003). Furthermore, rates in recycling 
can be accelerated as a consequence of EGF ligand-binding (Mineo et al., 1999; Wiley 
et al., 2003). EGFR are internalised from the cell surface in a number of ways, 
including clathrin-coated pits (Wiley et al., 2003; Gao et al., 2005; Puri et al., 2005; 
Sigismund et al., 2005). Once internalised, EGFR are delivered to endosomes (Baulida 
et al., 1996; Wiley et al., 2003), are sorted, and are either recycled back to the plasma 
membrane or directed to the lysosome for destruction (Mellman et al., 1996; Opreska et 
al., 1996; Burke et al., 1999). It is highly probable that the fluctuations noted in ILK 
expression in the WHCO1, WHCO5 and SNO cell lines are attributed to this receptor 
internalisation/recycling process where lowered EGF signalling occurs as a result of 
EGFR reduction at the plasma membrane. Since EGF has been shown to stimulate PI3K 
activity (Normanno et al., 2006), lowered EGF signalling results in a concommitant 
decrease in PI3K activity. As a consequence ILK concentration levels are decreased. 
 
When the OSCC cell lines were treated with TGFβ1 for identical time periods, 
increased ILK expression was noted in all of the five cell lines compared to untreated 
cell lysates. The TGFβ1-induced increases in ILK expression were similar to that of 
EGF. However, the response of ILK to TGFβ1 exposure did not produce the standard 
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increase in ILK expression as was the case when cells were treated with EGF. Instead, 
fluctuations in ILK expression levels were observed. This was especially apparent in the 
WHCO1 and SNO cell lines (see Figure 13b). 
 
Studies addressing the recycling of TGFβ1 receptors have been left largely unexamined. 
Although scarce, early reports do suggest that internalised receptors are either rapidly 
replaced or recycled back to the cell membrane (Sathre et al., 1991; Mitchell et al. 
2004). More recently, Mitchell et al. (2004) showed that TGFβ1 receptors do indeed 
recycle and degrade in a clathrin-dependent manner, but that this process is not 
dependent on ligand stimulation. The Mitchell et al. (2004) study was conducted on 
lung epithelial cells and it is possible that ligand stimulation by exposure to TGFβ1 is 
required in the case of HOSCCs. Thus, with regard to the HOSCCs in question, the 
fluctuations observed following TGFβ1 exposure may well be explained by receptor 
recycling. 
 
While the cellular expression of ILK in HOSCCs is comparable to that of other cell 
types, particularly noteworthy is that ILK expression in HOSCCs appears to be 
dependent on the receptor recycling of both the EGF and TGFβ1 receptors. 
EGF/TGFβ1 has been shown to result in a rapid, marked increase in ILK expression. 
Since it is known that EGFR overexpression occurs in these HOSCCs, it is plausible 
that a constitutive increase in ILK expression exists in these HOSCCs due to stimulation 
of PI3K. A direct consequence of EGF/TGFβ1 stimulation of the ILK pathways could 
thus be decreased cellular adhesion due to impaired integrin-mediated signalling, or a 
stimulation of mitogenic pathways such as MAPK thereby promoting transformation. 
 
These results show that ILK expression is regulated, not only by stimuli derived from 
integrin dependent cell adhesion (Delcommenne et al., 1998), but also in a growth 
factor dependent manner in all the cell lines under investigation. This provides support 
of a link between integrins and growth factor mediated signalling. In contrast to the data 
presented here, EGF has been shown to have no effect on ILK expression in HT-144 
melanoma cells (Janji et al., 2000). However, the melanoma study considered the ILK2 
isoform and no mention is made of the effect of EGF on ILK expression in these cells. 
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While informative, this data does not allow for any comparisons to be made to the 
metastatic oesophageal cell lines in question. Furthermore, the noted differences 
between the melanoma cell line and the oesophageal carcinoma cell line in question, in 
response to EGF, could be accounted for by the differences in their developmental 
origin. From these sets of data it could be argued that EGF does not affect ILK pre- or 
posttranscriptional expression levels similarly. It will be interesting to examine EGF 
effects on ILK mRNA expression in oesophageal SCCs to understand perhaps if EGF 
similarly affects ILK mRNA and protein. 
 
The identification of ILK expression in oesophageal SCCs in the present study provides 
a recent addition to the growing list of malignancies in which ILK has been shown to be 
present. Furthermore, this is the first evidence of ILK expression in oesophageal SCC 
cell lines. The data obtained has provided novel evidence concerning ILK expression 
levels and distribution within this class of moderately differentiated oesophageal SCC, 
and has indicated a role for ILK in cell-ECM adhesion and integrin signalling.  
 
This chapter has addressed the distribution of ILK as well as the growth factors effects 
on ILK expression. As the noted effects of EGF on ILK expression are almost certainly 
PI3K dependent perhaps more insight into this particular aspect of ILK could be 
attained by considering the effects of growth factors on the kinase activity of the 
catalytic domain of ILK1. The kinase domain is responsible for the regulation of cell-
ECM adhesion by being capable of directly phosphorylating the β integrin subunit. 
Accordingly, the ILK kinase domain forms the focus of chapter 3. 
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Chapter 3 
Growth factor modulation of ILK kinase activity in oesophageal 
SCCs 
 
3.1 Introduction 
The catalytic kinase domain of ILK regulates the β integrin subunits. In order to gain 
insight into the physiological roles of ILK during cell-ECM adhesion events, and its 
possible role in invasion and metastasis an understanding is required of the kinase 
domain of ILK (Troussard et al., 2000; Yoganathan et al., 2000; Ishii et al., 2001; 
Zhang et al., 2002; Cordes, 2004; Stevens et al., 2004). The ILK kinase domain will be 
examined from two aspects. First, and of immense interest to this study, is the effect of 
growth factors on the kinase activity of ILK. This is of particular importance with 
respect to EGFR since EGFR is upregulated in oesophageal SCCs (Normanno et al., 
2006) and in this study (see chapter 2) EGF was shown to upregulate ILK expression 
levels. Second, an understanding of the alterations of ILK kinase activity upon cell 
attachment to ECM substrates is provided. For the sake of clarity, these facets will be 
considered separately and while this chapter will place emphasis on the former, 
examination of altered ILK activity effects on cell-ECM adhesion will form the basis to 
chapter 6. 
 
The kinase domain of ILK is serine/threonine directed (Troussard et al., 2000; Persad 
and Dedhar, 2003; Ito et al., 2003; Grashoff et al., 2004; Chun et al., 2005) with ILK 
acknowledged as having a low basal kinase activity (Wu & Dedhar, 2001). ILK kinase 
activity is modulated by the interaction of cells with components of the extracellular 
matrix and subsequent integrin clustering (Janji et al., 2000; Yoganathan et al., 2000; 
Wu & Dedhar, 2001; Dai et al., 2003). ILK activity is stimulated in a 
phosphotidylinositol (PI) 3-kinase (PI3K)-dependent manner, which involves binding of 
the phosphoinositide phospholipid product of PI3K, PIP3, to the PH-like domain of ILK 
(Dedhar, 2000; Wu, 2001; Cordes and van Beuningen, 2003; Grashoff et al., 2004). 
Activated ILK in turn, is able to influence changes in cell survival, proliferation and 
differentiation by modulating integrin-mediated cell adhesion (Dedhar et al., 1999; Janji 
et al., 2000; Kaneko et al., 2004).  
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ILK has been demonstrated to be an upstream effector of the PI3K-dependent regulation 
of two important signalling proteins; namely GSK3β and PKB (see introduction and 
Persad et al., 2000; Yoganathan et al., 2000; Wu and Dedhar, 2001; Cordes and van 
Beuningen, 2003; Quélo et al., 2004; Pinkse et al., 2005). ILK inhibits GSK3β, which 
results in β-catenin translocation to the nucleus, causing a subsequent downregulation of 
E-cadherin expression and cell-cell adhesion respectively (see introduction and Novak 
et al., 1998; Tan et al., 2001; Oloumi et al., 2004). The regulation of cell survival is also 
influenced by ILK. ILK achieves this by phosphorylating PKB thus stimulating its 
activity (Attwell et al., 2000; Wu and Dedhar, 2001; Attwell et al., 2003; Stevens et al., 
2004), which results in inactivation of the proapoptotic factor Bad and consequently 
leads to inactivation of caspase-9 and protection from apoptosis (Wang et al., 2001; 
Cordes and van Beuningen, 2003). This was demonstrated in human prostate carcinoma 
cells where both ILK and PKB were constitutively activated, and subsequent inhibition 
of ILK resulted in apoptosis (Persad et al., 2000). 
 
EGF and TGFβ1 growth factors are of paramount importance in physiological functions 
such as proliferation, differentiation and cell adhesion (Ozanne et al., 1986; Janji et al., 
2000; Mayer et al., 2000; Fujimoto et al., 2001). Furthermore, growth factors such as 
these have been shown to regulate ILK activity (Delcommenne et al., 1998; Dedhar et 
al., 1999). TGFβ1 is an interesting growth factor to consider in regulation of ILK 
activity, since it is capable of stimulating cellular proliferation, in addition to being 
largely regarded as a growth inhibitor of epithelial cells (Sporn and Roberts, 1986; 
Fujimoto et al., 2001; Vogelmann et al., 2005). Although different cell types have been 
shown to respond differently to TGFβ1, varying responses within the same cell type 
may be exhibited under different experimental conditions (Moses et al., 1990). For 
example, TGFβ1 is able to regulate the growth of keratinocytes in cell culture by acting 
as a potent inhibitor of proliferation, even in the presence of mitogenic concentrations 
of EGF (Ozanne et al., 1986), but induces angiogenesis in vivo. Since the mechanism/s 
that direct TGFβ1 dependent processes are to a large degree still unknown (Janji et al., 
2000), it is these perplexing actions of TGFβ1 that make it an interesting growth factor 
to consider in the study of ILK activity in oesophageal SCCs. 
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EGF has been shown to influence ILK expression in oesophageal SCCs, and TGFβ1 has 
been shown to modulate the expression of β3 and β1 containing integrins (Lai et al., 
2000), which associate with ILK (Hannigan et al., 1996; Attwell et al., 2000). This 
investigation attempted to establish whether regulation of ILK expression occurs in a 
similar fashion to that of ILK activity, by growth factors as well as to extrapolate these 
results to the relevance of regulated ILK activity in cell-ECM adhesion events. 
 
As mentioned above positive regulation of ILK activity occurs through phosphorylation 
provided by PI3K. To ensure appropriate ILK levels, negative regulation is supplied by 
the PTEN tumour suppressor (Das et al., 2003; Leslie and Downes, 2004). While 
originally identified as a dual specificity phosphatase, it has been revealed by 
biochemical analysis that PTEN is not a capable protein phosphatase but rather a 
competent phosphoinositide D3-phosphatase (Al-Khouri et al., 2005). PTEN functions 
by specifically cleaving the D3 phosphate of this second messenger lipid produced by 
the activity of PI3K (Cristofano and Pandolfi, 2000). The removal of this phosphate 
group inhibits PI3K function. 
 
PTEN has particular relevance to the present study since it is known that ILK activation 
requires binding to PIP3 and subsequent PI3K-dependent activation (Boulter et al., 
2006). While this leads to the stimulation of ILK activity, the inhibition of ILK occurs 
through PTEN activity. PTEN negatively regulates ILK activity via the 
dephosphorylation of PIP3 (Zheng et al., 2003; Leslie et al., 2003). This has been 
demonstrated in PTEN-null prostate cancer cells in which PIP3 levels are high, ILK is 
constitutively active (Persad et al., 2000). 
 
Since there are no widely expressed PTEN homologues, PTEN activity strongly 
influences both basal and stimulated PI3K, signifying the importance of this 
phosphatase in a wide variety of tumour types (Backman et al., 2002). PTEN is mutated 
in a variety of sporadic tumours including glioblastomas and endometrial carcinomas 
(Ali et al., 1999; Bonneau and Longy, 2000; Leslie et al., 2001; Leslie and Downes, 
2004; Walker et al., 2004; Kerr et al., 2006). Furthermore, mutations have been 
observed in brain, breast, prostate and other advanced malignancies (Gu et al., 1998; 
Whang et al., 1998; Li et al., 2002; Sulis et al., 2003; Yang et al., 2003). Although 
inactivation of the PTEN gene occurs frequently there are instances in which tumours 
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appear to develop mechanisms that reduce the concentration levels of PTEN without 
mutation of the PTEN gene (Whang et al., 1998). Methylation of the PTEN promoter 
region, associated with reduced PTEN expression, occurs in non-small cell lung cancer 
(Soria et al., 2002). Loss of one allele of PTEN with the preservation of the remaining 
wild-type allele is also very common (Sulis et al., 2003). However, it has been 
demonstrated that PTEN+/- mice develop colonic adenomas and lymph node hyperplasia 
at high frequency due to haploinsufficiency (Podsypanina et al., 1999). Furthermore, it 
has been shown that haploinsufficiency results in tumour progression in a mouse 
SV40T antigen prostate-tumour model (Kwabi-Addo et al., 2001). However, PTEN 
mutations are not frequent in oesophageal carcinoma (Hu et al., 1999). Nevertheless, its 
likely involvement in ILK activity emphasises the importance of PTEN to the present 
study. 
 
PTEN is involved in many growth factor-mediated signalling pathways (Ebert et al., 
2002; Vogelmann et al., 2005). It seems likely that if indeed growth factors do impinge 
upon ILK kinase activity in these oesophageal carcinoma cells, it is highly probable that 
PTEN would mediate these growth factor effects and it is therefore imperative that 
PTEN be examined in these cell lines. Support of this notion is derived from evidence 
that demonstrates that TGFβ1-induced effects on cells involve PTEN activity. To 
corroborate this idea, Vogelmann et al. (2005) demonstrated that TGFβ1 treatment 
results in a reduction in phosphorylated PTEN and causes dissociation from the E-
cadherin/β-catenin complex. Furthermore, Ebert et al. (2002) demonstrated that TGFβ1 
dramatically reduces PTEN in human pancreatic cancer. 
 
ILK kinase activity was examined using myelin basic protein (MBP)-based kinase 
assays. MBP was used as an analogue, since it contains the β1 integrin cytoplasmic 
sequence (Wu, 1999), and phosphorylation of this substrate reveals ILK kinase 
functionality. Although previous studies involving ILK kinase assays refer to ILK 
activity as its ability to phosphorylate a myelin basic protein (MBP) substrate 
(Hannigan et al., 1996; Janji et al., 1998; Persad et al., 2000; Somasiri et al., 2000; Kiss 
et al., 2002), it is acknowledged that this is an activity assay and not a strict 
enzymological definition of enzyme activity. However, for consistency this study will 
use the published terminology when discussing ILK kinase capabilities (Hannigan et al., 
1996; Delcommenne et al., 1998; Tan et al., 2002). Data presented in this chapter 
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suggest that the EGF and TGFβ1 growth factors are able to modulate the kinase activity 
of ILK in oesophageal SCCs, and furthermore, that PTEN is directly involved in 
mediating the growth factor-induced effects of the ILK kinase activity in oesophageal 
SCC cell lines.  
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3.2 Methods and Materials 
 
3.2.1 Isolation of ILK Utilising Immunoprecipitation 
Cells seeded into Nunc™ culture dishes were treated with EGF (10 ng/ml) and TGFβ1 
(1 ng/ml) for a period of 24 hours. 10 ng/ml EGF has been shown to be sufficient for 
inducing changes in cellular morphology, which promotes dissociation and increases the 
invasive ability of poorly differentiated human oesophageal SCCs (Shiozaki et al., 
1996). TGFβ1 is able to either stimulate or inhibit cellular growth and at a concentration 
of 1 ng/ml has been shown to upregulate ILK expression (Sporn and Roberts, 1992; 
Janji et al., 2000). 
 
Triton X-100 extractions (see Chapter 2, Section 2.2.5) were performed on a dish of 
either, untreated cells, EGF-treated (10 ng/ml) and TGFβ1-treated (1 ng/ml) cells for the 
respective oesophageal cell lines. Protein concentrations were determined using the 
Bradford assay (see Chapter 2, Section 2.2.6). Immunoprecipitation was performed 
following a modified protocol from Zhang et al. (2002). Briefly, cell lysates were 
incubated with a polyclonal rabbit anti-ILK primary antibody (10 µl) overnight at 4 °C. 
Traditionally used S.aureus cells and currently used protein G sepharose beads (Sigma, 
USA) were washed 4 times with a 10 mM Tris buffer pH 8 (Appendix 1.7.1). 
Thereafter, 75 µl of the washed S.aureus cells and sepharose beads were added to the 
supernatant and allowed to incubate for 4 hours at 4 °C. The subsequent immune 
complexes were centrifuged at 3000 rpm in a MSE bench-top centrifuge for 3 minutes. 
The supernatant was decanted and 200 µl of kinase buffer (Appendix 1.7.2) was added 
to the pellet and the tubes gently agitated. Samples were once again centrifuged at 3000 
rpm and the supernatant decanted. Pellet samples were stored at −70 °C. 
 
3.2.2 Densitometric Evaluation of ILK Activity Levels When Exposed to 
EGF and TGFβ1 
The immunoprecipitated ILK pellet had the following added to it: 35 µl kinase buffer 
(see Appendix 1.7.2), 10 µCi [γ-32P] ATP (Amersham, UK) and 10 µg myelin basic 
protein (MBP) from Sigma, USA. These kinase reaction mixtures were incubated for 2 
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hours (single time point analysis) at 4 °C with gentle agitation. (An equal volume of 
double lysis buffer (see Appendix 1.6.4) was added to the samples for two reasons. 
Firstly, to denature the ILK enzyme thus stopping the kinase reactions, and secondly, to 
bring the salt concentration of the liquid samples to the same concentration as that of 
single lysis buffer, which is the ionic concentration required in SDS-PAGE separation. 
Thereafter, samples were heated in a boiling water bath for 5 minutes. Eppendorf tubes 
were briefly centrifuged at 10000 rpm in a Sorvall® MC 12 V centrifuge for 10 
minutes. Thereafter, the supernatant was transferred to a sterile eppendorf tube. These 
supernatant samples constituted kinase reaction products of phosphorylated MBP. 
 
Kinase reaction products of phosphorylated MBP were resolved on 8 % SDS-PAGE 
(see Appendix 1.5.4). Gels were immersed in Coomassie blue stain (see Appendix 
1.3.6) for 1 hour and destained, and rinsed in dH2O and 10 % ethanol for 20 minutes 
respectively. Gels were dried for 2 hours on a SE1160 slab gel drier. The dried gels 
were exposed to hyperfilm™ MP autoradiography film overnight at −70 °C. The 
exposed film was developed in D19B developer (see Appendix 1.4.3) for 5 minutes, 
briefly rinsed in H2O and fixed (see Appendix 1.4.4) for 5 minutes. 
 
Kinase assay x-ray plates were semi-quantitatively analysed by laser densitometry using 
a LKB 2202 Ultrascan Laser Densitometer in order to ascertain ILK activity levels 
between oesophageal carcinoma cell lines when exposed to growth factors. The area 
under the peak for each sample was used as a basis for comparison between samples. 
Activity levels were represented as a percentage of the maximum per 35 µg of protein. 
Experiments were repeated three times. 
 
3.2.3 Triton X-100 Extraction 
As previously documented see Chapter 2, Section 2.2.5 
 
3.2.4 Protein Estimation 
As previously documented see Chapter 2, Section 2.2.6 
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3.2.5 Western Blot Analysis 
Triton X-100 extracted lysates from the HOSCCs were resolved on 12 % SDS-PAGE, 
and transferred to Nitrobind nitrocellulose transfer membrane (MSI, USA), in a BioRad 
Trans-Blot™ Cell at 400 mA for 3 hours (4 °C) in Western Blot Transfer Buffer 
(Appendix 1.4.5). After transfer was complete, the nitrocellulose membranes were 
rinsed twice with PBS (see Appendix 1.1.1), and stored overnight at 4 °C.  
 
Each membrane was blocked in BLOTTO (see Appendix 1.4.1) for 5 minutes to prevent 
non-specific antibody binding and washed 6 times in PBS. The blots were incubated in 
a rabbit anti-PTEN primary antibody (1:10000) for 1 hour. Washing was performed 6 
times at 5-minute intervals with PBS to remove any residual antibody. When probing 
for PTEN, membranes were incubated with a HRP-bound secondary anti-rabbit 
antibody (1:10000) for 1 hour in the dark. Once again membranes were washed 6 times 
at 5-minute intervals with PBS before being exposed to the Supersignal® West Pico 
Working Solution (see Appendix 1.4.2) from the West Pico Chemiluminescent 
Substrate Kit (Pierce, USA) for 5 minutes. Blots were sealed in polyethylene ‘saran 
wrap’ and exposed to hyperfilm™ MP autoradiography film (Amersham, UK) for 1.5 
minutes. Film was developed in D19B developer (see Appendix 1.4.3) for 5 minutes, 
rinsed briefly in H2O before fixing (see Appendix 1.4.4) for 5 minutes. The experiment 
was repeated three times. 
 
3.2.6 Co-Immunoprecipitation Analysis of ILK and PTEN 
Cell lysates were preabsorbed with protein G sepharose beads overnight at 4 °C, 
centrifuged at 3000 rpm and the supernatant transferred to fresh eppendorf tubes. Cell 
lysates were either incubated with 5 µl polyclonal rabbit anti-PTEN (Sigma, USA) or 
polyclonal rabbit anti-ILK antibody overnight at 4 °C. The following day protein G 
sepharose beads (100 µl) (Amersham, SA) were added to the immune complex for 4 
hours. The protein G-ILK1-PTEN complex was centrifuged at 3000 rpm in a Sorvall® 
MC 12 V centrifuge for 2 minutes. The supernatant was decanted, and 800 µl Tris.HCl 
buffer pH 8.0 added. Centrifugation was performed once again at 3000 rpm. This 
washing step was repeated twice more. The supernatant was decanted and an equal 
volume of double lysis buffer (Appendix 1.6.4) was added to the pellet. The suspension 
was boiled for 5 minutes and centrifuged for 10 minutes at 12000 rpm in a Sorvall® 
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MC 12 V centrifuge. The product was resolved on a 12 % SDS-PAGE gel (see 
Appendix 1.5.4) and transferred to nitrocellulose for 3 hours as in Methods and Material 
Section 2.2.8. The blot was probed for ILK and the PTEN integrin subunit using 
standard antibody concentrations. Blots were then exposed to the Supersignal® West 
Pico Working Solution (see Appendix 1.4.2) for 5 minutes, sealed in polyethylene ‘glad 
wrap’ and then exposed to hyperfilm™ MP autoradiography film (Amersham, UK) for 
1.5 minutes. Film was developed in D19B developer (see Appendix 1.4.3) for 5 
minutes, rinsed briefly in H2O, before fixing (see Appendix 1.4.4) for 5 minutes. 
 
3.2.7 Indirect Immunofluorescence 
The localisation of PTEN was performed utilising indirect immunofluorescence 
microscopy. All cell lines were grown to 80 % confluency and seeded onto sterile glass 
coverslips. Coverslips were washed five times in cold PBS, fixed with 4 % 
paraformaldehyde (Appendix 1.6.1) for 30 minutes and washed again with PBS. 
Coverslips were immersed in 0.25 % Triton X-100 (Appendix 1.6.2) for 10 minutes to 
further permeabilise the cells, washed twice with PBS, dipped into dH2O, and allowed 
to dry partially. This allowed the DAKO® pen (Denmark) to adhere properly to the 
glass coverslips. Two circles or wells per coverslip were drawn with the DAKO® pen 
to create a fluid barrier. One well per coverslip was incubated with a polyclonal rabbit 
anti-PTEN primary antibody (1:250) for one hour. The other well was incubated in PBS 
(control). This was followed by a thorough washing in PBS as before. All circled areas 
were incubated with an anti-rabbit Fluorescine Isothiocyanate (FITC)-conjugated anti-
rabbit antibody (1:250). Both wells were incubated for one hour in the dark. The 
coverslips were washed six times with sterile PBS and then mounted with Elvanol 
mounting agent (Appendix 1.6.3) onto sterilised glass slides. All incubations were 
carried out in a humidity chamber to prevent desiccation. Slides were viewed under a 
Zeiss LSM 410 confocal microscope (FITC excitation 490, emission 525). 
 
3.2.8 Image Capturing 
As previously documented see Chapter 2, Section 2.2.13.
 104
3.3 Results 
 
3.3.1 EGF and TGFβ1 Treatment Modulates ILK Kinase Activity 
ILK was isolated from total cell lysates by means of immunoprecipitation using protein 
G sepharose beads and killed S.aureus cells. Indeed, the ILK that was 
immunoprecipitated was utilised to ascertain whether ILK was capable of 
phosphorylating the MBP substrate during the course of the kinase reaction. It was 
revealed that both the protein G sepharose beads and S.aureus cells precipitated ILK (59 
kDa) from all cell lines (Figure 14a). It was further noted that the ILK band 
immunoprecipitated by S.aureus cells was more apparent than ILK immunoprecipitated 
using the protein G sepharose beads, suggesting the S.aureus cells to be binding with 
greater affinity to the immune complex of ILK. Even though S.aureus cells were shown 
to be more efficient in precipitating ILK, protein G sepharose beads were used in 
conducting the MBP-based kinase assays, as protein G sepharose beads show increased 
specificity towards IgG molecules and are at present the method of choice. 
 
ILK kinase assays showed that the ILK kinase catalytic domain was active and capable 
of phosphorylating the MBP substrate (Figures 14b). Since MBP was a synthetic 
peptide it lacked kinase activity and not able to undergo autophosphorylation. 
Therefore, a protein G sepharose only negative control was not included in the study. 
ILK activity gel separations were densitometrically analysed, which revealed the ILK 
basal kinase activity to be dissimilar across the cell lines. It must be remembered that 
per µg of total protein equivalent protein concentrations were loaded for the HOSCCs. 
A uniform pattern of activity was noted in the WHCO1, WHCO6 and SNO cell lines. 
The WHCO5 line was 5 fold higher in activity in comparison to the WHCO3 cell line 
and exhibited a 2.5 fold difference over the WHCO1 and SNO cell lines. The ILK 
kinase activity of WHCO5 was also 2 fold higher than the WHCO6 cell line (Figure 
15a). Lowest ILK activity was noted in the WHCO3 cell line. These data demonstrate 
that ILK activity levels are inconsistent across the five moderately differentiated 
oesophageal SCC cell lines examined. 
 
Interestingly, it was observed that treatment of cell cultures with EGF (10 ng/ml) and 
TGFβ1 (1 ng/ml) caused a decline in the ILK kinase activity in cell lines WHCO1, 
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WHCO6 and SNO between 1 to 3 fold (established by laser densitometry, Figure 15b). 
However, paradoxical results were obtained in the case of the WHCO5 cell line, where 
treatment with TGFβ1 reduced ILK activity, whereas EGF augmented ILK activity in 
comparison to standard untreated WHCO5. The addition of growth factor had the 
greatest effects on the WHCO3 line, which showed a dramatic increase in activity to 
both EGF (3 fold) and, TGFβ1 (3.5 fold). Although TGFβ1 treatment produced a 
similar result to that of EGF, its effect on ILK activity was more profound. 
Delcommenne et al. (1998) have previously shown that growth factors are able to 
upregulate ILK activity. While the present data indicate a modulation of ILK activity by 
the EGF and TGFβ1, a time course analysis would be necessary to fully understand the 
effects of EGF and TGFβ1 on ILK activity. 
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Figure 14: ILK Kinase Assays Characteristic of the Various Cell Lines.  
a) SNO immunoprecipitated ILK band using killed S.aureus cells and protein G 
sepharose beads characteristic of all cell lines (blue arrow). Lane 1 – S.aureus 
immunoprecipitated ILK, lane 2 – protein G sepharose immunoprecipitated ILK. b) ILK 
kinase activity of WHCO1, WHCO3, WHCO6 and SNO cell lines indicating MBP 
phosphorylation (red arrow). Cell line WHCO3 shows reverse effect of growth factor 
treatment not characteristic of other cell lines. Cell lysates were preabsorbed with 
protein G sepharose to prevent non-specific protein G associated products. Lane 1 – 
phosphorylated MBP (untreated), lane 2 – MBP phosphorylation following EGF 
treatment, lane 3 – MBP phosphorylation (TGFβ1 treated) and lane 4 − Negative 
substrate control (MBP excluded). Experiments were repeated three times. 
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Figure 15: Densitometric Analysis of ILK Activity Levels.  
a) Standard ILK activity levels following protein G sepharose immunoprecipitation of 
ILK and a MBP-based kinase assay. WHCO5 cell line exhibited highest levels of ILK 
activity, whereas the WHCO3 showed lowest levels of ILK activity. b) Comparative 
levels of ILK activity are shown between standard untreated cell lines, EGF treated and 
TGFβ1 treated cell lines. While the WHCO1, WHCO6 and SNO lines all exhibited 
diminished activity following growth factor addition, the WHCO3 line showed a 
marked increase in ILK activity. The WHCO5 cell line demonstrated conflicting results 
with an increase in activity by EGF (10 ng/ml) and a decrease in activity by TGFβ1 (1 
ng/ml). Experiments were repeated three times. 
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3.3.2 Growth Factors Influence PTEN Expression Levels 
As described earlier, the activity of ILK is sensitive to PTEN levels which negatively 
regulates ILK via the dephosphorylation of PIP3, the product of PI3K, which in turn 
prevents the activation of ILK (Persad et al., 2000; Backman et al., 2002; Leslie and 
Downes, 2004; Walker et al., 2004). Thus in normal cellular conditions ILK activity 
levels are maintained under stringent control by the activities of PI3K and PTEN 
(Kaneko et al., 2003; Miller et al., 2003). It is expected that the regulation of PTEN 
levels via EGF and TGFβ1 would influence ILK kinase activity in these HOSCC cell 
lines. 
 
The presence of a 56 kDa PTEN band was confirmed via Western blotting analysis in 
all five HOSCCs (Figure 16a). Densitometric analysis revealed that levels of PTEN 
expression demonstrated great variation between the various cell lines. PTEN 
expression was highest in the WHCO1 line, on average 4 fold higher than PTEN 
expression in the WHCO6 and SNO cell lines. Furthermore, PTEN expression in 
WHCO1 cells was 1.3 and 2 fold higher than the WHCO3 and WHCO5 cell lines 
respectively. In contrast, the WHCO6 exhibited lowest PTEN expression, 4 and 2.5 fold 
lower than WHCO3 and WHCO5 cells respectively (Figure 16b). 
 
When the respective HOSCCs were treated with EGF (10 ng/ml) for a period of 24 
hours, the WHCO1 cell line exhibited a vast increase in PTEN expression of 6.4 fold in 
comparison to the untreated cell lysate. Similarly, the WHCO5 and SNO cell lines also 
displayed substantial increases in the expression of PTEN of 6.2 and 3.4 fold 
respectively. Surprisingly, in the WHCO3 and WHCO6 cell lines noticeable decreases 
in PTEN expression were observed of 3 and 2.3 fold respectively (Figure 17a and b). 
 
EGF exposure resulted in both an increase and decrease of the protein expression of 
PTEN. TGFβ1 on the other hand, increased PTEN expression in all five HOSCCs 
(Figure 18a). Although this increase was modest in the WHCO5 cell line (1.5 fold), 
more noteworthy increases were shown in the remaining cell lines. In the WHCO3, 
WHCO6 and SNO cell lines, an average increase of 2 fold was observed, while 
WHCO1 cells demonstrated the highest increase of 3.9 fold (Figure 18b). A lower 
 109
molecular weight band was observed below the PTEN band (Figure 17a and 18a, black 
arrows). This is attributed to degradation products that are present in the cell lysates. 
.
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Figure 16: Western Blot and Densitometric Analysis of PTEN Expression Levels.  
a) Western blots performed utilising a rabbit anti-PTEN antibody (1:10000) on the 
soluble supernatants of the membrane/cytoplasmic cell lysates revealed PTEN 
expression at a molecular weight of approximately 56 kDa across all cell lines 
(indicated by red arrow). Lane 1 – WHCO1, lane – WHCO3, lane 3 – WHCO5, lane 4 – 
WHCO6, and lane 5 – SNO. b) Densitometric analysis revealed PTEN expression levels 
were not uniform across all human oesophageal SCC lines under standard culture 
conditions. The WHCO1 displayed highest PTEN expression 5 fold higher than the 
WHCO6 cell line (lowest PTEN expression), 1.3 fold higher than WHCO3 PTEN 
expression, 2 fold higher than WHCO5 PTEN expression, and 3.3 fold higher than SNO 
PTEN expression. Note: the expression levels are representative as a percentage of 
maximum per 10 µg of protein from concentrated fractions (included to normalise for 
loading variation). Experiments were repeated three times. 
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Figure 17: The Effect of EGF on PTEN Expression Levels.  
a) Western blot analysis of PTEN expression (red arrow) using a rabbit anti-PTEN 
antibody (1:10000) following exposure to EGF (10 ng/ml) for 24 hours in the five 
HOSCCs. Degradation products are indicated by the black arrow. PTEN expression was 
increased in the WHCO1, WHCO5 and SNO cell lines. A decrease in PTEN expression 
was in the WHCO3 and WHCO6 cell lines. Lane 1 – untreated WHCO1, lane 2 - EGF-
treated WHCO1, lane 3 – untreated WHCO3, lane 4 - EGF-treated WHCO3, lane 5 – 
untreated WHCO5, lane 6 - EGF-treated WHCO5, lane 7 – untreated WHCO6, lane 8 - 
EGF-treated WHCO6, lane 9 – untreated SNO and lane 10 - EGF-treated SNO. b) 
Densitometric analysis of PTEN protein expression levels revealed that PTEN 
expression was increased substantially in the WHCO1, WHCO5 and SNO cell lines by 
6.4, 6.2 and 3.4 fold respectively. In the WHCO3 and WHCO6 cell lines, PTEN 
expression was decreased following EGF exposure by 3 and 2.3 fold respectively. Note: 
the expression levels are representative as a percentage of maximum per 10 µg of 
protein from concentrated fractions (included to normalise for loading variation). 
Experiments were repeated three times. 
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Figure 18: The Effect of TGFβ1 on PTEN Expression Levels.  
a) Western blot analysis of PTEN expression (red arrow) utilising a rabbit anti-PTEN 
antibody (1:10000) following exposure to TGFβ1 (1 ng/ml) for 24 hours in the five 
HOSCCs. Degradation prodcuts are indicated by the black arrow. Lane 1 – untreated 
WHCO1, lane 2 – TGFβ1-treated WHCO1, lane 3 – untreated WHCO3, lane 4 - 
TGFβ1-treated WHCO3, lane 5 – untreated WHCO5, lane 6 - TGFβ1-treated WHCO5, 
lane 7 – untreated WHCO6, lane 8 – TGFβ1-treated WHCO6, lane 9 – untreated SNO 
and lane 10 – TGFβ1-treated SNO. b) Densitometric analysis of PTEN protein 
expression levels. PTEN showed a marked increase in the presence of TGFβ1 in the 
WHCO1, WHCO3, WHCO5, WHCO6 and SNO cell lines with the WHCO5 cell line 
exhibiting the highest PTEN expression of 7.1 fold. Note: the expression levels are 
representative as a percentage of maximum per 10 µg of protein from concentrated 
fractions (included to normalise for loading variation). Experiments were repeated three 
times. 
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3.3.3 ILK and PTEN are Associated in HOSCCs 
Due to the regulatory role PTEN plays with regards to ILK function, it stands to reason 
that these protein moieties should be in close proximity to one another. The approach 
taken to confirm this idea was co-immunoprecipitation analysis. PTEN was 
immunoprecipitated from protein cell lysates by precipitating PTEN utilising an 
antibody directed against PTEN. This immunocomplex was allowed to bind to protein 
G sepharose and was subsequently probed for ILK by Western blotting. A ILK band 
was detected in PTEN-immunoprecipitates at the correct molecular weight of 59 kDa in 
all five cells examined (Figure 19a, purple arrow). To ensure that the identified bands 
were of the appropriate molecular weight corresponding to ILK, a WHCO1 cell lysate 
was included as a positive control. The positive control was separated in conjunction 
with the immunoprecipitated samples. It must be mentioned that in all the 
immunoprecipitated fractions, nonspecific bands presumed to be IgG of both the heavy 
and light chain (see also Kim et al., 2000) were also nonspecifically identified (Figure 
19, blue and green arrows). 
 
However, when the reverse experiment was performed (i.e. ILK immunoprecipitated 
and probed for PTEN), a PTEN band was not observed. A smaller molecular weight 
protein product was present, which was identified as the small chain of IgG at an 
approximate molecular weight of 30 kDa (Figure 19b, blue arrow). In spite of PTEN not 
being present in ILK immunoprecipitates, the identification of ILK in PTEN 
immunoprecipitates suggests a novel interaction between these two moieties. This 
supports the above data that a protein interaction does indeed occur between ILK and 
PTEN in HOSCCs. In both co-immunoprecipitation experiments, cell lysates were 
preabsorbed with protein G sepharose to prevent non-specific associated products (see 
Methods and Materials). 
 
3.3.4 PTEN and ILK Are Similarly Distributed 
Having identified a physical relationship between ILK and PTEN, it is reasonable to 
presume that these signalling moieties move to similar cellular distributions. Since we 
considered the influence of PTEN on ILK in particular, immunofluorescence studies 
were conducted, which confirmed PTEN localisation to be similar to that of ILK. In 
chapter 2 Figure 10 it was revealed that although ILK was shown to be largely 
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distributed in the cytoplasmic/nuclear region, with variable amounts observed at the 
membrane (Figure 20, red arrows). PTEN closely followed this distribution pattern, 
with the majority of PTEN occurring throughout the nuclear region (but not at FAs) 
(Figure 20, blue arrows). A smaller proportion of PTEN was also noted at a cytoplasmic 
level and is particularly apparent in the WHCO1 cell lines (Figure 20, red arros). The 
localisation pattern of PTEN in these HOSCCs is similar to that of previous studies, 
which have shown PTEN to be largely cytosolic and even nuclear in some cells (Walker 
et al., 2004). 
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Figure 19: The Association between PTEN and ILK.  
a) An ILK band of approximately 59 kDa (indicated by purple arrow) was identified 
following protein G sepharose immunoprecipitation of PTEN and Western blotting with 
either a rabbit anti-ILK (1:1500) or a rabbit anti-PTEN antibody (1:10000). The light 
chain of IgG was also identified (indicated by green arrow). Lane 1 – Control WHCO1, 
lane 2 – WHCO1, lane 3 – WHCO3, lane 4 – WHCO5, lane 5 – WHCO6 and lane 6 
SNO. b) PTEN was not identified when ILK was immunoprecipitated utilising protein 
G sepharose and subsequently probed for PTEN. PTEN was however observed in the 
control WHCO1 protein extract (indicated by red arrow). Lane 1 – control WHCO1, 
lane 2 – WHCO1, lane 3 – WHCO3, lane 4 – WHCO5, lane 5 – WHCO6, lane 6 – 
SNO. 
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a) WHCO1    b) WHCO3 
 
 
 
 
 
 
 
 
 
c) WHCO5    d) WHCO6 
 
 
 
 
 
 
 
 
 
e) SNO     f) Control 
 
 
 
 
 
 
 
 
Figure 20: Indirect Immunofluorescence of PTEN in HOSCCs.  
a-e) PTEN expressed by HOSCCs showing variable amounts of PTEN distribution with 
majority of PTEN being located at a nuclear region (blue arrows). A proportion of 
cytoplasmic localisation was also observed and is particularly visible in the WHCO1 
cell line (red arrows). f) Negative control (excluding FITC-conjugated antibody) 
indicating diffuse staining. Bar represents 10 µm.
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3.4 Discussion 
Signal transduction events provide a communication network between intracellular and 
extracellular compartments of cells. Protein phosphorylation is a critically important 
posttranslational modification, which lies at the heart of the regulatory mechanism 
controlling cellular activities (Yoganathan et al., 2000; Cordes and van Beuningen, 
2003; Wu, 2005). These events are regulated by protein kinases and protein 
phosphatases. Protein kinases are particularly pertinent to tumourigenesis since many 
cancers are known to express dysregulated kinase activities, examples to date being, 
colon cancer, breast cancer, lung cancer, and leukaemia’s (Yoganathan et al., 2000; 
Cornillon et al., 2003; Khyrul et al., 2004; Tsuboi et al., 2004; Fang and Richardson, 
2005). 
 
This study has focused on a key protein kinase, ILK, which is known to be essential not 
only during normal cellular processes but in addition, critical in the development of 
metastatic spread of malignant cells (Persad et al., 2000; Attwell et al., 2003; Khyrul et 
al., 2004; Aoyagi et al., 2005). ILK regulates numerous signalling molecules, including 
GSK3β and PKB (Hannigan et al., 1996; Troussard et al., 2000; Gary et al., 2003), 
which elicit a wide variety of cellular responses including growth of epithelial cells, 
apoptosis and cell differentiation (Hannigan et al., 1996; Huang et al., 2000; Attwell et 
al., 2003; Chun et al., 2005). ILK is able to decrease apoptotic tendencies in cells via 
PKB stimulation and increase invasion and proliferation processes through GSK3β 
inhibition, thus implicating ILK in tumourigenesis. The final two data chapters of this 
study are concerned with growth factor effects on ILK kinase activity, the expression of 
ILK in the nucleus and the role of ILK activity during cell-ECM adhesion, since these 
oesophageal SCC cell lines in question are known to be highly metastatic most likely 
through their ability to breach cell-ECM contacts. 
 
ILK isolation accomplished via immunoprecipitation revealed an ILK band of 59 kDa 
(see Figure 14a). Immunoprecipitated ILK was apparent for both protein G sepharose 
beads and S.aureus, although the formalin fixed intact S.aureus cells were more 
effective in immunoprecipitating the ILK immune complex. In most strains of S.aureus, 
a covalent link attaches protein G to the cell wall and is able to bind immunoglobulin 
molecules with high affinity (Goding, 1978). IgG is the principal molecule that binds 
although IgM and IgA are also capable of binding in certain species (Goding, 1978). An 
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explanation for this strong reaction may be that per volume, S.aureus cells contain a 
larger concentration of protein G in comparison to purified protein G sepharose beads, 
resulting in relatively more ILK binding to the S.aureus cells.  
 
Although S.aureus cells seemed to be the obvious choice when proceeding with the 
MBP-based kinase assays, we avoided their use since the possibility exists that other 
protein molecules on their cell surfaces could potentially phosphorylate MBP and 
consequently produce false positives. Protein G is the active component of S.aureus in 
terms of antibody interactions and therefore purified protein G sepharose beads seemed 
the obvious choice for the ILK kinase assays (Hannigan et al., 1996; Attwell et al., 
2003). Protein G sepharose beads only possess epitopes to bind γ-globulins and do not 
contain any other protein constituents which may be able to phosphorylate the MBP 
substrate.  
 
In Chapter 2 it was shown that ILK is able to associate with both the integrin and 
growth factor receptors suggesting that ILK provides a link between these two classes 
of receptors. As has been outlined above, the kinase activity of ILK plays a major role 
in signal transduction pathways that influence many cellular processes and is directly 
involved in directing the attachment of cells to the ECM by regulating β integrins (Li et 
al., 1999; Zervas et al., 2001; Oloumi et al., 2004). However, conflicting results have 
been published with respect to the activity of ILK, as it is not known for certain whether 
ILK possesses full kinase capabilities (Wu and Dedhar, 2001). This follows a study by 
Lynch et al. (1999), where ILK kinase activity was undetected in ILK 
immunoprecipitates. Recent evidence indicates that ILK acts as a kinase in certain 
circumstances where it is capable of phosphorylating substrates such as PKB and 
GSK3β (Obara et al., 2004; Quélo et al., 2004; Grashoff et al., 2004). 
 
Since the growth factor EGF was shown to increase ILK expression in oesophageal 
SCCs, it was of interest to examine the kinase activity of ILK and to ascertain the 
effects of growth factor on its activity. This would perhaps provide a basic 
understanding of the mechanism/s by which growth factors regulate ILK in carcinoma 
of the oesophagus. Furthermore, discernment of ILK activity would indicate the 
propensity of these oesophageal carcinoma cells to metastasise since it has been 
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established that increased ILK activity correlates with increased invasiveness (Novak et 
al., 1998; Wu et al., 1998; Troussard et al., 2000).  
 
The activation or inhibition of ILK activity is cell-type dependent and can be modified 
by growth factors (Delcommenne et al., 1998; Novak et al., 1998). The effect/s of 
growth factors on ILK kinase activity has been previously demonstrated where it was 
shown that rapid stimulation of ILK activity by insulin and PDGF occurred in intestinal 
epithelial cells (Delcommenne et al., 1998). In addition, these authors showed that 
inhibition of PI3K inhibited insulin-induced ILK activation and that overexpression of a 
subunit of PI3K activated ILK in vivo demonstrating that the PH motif of ILK 
participates in regulation of ILK kinase activity in response to insulin (Delcommenne et 
al., 1998). Thus, the link that exists between integrins and growth factor mediated 
signalling is well established (Dedhar et al., 1999; Janji et al., 2000; Grashoff et al., 
2004; Kaneko et al., 2004). ILK is a crucial mediator in this relationship, as it 
physically interacts with the β integrins through its kinase domain and links to the 
growth factor receptors via PINCH and Nck-2 (Nikolopoulos and Turner, 2002). 
 
The mechanisms by which growth factors regulate ILK activity are almost certainly 
PI3K-dependent since PI3K has been shown on numerous occasions to activate ILK 
(Delcommenne et al., 1998; Dedhar et al., 1999; Somasiri et al., 2000). Furthermore, 
ILK is activated in a response to a variety of extracellular stimuli, including cytokines, 
growth factors, as well as adhesion to extracellular matrices (Delcommenne et al., 1998) 
and inhibition of the lipid phosphatase PTEN, which is known to be a negative regulator 
of ILK expression (Persad et al., 2000; Attwell et al., 2003; Grashoff et al., 2004).  
 
In this study, growth factors increased ILK protein expression, but caused both 
increases and decreases in ILK activity in the oesophageal SCC cell lines examined (see 
Figure 15b). While these HOSCCs exhibit increased EGFR, not all cell lines responded 
in the same way to EGF exposure. The WHCO3 cell line, in response to EGF and 
TGFβ1, showed an increase in ILK activity (increased ILK protein expression), whereas 
the WHCO1, WHCO6 and SNO cell lines all exhibited decreased ILK activity (protein 
expression increased). The increase in ILK protein expression noted in cell lines 
WHCO1, WHCO6 and SNO (see Chapter 2, Figure 7), with a decrease in ILK activity 
in the same cell lines, suggests that PI3K concentrations are not similarly increased by 
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growth factors. The consequence of this may well be insufficient PI3K to activate the 
elevated ILK concentrations. Assuming that PI3K levels have remained unchanged, the 
substantial increase in ILK activity in the WHCO3 cell line was attributed to decreased 
PTEN since TGFβ1 has been shown to downregulate PTEN mRNA in keratinocytes 
(Janji et al., 2000).  
 
Indeed EGF was shown to reduce PTEN expression levels in the WHCO3 cell line by 3 
fold confirming the notion that the ILK-induced kinase activity by EGF is a direct result 
of reduced PTEN expression (see Figure 17b). In contrast it was thought that EGF and 
TGFβ1 were stimulating PTEN activity in the WHCO1 and SNO cell lines. Indeed, 
EGF was shown to increase PTEN expression levels in these cell lines, corroborating 
our results that EGF regulates ILK activity via PTEN. In the case of WHCO5 and 
WHCO6 however, PTEN expression levels in the presence of EGF did not correspond 
to EGF-treated ILK activity levels. While EGF caused ILK activity to increase in 
WHCO5 cells, this cell line also showed increased PTEN expression when exposed to 
EGF. Similarly, in the WHCO6 cell line, EGF caused a decrease in ILK activity with a 
concomitant decrease in PTEN expression levels (see Figure 17b). This implies that 
another mechanism is in place for the EGF-mediated effects on the WHCO5 and 
WHCO6 cell lines.  
 
In response to the increased EGFR that have been reported with regards to the 
oesophageal SCC lines (Veale and Thornley, 1989), one could argue that the WHCO6 
cell line is at an upper limit of growth factor response. Thus, growth factor treatment of 
these cell lines would not elicit any further cellular responses, a consequence being that 
ILK would not be activated, accounting for the low levels of ILK kinase activity 
observed in this cell line. This speculation is supported by the suggestion that in 
fibroblasts higher TGFβ1 concentration results in inhibition of both cell migration and 
proliferation (Moses et al., 1990). 
 
Unlike EGF, TGFβ1 reduced ILK activity in the WHCO5 cell line and produced a 
similar substantial increase in ILK activity in the WHCO3 cell line. TGFβ1 has 
previously been shown to elicit a dual effect on cells, either inhibiting cell growth in 
cancers such as colon, breast and squamous cell carcinoma (Zugmaier et al., 1989; Wu 
et al., 1992; Fujimoto et al., 2001), or stimulating cell proliferation in malignancies of 
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squamous carcinoma cell lines and prostate carcinomas (Ozanne et al., 1986; Steiner 
and Barrak, 1992; Fujimoto et al., 2001).  
 
A vast increase in ILK activity occurred in the presence of TGFβ1 in the WHCO3 cell 
line. One would then expect TGFβ1-treated WHCO3 cells to demonstrate a decrease in 
PTEN expression levels. However, TGFβ1 resulted in an increase in PTEN expression 
levels in this cell line, suggesting that PTEN is not involved in TGFβ1-mediated 
regulation of ILK activity in this cell line. On the other hand the results obtained in the 
WHCO1, WHCO5, WHCO6 and SNO cell lines could be due to the effect of TGFβ1 
stimulating PTEN expression in these cells as TGFβ1 increased PTEN expression by as 
much as 7.1 fold  (see Figure 18b). 
 
From these data it is apparent that PTEN does not play a role in the EGF-mediated 
effects on ILK kinase activity in the case of the WHCO5 and WHCO6 cell lines. 
Furthermore, when exposed to TGFβ1, WHCO3 cells do not respond in a fashion which 
would suggest an involvement of PTEN. Another phosphatase capable of inhibiting ILK 
function which is known as ILK-alkaline phosphatase (ILKAP) may be influenced by 
the action of growth factors. ILKAP is a protein phosphatase, known to directly 
associate with ILK, thereby allowing for the inhibition of ILK activity (Leung-
Hagesteijn et al., 2001; Kumar et al., 2004). While ILKAP is able to downregulate 
integrin- and growth factor-stimulated ILK activity (Leung-Hagesteijn et al., 2001), no 
mention is made concerning the effect of growth factors upon the activity of ILKAP. It 
is conceivable that EGF and TGFβ1 may be exerting their effects on ILK kinase activity 
via ILKAP. Thus, for WHCO3 and WHCO5 cells, ILKAP may be downregulated by 
TGFβ1 (WHCO3) and EGF (WHCO5) accounting for the increases in ILK activity. In 
the WHCO6 cell line, EGF may also stimulate ILKAP, thus decreasing ILK activity. 
 
The discrepancies that were observed with respect to growth factor modulation of ILK 
activity within these cell lines may be of particular relevance to oesophageal squamous 
cell carcinoma. A reasonable assumption may be that cell adhesion is decreased through 
a disruption of ILK activation by PI3K in the WHCO1, WHCO5, WHCO6 and SNO 
cell lines. The assumption made here of PI3K levels being unaffected by growth factors 
would be in disagreement to previous reports. Indeed, PI3K has been shown to be 
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increased via EGF in malignancies of head and neck squamous cell carcinomas 
(HNSCC), ovarian tumour cell lines and prostate carcinomas (Ellerbroek et al., 2001; 
Bancroft et al., 2002) with a similar interaction occurring between TGFβ1 and PI3K 
(Gotzmann et al., 2002). Another possible explanation could be due to the single time 
point analysis that was utilised. A time course analysis would perhaps clarify the 
discrepancies that were observed with regards to growth factor effects on ILK acitivity. 
 
It was clear that in the majority of the cell lines examined, PTEN played a major role in 
the regulation of growth factor-mediated changes in ILK activity. This implied that an 
association between ILK and PTEN existed in these cell lines. This was confirmed by 
co-immunoprecipitation analysis where a physical relationship between ILK and PTEN 
was identified (see Figure 19a). Surprisingly, when ILK was immunoprecipitated and 
probed for the presence of PTEN, no PTEN band was observed (see Figure 19b). There 
are various explanations for PTEN not being identified in ILK-precipitated lysates. ILK 
may not be associating with PTEN in a 1:1 molar ratio. In other words, when ILK was 
immunoprecipitated from cell lysates, the concentration of bound PTEN may have been 
very low, which would account for PTEN not being identified in ILK lysates. In 
addition, the binding epitopes of PTEN may have been masked, preventing antibody 
recognition and binding. Subsequently no PTEN product would be observed. However, 
further support of the notion that ILK and PTEN are associated in these HOSCCs was 
demonstrated by the similar localisation patterns being observed between PTEN and 
ILK (see Figure 20). 
 
Although not examined, the role of this interaction may include phosphorylation-based 
regulation of PTEN activity. Indeed, posttranslational regulation of PTEN is known to 
occur via serine/threonine phosphorylation (Al-Khouri et al., 2005). Studies propose 
that the phosphorylation of PTEN serves to maintain PTEN in a conformation that 
blocks membrane association, which could regulate its biological activity (Walker et al., 
2004). For a while now, Casein kinase II (CKII) has been thought to be the predominant 
molecule capable of phosphorylating PTEN (Torres and Pulido, 2001; Al-Khouri et al., 
2005; Gericke et al., 2006). However, CKII is not capable of phosphorylating all sites 
on PTEN and GSK3β has also been shown to be capable of phosphorylating PTEN (Al-
Khouri et al., 2005). This phosphorylation of PTEN by CKII has important 
consequences with regards to the biological activity of PTEN, as well as modulating its 
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stability to proteasome-mediated degradation (Vazquez et al., 2000; Torres and Pulido, 
2001. 
 
Since ILK is a serine/threonine kinase phosphorylating substrates such as PKB and 
GSK3β (Cordes and van Beuningen, 2003), the physical association between PTEN and 
ILK could serve to allow for ILK-mediated PTEN serine phosphorylation. If this were 
indeed the case, this would suggest that a feedback mechanism would be in place where 
PTEN could regulate ILK activity via PI3K and ILK in turn could directly regulate 
PTEN activity (see Figure 21 below). The determination of PTEN expression levels in 
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Figure 21: Proposed Feedback Mechanism of ILK Mediated Regulation of PTEN. 
ILK activation occurs via PI3K phosphorylation. ILK in turn is capable of regulating 
PTEN phosphorylation. This occurs either indirectly via GSK3β or directly whereby 
ILK associates with PTEN. 
 
these cell lines has clearly shown that in the WHCO1, WHCO5 and SNO cell lines 
growth-factor mediated changes in ILK activity depends on the ability of EGF and 
TGFβ1 to influence PTEN expression. It seems that the WHCO3 cell line has lost its 
sensitivity to the regulatory mechanisms of EGF and TGFβ1 and if this is indeed the 
case, elucidating TGFβ1 function in this cell line becomes of paramount importance. 
Furthermore, it is suggested here that an inverse relationship exists between ILK protein 
expression and activity in response to growth factors. 
 
The data presented here support evidence that HOSCC ILK is an active kinase (Wu and 
Dedhar, 2001) and indicates a distinct mechanism of regulation of ILK activity by 
growth factors within this class of SCCs (Delcommenne et al., 1998). These effects may 
have further consequences in altering cell-ECM adhesion events as an outcome of 
altered ILK activity. Although not tested, the ability of ILK to phosphorylate MBP in all 
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the oesophageal SCC cell lines suggests that in addition to associating with the β3 
integrin, ILK may be regulating the β1 integrin subunit since MBP contains a β1 integrin 
sequence. The focus of the chapter 5 will examine the role played by the activity of ILK 
in cell-ECM adhesion in these cell lines. 
 
The proceeding chapter however will examine the nuclear localisation of ILK that was 
displayed in chapter 2. In this regard, the caveolae protein, caveolin-1 is important to 
ILK-mediated nuclear localisation and thus forms the focus of chapter 4. 
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Chapter 4 
 
ILK Subcellular Localisation is mediated by Caveolin-1 
 
4.1 Introduction 
Caveolae (‘little caves’) were first described morphologically in the 1950’s as non-
coated vesicles (Razani et al., 2000). Caveolae exist as distinct plasma membrane 
invaginations, which allow for the organisation and recruitment of signal transduction 
machinery, the transport of cholesterol, as well as the uptake of vitamins and toxins (Pol 
et al., 2000; Park et al., 2000; Wiechen et al., 2001; Hnasko and Lisanti, 2003). They 
are vesicular organelles that are especially prevalent in terminally differentiated cell 
types including adipocytes, endothelial cells and myocytes, but have been identified in 
the majority of cell types (Couet et al., 1997; Razani et al., 2000; Epand et al., 2005).  
 
Traditionally, caveolae were implicated in transcytosis and potocytosis (Razani et al., 
2000). Recently though, it has been noted that caveolae are enriched in cell surface 
receptors such as those for EGF and PDGF and contain intracellular signalling 
molecules, including Ras and Src (Couet et al., 1997; Anderson et al., 1998; Kim et al., 
2002; Tagawa et al., 2005). The identification of these signalling molecules now 
suggest that caveolae further participate in signal transduction events (Kim et al., 2000; 
Williams et al., 2004; Lee et al., 2005). It has been proposed that caveolae serve as 
crucial mediators of transport processes where they store inactive signalling molecules 
for regulated activation and also to facilitate cross-talk between distinct signalling 
cascades (Couet et al., 1997; Williams et al., 2004; Epand et al., 2005). 
 
The major structural component of caveolae membrane domains are the caveolin 
proteins, a family of 21-24kDa integral membrane proteins (Liu et al., 2001; Williams 
et al., 2004; Epand et al., 2005; Orlichenko et al., 2005). Three caveolin genes exist 
(CAV-1, CAV-2 and CAV-3), but it is CAV-1, encoding for caveolin-1 which is of 
particular interest, since it is able to associate with numerous cell surface growth factor 
receptors (Couet et al., 1997; Lin et al., 2005) and cell adhesion receptors (Wary et al., 
1998; Kim et al., 2002; Liu et al., 2001). It has been noted, that the binding of caveolin-
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1 to these signalling moieties results in an inhibition of their in vitro kinase activity, 
suggesting that caveolin-1 serves as a negative regulator of many signalling proteins 
(Chun et al., 2005).  
 
The interaction of caveolin-1 with EGFR is particularly interesting, since EGF 
stimulates the recruitment of multiple signalling molecules to caveolae (Kim et al., 
2000; Epand et al., 2004). Furthermore, EGF is known to tyrosine phosphorylate 
caveolin-1, but surprisingly, the role of tyrosine-phosphorylated caveolin-1 remains 
largely unknown (Labrecque et al., 2004). Studies have suggested however, that 
tyrosine-phosphorylated caveolin-1 is specifically associated with Grb7, a signalling 
protein involved in growth factor-induced cell migration (Labrecque et al., 2004). 
 
Although caveolin-1 is expressed in the majority of cell types, its expression is 
downregulated, or absent in oncogenically transformed NIH/3T3 cells, as well as in 
human breast, colon carcinoma cell lines, and human mammary and lung carcinoma 
cells (Kato et al., 2004; Koleske et al., 1995; Engelman et al., 1997; Lee et al., 1998 
cited in Chun et al., 2005; Racine et al., 1999; Liu et al., 2001). However, tissue studies 
of human breast and prostate cancers have supported a positive association of caveolin-
1 expression with tumour initiation and progression, suggesting a tumour promoting 
function. These reciprocal functions suggest that caveolin-1 may have a variable role 
depending on the stage of carcinogenesis (Kato et al., 2004). Caveolin-1has been 
previously identified in carcinoma of the oesophagus, where immunoreactivity was 
shown to correlate with a poor survival rate (Kato et al., 2004). 
 
While caveolin-1 possesses the qualities of a scaffolding protein, more interesting is its 
role as a modulator of cell signalling (Razanai et al., 2000). Recently it has been shown 
that a bona fide caveolin-binding motif exists within the catalytic domain of ILK, which 
is conserved in the ILK family (Chun et al., 2005). This has obvious relevance to this 
study as caveolin-1 may be directing the signalling of ILK in HOSCCs. The cytosolic 
retention of ILK could also be attributed to the binding of caveolin-1 since a putative 
nuclear localization signal (nls), shown to exist within ILK, blocked upon binding to 
caveolin-1 (Chun et al., 2005). Furthermore, in this same study, caveolin-1 binding also 
resulted in downregulation of the autophosphorylation activity of ILK (Chun et al., 
2005).  
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The preceding data chapter dealt largely with how ILK serves as a link between 
integrin, and growth factor signalling pathways. Due to the cytoplasmic/nuclear 
distribution of ILK, demonstrated in Chapter 2, we postulated that the above association 
allows for the internalisation of ILK and subsequent shuttling to the nucleus in 
oesophageal carcinoma.  
 
Interactions between caveolin-1 and EGFR have been clearly demonstrated in 
epidermoid carcinoma, human glioblastoma and squamous carcinoma (Kim et al., 
2006), where EGF has been shown to cause a decrease in caveolin-1 protein expression 
(Lu et al., 2003). This led us to believe that EGF induced a downregulation of caveolin-
1 expression in HOSCCs thus providing the necessary stimulus for ILK nuclear 
localisation. Moreover, we suggest that tyrosine phosphorylation of caveolin-1 provides 
the mechanism for the EGF-dependent downregulation of caveolin-1. 
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4.2 Materials and Methods 
 
4.2.1 Cell Lines 
As previously documented − see Chapter 2, Section 2.2.1 
 
4.2.2 Antibodies 
Caveolin-1 was specifically detected with a polyclonal antibody (Sigma, USA). A 
polyclonal rabbit anti-ILK antibody and a rabbit anti-caveolin-1 antibody were used in 
co-immunoprecipitation experiments. Polyclonal horseradish peroxidase (HRP)-bound 
anti-rabbit secondary antibody was used in Western blot experiments (Separations, SA). 
Anti-phosphotyrosine (Sigma, USA) was utilised in the detection of phosphorylated 
caveolin-1. Fluoroscine isothiocyanate (FITC)-conjugated anti-rabbit secondary 
antibody from Chappel, USA were used in the immunofluorescence experiments. 
 
4.2.3 Nuclear Extraction 
As previously documented − see Chapter 2, Section 2.2.11 
 
4.2.4 Protein Estimation 
As previously documented − see Chapter 2, Section 2.2.6 
 
4.2.5 Western Blotting Analysis 
Samples from cell lines WHCO1, WHCO3, WHCO5, WHCO6 and SNO were resolved 
on 15 % SDS-PAGE gels. The molecular weight was ascertained utilising a 
PageRuler™ Prestained Protein Ladder (Fermentas, Canada), which was 
electrophoresed in conjunction with cell lysates. Samples were transferred to Nitrobind 
nitrocellulose transfer membrane (MSI, USA), in a BioRad Trans-Blot™ Cell at 400 
mA for 3 hours (4 °C) in Western Blot Transfer Buffer (Appendix 1.4.5). After transfer 
was complete, the nitrocellulose membranes were rinsed twice with PBS (see Appendix 
1.1.1), and stored overnight at 4 °C. 
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Each membrane was blocked in BLOTTO (see Appendix 1.4.1) for 1 hour and washed 
6 times in PBS. The blots were incubated in either rabbit anti-caveolin-1 primary 
antibody (1:5000), anti-ILK antibody (1:1500) or anti-phosphotyrosine antibody (1:500) 
for 1 hour where the experiment required. Washing was performed 6 times at 5-minute 
intervals with PBS to remove any residual antibody. Membranes were incubated with a 
HRP-bound secondary anti-rabbit antibody (1:1500) for 1 hour in the dark. Once again 
membranes were washed 6 times at 5-minute intervals with PBS before being exposed 
to the Supersignal® West Pico Working Solution (see Appendix 1.4.2) from the West 
Pico Chemiluminescent Substrate Kit (Pierce, USA) for 5 minutes. Blots were sealed in 
polyethylene ‘saran wrap’ and exposed to hyperfilm™ MP autoradiography film 
(Amersham, UK) for 1.5 minutes. The film was developed in D19B developer (see 
Appendix 1.4.3) for 5 minutes, rinsed briefly in H2O before fixing (see Appendix 1.4.4) 
for 5 minutes. The experiment was repeated three times. 
 
4.2.6 Indirect Immunofluorescence Microscopy 
Similar to ILK localisation, caveolin-1 distribution was analysed utilising indirect 
immunofluorescence microscopy. Briefly, WHCO1, WHCO3, WHCO5, WHCO6 and 
SNO cell lines grown to 80 % confluency were seeded onto sterile glass coverslips. The 
coverslips were washed five times in cold PBS, fixed with 4 % paraformaldehyde 
(Appendix 1.6.1) for 30 minutes and washed again. Coverslips were immersed in 0.25 
% Triton X-100 (Appendix 1.6.2) for 10 minutes, washed twice with PBS, dipped into 
dH2O, and allowed to dry partially. Two circles or wells per coverslip were drawn with 
the DAKO® pen. One well per coverslip was incubated with a polyclonal rabbit anti-
caveolin-1 primary antibody (1:500) for one hour. The other well was incubated in PBS 
(control). This was followed by a thorough washing in PBS as before. All circled areas 
were incubated with an anti-rabbit Fluoroscine Isothiocyanate (FITC)-conjugated anti-
rabbit antibody (1:1000). Both wells were incubated for one hour in the dark. The 
coverslips were washed six times with sterile PBS and then mounted with Elvanol 
mounting agent (Appendix 1.6.3) onto sterilised glass slides. All incubations were 
carried out in a humidity chamber to prevent desiccation. Slides were viewed under a 
Zeiss LSM 410 confocal microscope (FITC excitation 490, emission 525). 
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4.2.7 Co-immunoprecipitation Analysis of ILK and Caveolin-1 
Cell lysates were precleared with protein G sepharose overnight at 4 °C, centrifuged at 
3000 rpm and the supernatants transferred to fresh eppendorf tubes. Co-
immunoprecipitation analysis was performed utilising a protein G immunoprecipitation 
kit (Sigma, USA). Nuclear cell lysates were preabsorbed with protein G sepharose 
overnight at 4 °C. Cell lysates were centrifuged at 3000 rpm and the supernatant 
transferred to fresh eppendorf tubes. Nuclear cell lysates (100 µg) were incubated with 
undiluted polyclonal anti-rabbit caveolin-1 antibody (2 µl) overnight at 4 °C. The 
following day protein G sepharose beads were washed in 1 ml ice cold PBS. The slurry 
was centrifuged for 30 seconds at 12000 rpm in a Sorvall® MC 12 V centrifuge and the 
supernatant decanted. This washing procedure was repeated twice. Thereafter, washed 
protein G beads in PBS were transferred to the protein-antibody complex and incubated 
overnight at 4 °C. Immunoprecipitation buffer (500 µl) was then added to the immune 
complexes containing protein G sepharose and centrifuged for 30 seconds at 12000 rpm. 
The supernatant was decanted and the washing procedure repeated twice more. After 
the final wash, 70 µl 2× lysis buffer was added and the immune complexes were boiled 
for 5 minutes. Samples were then centrifuged for 30 seconds at 12000 rpm and 
immunoprecipitated caveolin-1 supernatants were transferred to fresh eppendorf tubes. 
Samples were stored at −20 °C. 
 
4.2.8 Densitometric Analysis 
Labworks TM Image Acquisition and Analysis software (Labworks version 4.5) was 
used for densitometric analysis to determine quantitatively the concentration level of 
caveolin-1 in the Western blots. Note: the densitometric analysis results are an average 
of 3 repeated experiments. 
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4.3 Results 
 
4.3.1 Membrane/Cytoplasmic and Nuclear Caveolin-1 Protein Levels 
Following EGF Exposure 
A caveolin-1 band of 21 kDa was specifically identified in all the HOSCC cell lines by 
Western blotting utilising an anti-caveolin-1 polyclonal antibody (Figure 22a). 
Densitometric analysis per µg of total protein Triton X-100 extracts loaded revealed that 
expression levels of caveolin-1 protein were similar across the WHCO1, WHCO3 and 
WHCO6 cell lines. Expression levels of caveolin-1 were greatest in the SNO cell line, 
1.3 fold above the average of the WHCO1, WHCO3 and WHCO6 cell lines. Lowest 
expression levels were noted in the WHCO5 cell line, which showed a disparately low 
concentration of caveolin-1. Caveolin-1 expression in the WHCO5 cell line was 
approximately 8 fold lower than the average of the other four HOSCC cell lines (Figure 
22b). 
 
Treating the HOSCC cells with EGF (10 ng/ml) tended to cause a reduction in caveolin-
1 protein expression over time in the WHCO3, WHCO5, WHCO6 and SNO cell lines 
(Figure 23a). WHCO1 cells initially also exhibited decreased caveolin-1 expression. 
However, prolonged exposure to EGF however, caused caveolin-1 expression levels to 
increase. The greatest reduction in caveolin-1 expression was noted in the WHCO6 and 
SNO cell lines, which showed a steady decrease in caveolin-1 expression throughout the 
EGF exposure period. Although the WHCO6 cell line demonstrated a 1.3 fold increase 
in caveolin-1 expression following EGF exposure for 1 hour, in contrast to the 1.7 fold 
reduction observed at 0.5 hours, an overall reduction was observed during the course of 
EGF treatment. Indeed, a reduction in caveolin-1 expression of 7 fold was noted at 6 
hours EGF treatment. EGF exposure for 0.5, 1 and 3 hours respectively in SNO cells, 
caused caveolin-1 expression to decrease substantially, on average 3.3 fold lower than 
the untreated membrane/cytoplasmic cell lysate. SNO caveolin-1 expression continued 
to decrease in that a further reduction of 10 fold was observed after 6 hours EGF 
treatment (Figure 23b). 
 
With regard to the WHCO5 cell line, an initial decrease, after 0.5 hours EGF exposure, 
was noticed followed by a subsequent increase in caveolin-1 expression as the cells 
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were exposed to EGF for greater periods of time. However, throughout the time course, 
caveolin-1 expression levels were at all times lower than untreated cell lysates. In 
WHCO5 cells, an initial reduction of 1.4 fold in caveolin-1 expression was noted, which 
was maintained through to 1 hour EGF exposure. Thereafter, caveolin-1 
membrane/cytoplasmic expression levels increased by as much as 1.3 fold at the 3 hour 
treatment period in comparison to the 0.5 hour period (Figure 23b). WHCO1 cells 
showed a 1.7 fold reduction in caveolin-1 expression following 0.5 hours EGF in 
comparison to the untreated control. Following prolonged exposure to EGF however 
caused caveolin-1 expression levels to increase, where by 6 hours EGF treatment, 
caveolin-1 had reached expression levels similar to that of the untreated cell lysate 
(Figure 23b). 
 
The results above support the claim by Lu et al., (2003) that a constitutive 
downregulation of caveolin-1 occurs in response to EGF in human epidermoid 
carcinoma cells. Furthermore, due to the noted decrease in caveolin-1 expression, it 
seemed reasonable to assume that caveolin-1 was redistributed to the nucleus following 
EGF treatment. Examination of this possibility utilised Western blotting of nuclear 
fractions exposed to EGF for 0.5 hours. Nuclear caveolin-1 concentration levels 
increased following exposure to EGF in the majority of cell lines examined (Figure 
24a). The 0.5 hour EGF time period was chosen since this time period seemed to elicit 
the greatest reduction in terms of caveolin-1 expression at the membrane/cytoplasm. 
The largest increases in nuclear concentrations were noted in the WHCO1 and SNO cell 
lines, producing an increase of 1.2 and 1.4 fold respectively, the WHCO5 cell line only 
showed a small increase of 1.1 fold in nuclear caveolin-1. The WHCO6 cell line on the 
other hand, showed no increase in nuclear caveolin-1 concentration, whereas the 
WHCO3 cell line showed a 1.3 fold decrease in expression (Figure 24b). From these 
data it could be inferred that EGF treatment results in substantial changes in the cellular 
distribution of caveolin-1 in the WHCO5 and SNO cell lines, where nuclear 
concentrations of caveolin-1 are increased with a concomitant decrease in 
membrane/cytoplasm-associated caveolin-1. Since WHCO1 showed increases in 
caveolin-1 expression, both at the membrane/cytoplasm and nuclear regions in response 
to EGF treatment, it can be assumed that no redistribution occurs as a result of EGF. To 
substantiate these data, we subsequently analysed caveolin-1 distribution following 
EGF exposure utilising indirect immunofluorescence (Figure 27). 
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Figure 22: Membrane/Cytoplasmic Expression Levels of Caveolin-1 in HOSCCs.  
a) Western blot analysis of caveolin-1 expression utilising a rabbit anti-caveolin-1 
antibody (1:5000). Caveolin-1 was identified at a molecular weight of 21 kDa in all 
HOSCCs (indicated by blue arrow). Lane 1 – WHCO1, lane 2 – WHCO3, lane 3 – 
WHCO5, lane 4 – WHCO6 and lane 5 – SNO. b) Expression levels of caveolin-1, 
following densitometric analysis revealed highest caveolin-1 expression in the SNO cell 
line and lowest caveolin-1 expression in the WHCO5 cell line. Note: the expression 
levels are representative as a percentage of maximum per 10 µg of protein from 
concentrated fractions (included to normalise for loading variation). Experiments were 
repeated three times. 
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Figure 23: Caveolin-1 Expression Levels Following EGF Exposure.  
a) Western blot of caveolin-1 expression utilising a rabbit anti-caveolin-1 antibody 
(1:5000) following exposure to EGF for 0, 0.5, 1, 3 and 6 hours respectively in the five 
HOSCCs (red arrows). Lane 1 – 0 hours EGF exposure, lane 2 – 0.5 hours EGF 
exposure, lane 3 – 1 hour EGF exposure, lane 4 – 3 hours EGF exposure, lane 5 – 6 
hours EGF exposure. b) Expression levels of caveolin-1 following EGF exposure as 
analysed by densitometry. Throughout the EGF exposure period, caveolin-1 expression 
was reduced in all five HOSCCs Note: the expression levels are representative as a 
percentage of maximum per 10 µg of protein from concentrated fractions (included to 
normalise for loading variation). Experiments were repeated three times. 
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Figure 24: Nuclear Caveolin-1 Protein Levels Following EGF Treatment.  
a) Western blot analysis of caveolin-1 utilising a rabbit anti-caveolin-1 antibody 
(1:5000) in nuclear extracts following EGF (10 ng/ml) treatment for 0.5 hours across all 
HOSCCs. Lane 1 – untreated WHCO1, lane 2 – EGF-treated WHCO1, lane 3 – 
untreated WHCO3, lane 4 – EGF-treated WHCO3, lane 5 – untreated WHCO5, lane 6 – 
EGF-treated WHCO5, lane 7 – untreated WHCO6, lane 8 – EGF-treated WHCO6, lane 
9 – untreated SNO and lane 10 – EGF-treated SNO. b) Nuclear caveolin-1 protein levels 
following densitometric analysis revealed an increase in nuclear caveolin-1 in the 
WHCO1, WHCO3 and SNO cell lines with no subsequent change observed in the 
WHCO6 cell line. Surprisingly, the WHCO3 cell line demonstrated reduced caveolin-1 
expression following EGF exposure. Note: the expression levels are representative as a 
percentage of maximum per 10 µg of protein from concentrated fractions (included to 
normalise for loading variation). Experiments were repeated three times. 
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4.3.2 Nuclear ILK Concentration Following Exposure to EGF 
Due to the observed effects of EGF on the expression of caveolin-1, both at the 
membrane/cytoplasm and the nucleus, EGF was thought to be involved in nuclear 
translocation of ILK. HOSCCs were exposed to EGF for 0.5 hours since at this time the 
most substantial changes in ILK membrane/cytoplasm expression and ILK nuclear 
levels were noted (Chapter 2, Figure 12).  
 
The response of nuclear ILK to EGF exposure was very similar to that of caveolin-1, 
where an increased level of ILK was demonstrated. Treatment of HOSCCs with 10 
ng/ml EGF for 0.5 hours produced an average increase of 1.1 fold in ILK protein levels 
in the nuclear extract of the WHCO6 cell line. The WHCO5 cell line produced a much 
larger increase in ILK expression of 1.6 fold in comparison to the untreated nuclear 
fraction. Surprisingly, in the WHCO3 cell line a decrease in ILK expression of 1.3 fold 
was observed following 0.5 hours EGF exposure, while the WHCO1 and SNO cell lines 
showed no change in ILK expression (Figures 25a and b). 
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Figure 25: Nuclear ILK Protein Levels Following EGF Treatment.  
a) Western blot analysis of nuclear ILK following exposure to 10 ng/ml EGF for 0.5 
hours. Lane 1 – untreated WHCO1, lane 2 – EGF-treated WHCO1, lane 3 – untreated 
WHCO3, lane 4 – EGF-treated WHCO3, lane 5 – untreated WHCO5, lane 6 – EGF-
treated WHCO5, lane 7 – untreated WHCO6, lane 8 – EGF-treated WHCO6, lane 9 – 
untreated SNO and lane 10 – EGF-treated SNO. b) Densitometric analysis revealed that 
nuclear ILK concentration was increased in the WHCO5, WHCO6 and SNO cell lines. 
Surprisingly, ILK expression was reduced in the WHCO3 cell line with no change 
observed in the WHCO1 cell line. Note: the expression levels are representative as a 
percentage of maximum per 10 µg of protein from concentrated fractions (included to 
normalise for loading variation). Experiments were repeated three times. 
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4.3.3 Caveolin-1 is Tyrosine Phosphorylated in HOSCCs 
The tyrosine phosphorylation of caveolin-1 has been clearly demonstrated in response 
to treatment with growth factors such as VEGF, PDGF, as well as EGF where it is 
thought that the Src family tyrosine kinases are critically involved in this process (Kim 
et al., 2000; Labrecque et al., 2004). Surprisingly however, the states of tyrosine 
phosphorylated caveolin-1 remain largely unknown (Lee et al., 2005). A suggestion has 
been made that phosphorylated caveolin-1 serves as a docking site for other tyrosine 
phosphorylated molecules (Lee et al., 2005). 
 
In terms of caveolin-1 distribution there are indications that tyrosine phosphorylation of 
caveolin-1 alters its cellular distribution (Pol et al., 2000). In order to understand how 
EGF impacts on caveolin-1 function in oesophageal carcinoma requires investigating 
the effect of EGF on caveolin-1 tyrosine phosphorylation is required. Since there is 
evidence that EGF tyrosine phosphorylates caveolin-1 (Kim et al., 2000), we examined 
the tyrosine phosphorylation status of caveolin-1 in the relevant HOSCCs in question, 
either in the presence or absence of EGF.  
 
Immunoprecipitation analysis revealed that under untreated conditions, a 25 kDa 
tyrosine phosphorylated caveolin-1 band was identified in the WHCO1 and WHCO5 
cell lines when utilising an anti-phosphotyrosine antibody (Figure 26, orange arrow). 
Nonphosphorylated caveolin-1 normally migrates at approximately 22-24 kDa (Liu et 
al., 2001; Lee et al., 2005). No caveolin-1 tyrosine phosphorylation was noted in the 
WHCO3, WHCO6 and SNO cell lines. The heavy chain of IgG was observed at an 
approximate molecular weight of 56 kDa in all cell lines (Figure 26, blue arrow). 
 
While investigating the effect of EGF upon caveolin-1 tyrosine phosphorylation, 
densitometric analysis could not be performed as a result of inconsistent background 
(data not shown). Treatment with EGF, and subsequent immunoprecipitation of 
caveolin-1, revealed that caveolin-1 was not tyrosine phosphorylated. This occurred 
despite ranging antibody concentrations and reaction conditions being utilised during 
optimisation. A successful result was achieved with high antibody concentration. 
However, the background increased concomitantly making it difficult to discern if 
phosphorylated caveolin-1 was indeed present. It was not possible to say with any 
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certainty whether EGF resulted in a notable increase in the tyrosine phosphorylation of 
caveolin-1. 
 
Although the effects of EGF upon the tyrosine phosphorylation of caveolin-1 could not 
be satisfactorily resolved, it still does not detract from the demonstration that caveolin-1 
is tyrosine phosphorylated in HOSCCs and EGF cannot be ruled out as having an effect. 
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Figure 26: Caveolin-1 Tyrosine Phosphorylation.  
Protein G sepharose immunoprecipitated caveolin-1 utilising rabbit anti-caveolin-1 
antibody (1:5000) was subjected to Western blot analysis. A phospho-specific tyrosine 
antibody (1:500) was used to detect tyrosine phosphorylated caveolin-1. Tyrosine 
phosphorylated caveolin-1 is shown in the WHCO1 and WHCO5 cell lines. Negligible 
tyrosine phosphorylation was noted in the WHCO6 cell line. Tyrosine phosphorylation 
of caveolin-1 was not observed in the WHCO3 and SNO cell lines and may be due to an 
undetectable level of phosphorylation in these cell lines. Lane – WHCO1, lane 2 – 
WHCO3, lane 3 – WHCO5, lane 4 – WHCO6 and lane 5 – SNO cell lines. 
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4.3.4 Caveolin-1 Distribution Following EGF Treatment 
In an attempt to visualise the change in caveolin-1 distribution, indirect 
immunofluorescence was utilised. This followed from the determination that EGF 
lowers caveolin-1 expression at the membrane/cytoplasm together with a subsequent 
increase in expression in the nucleus. Furthermore, Pol et al. (2000) demonstrated that 
caveolae internalise into endocytic compartments, triggered in particular by EGF 
tyrosine phosphorylation of caveolin-1; the distribution of caveolin-1 was ascertained in 
response to 0.5 hours EGF exposure. 
 
Previous studies have shown that a short exposure period to EGF is sufficient to elicit 
caveolin-1 redistribution (Kim et al., 2000; Pol et al., 2000). No obvious redistribution 
of caveolin-1 was revealed in the presence of EGF for 0.5 hours; this was apparent in 
the five cell lines tested. The majority of caveolin-1 seemed to be largely localised at 
the cell membrane. This was especially apparent for the WHCO1, WHCO3 and 
WHCO5 cell lines, which showed prominent membrane caveolin-1, both in the 
presence and absence of EGF (Figure 27, yellow arrows). In the WHCO6 and SNO cell 
lines however, caveolin-1 exhibited a greater cytoplasmic localisation, with membrane 
localisation occurring to a lesser degree. Furthermore, there appeared to be no 
substantial change in the distribution of caveolin-1 following EGF treatment in these 
two cell lines (Figure 27, red arrows). 
 
4.3.5 The Association of Caveolin-1/ILK at the Nucleus  
Reports have previously documented the association between caveolin-1 and ILK in 
neuroblastoma (Chun et al., 2005). The obvious course of action to follow next was to 
confirm whether a direct physical interaction existed between caveolin-1 and ILK. Prior 
to this study it was not known whether a similar protein interaction existed in carcinoma 
of the oesophagus. In order to establish whether an interaction does indeed occur 
between caveolin-1 and ILK in HOSCCs, co-immunoprecipitation analysis was 
performed on nuclear cell lysates, which revealed that caveolin-1 and ILK do indeed 
associate at nuclear regions of the cell across all cell lines tested. When caveolin-1 was 
protein G immunoprecipitated from nuclear cell lysates utilising an anti-caveolin-1 
antibody, ILK was identified in caveolin-1 fractions following subsequent Western 
blotting with an anti-ILK antibody (Figure 28, red arrow). The heavy chain of IgG was 
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present and is seen just below the 59 kDa of ILK, at an approximate molecular weight 
of 56 kDa (Figure 28, purple arrow). Once again the reader is reminded that cell lysates 
were preabsorbed with protein G so as to reduce non-specific protein G associated 
products (see Methods and Materials). 
 
Assuming that membrane/cytoplasmic localisation of ILK requires the interaction with 
caveolin-1, it stands to reason that for the nuclear entry of ILK to occur, either i) 
disruption of the caveolin-1/ILK association must take place thereby unblocking the nls 
of ILK, or ii) transport must occur in conjunction with caveolin-1. Since ILK was also 
found to be associated with caveolin-1 in the nucleus, the latter option was considered 
the more feasible. To test this assumption, cell lines were treated with a known inhibitor 
of caveolin-1 function, namely methyl-β-cyclodextrin. 
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Figure 27: Distribution of Caveolin-1 Following EGF Exposure in HOSCCs.  
a-e) Indirect immunofluorescence of caveolin-1 utilising a rabbit anti-caveolin-1 
antibody (1:500) and a FITC-conjugated anti-rabbit antibody (1:1000) in HOSCCs, 
either in the absence or presence of 0.5 hours EGF (10 ng/ml). A significant proportion 
of caveolin-1 localisation occurred at the plasma membrane in the absence of EGF in 
the WHCO1, WHCO3 and WHCO5 cell lines (yellow arrows), while WHCO6 and 
SNO cells showed a greater degree of cytoplasmic caveolin-1 (red arrows). Following 
EGF exposure no detectable variation in caveolin-1 distribution was apparent in the five 
cell lines and the majority of caveolin-1 remained localised to the membrane. Bar 
represent 10 µm. 
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Figure 28: Nuclear Association between Caveolin-1 and ILK.  
a) The association between caveolin-1 and ILK in the nucleus was determined by 
protein G sepharose immunoprecipitated caveolin-1 utilising an anti-caveolin-1 
antibody. Western blots of the immunoprecipitated lysates was performed to detect for 
the presence of ILK with an anti-ILK antibody (1:1500) in all five HOSCCs. ILK was 
identified at a molecular weight of 59 kDa (orange arrow) with IgG present at a slightly 
smaller molecular weight (purple arrow). Lane 1 – WHCO1, lane 2 – WHCO3, lane 3 – 
WHCO5, lane 4 – WHCO6 and lane 5 – SNO. 
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4.3.6 Inhibition of Caveolin-1 via Methyl-β-Cyclodextrin Prevents ILK 
Nuclear Localisation 
To determine whether ILK requires an association with caveolin-1 for nuclear 
translocation, cells were exposed to an inhibitor of caveolin-1 function, namely methyl-
β-cyclodextrin (10 mM). Methyl-β-cyclodextrin has been shown to sequester 
cholesterol, disrupt caveolae and causes the mis-localisation of caveolin-1 (Lin et al., 
2005). Examination of the membrane/cytoplasmic protein levels of ILK expression 
revealed a reduction in ILK levels upon exposure to methyl-β-cyclodextrin (Figure 
29a). This was apparent in all five HOSCCs. In the WHCO1, WHCO3 and WHCO6 
cell lines there was an average decrease of 1.7 fold in ILK cytoplasmic protein 
expression. There were substantial decreases demonstrated in ILK protein expression in 
the WHCO5 and SNO cell lines of 4 and 2.5 fold respectively (Figure 29b). 
 
When considering the effect of methyl-β-cyclodextrin on nuclear ILK concentration, it 
was confirmed that similar reductions in ILK protein expression occurred (Figure 30a). 
On average ILK expression decreased by 1.7 fold in the WHCO1, WHCO3 and SNO 
cell lines when compared to the untreated cell lysate. Much larger decreases were 
apparent in the WHCO5 and WHCO6 cell lines with fold decreases of 4 and 2.5 
respectively (Figure 30b). 
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Figure 29: Methyl-β-Cyclodextrin Inhibits Cytoplasmic ILK Protein Expression.  
a) Western blot analysis of cytoplasmic ILK utilising a rabbit anti-ILK antibody 
(1:1500) following exposure to the caveolin-1 inhibitor, methyl-β-cyclodextrin (2 
ng/ml). Lane 1- untreated WHCO1, lane 2 – cyclodextrin-treated WHCO1, lane 3 – 
untreated WHCO3, lane 4 – cyclodextrin-treated WHCO3, lane 5 – untreated WHCO5, 
lane 6 – cyclodextrin-treated WHCO5, lane 7 – untreated WHCO6, lane 8 – 
cyclodextrin-treated WHCO6, lane 9 – untreated SNO and lane 10 – cyclodextrin-
treated SNO. b) Densitometric analysis revealed that a decrease in cytoplasmic levels of 
ILK occurred to the greatest extent in the WHCO5 and SNO cell lines, i.e. 4 and 2.5 
fold respectively. Note: the expression levels are representative as a percentage of 
maximum per 10 µg of protein from concentrated fractions (included to normalise for 
loading variation). Experiments were repeated three times. 
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Figure 30: Methyl-β-Cyclodextrin Inhibits Nuclear ILK Protein Expression.  
a) Western blot analysis of nuclear ILK utilising a rabbit anti-ILK antibody (1:1500) 
following exposure to the caveolin-1 inhibitor, methyl-β-cyclodextrin (2 ng/ml). Lane 
1- untreated WHCO1, lane 2 – cyclodextrin-treated WHCO1, lane 3 – untreated 
WHCO3, lane 4 – cyclodextrin-treated WHCO3, lane 5 – untreated WHCO5, lane 6 – 
cyclodextrin-treated WHCO5, lane 7 – untreated WHCO6, lane 8 – cyclodextrin-treated 
WHCO6, lane 9 – untreated SNO and lane 10 – cyclodextrin-treated SNO. b) 
Densitometric analysis revealed that nuclear levels of ILK were decreased to the 
greatest extent in the WHCO5 and WHCO6 cell lines, i.e. 4 and 2.5 fold respectively. 
Note: the expression levels are representative as a percentage of maximum per 10 µg of 
protein from concentrated fractions (included to normalise for loading variation). 
Experiments were repeated three times. 
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4.4 Discussion 
The retention of ILK at the membrane has been suggested to occur through caveolin-1 
binding (Chun et al., 2005). This has vital cellular consequences, suitably placing ILK 
to maintain the biological activities of crucial signalling molecules such as GSK3β and 
PKB. Ultimately crucial cellular events, such as cell proliferation, migration and 
differentiation are influenced (Li et al., 1999; Cordes and van Beuningen, 2003; Khyrul 
et al., 2004; Graness et al., 2005; Vespa et al., 2005). The role of growth factors, in 
particular EGF, on the functioning of ILK formed the subject of previous chapters. EGF 
was shown not only to directly increase membrane/cytoplasmic ILK expression levels, 
but also to modulate the kinase activity of ILK. Data presented here lead to the 
suggestion that EGF has far reaching effects in the nuclear localisation of ILK by 
downregulating a known membrane-associated protein, caveolin-1. 
 
Lu et al., (2003) have shown that EGF exposure for a maximum period of five days 
elicited a noticeable reduction in caveolin-1 expression; this occurred from 
approximately three days onwards. However the present study showed that EGF 
reduced caveolin-1 at a much quicker rate, a considerable decrease was seen as early as 
0.5 hours. In terms of caveolin-1, we considered EGF to be important with regards to 
the distribution and expression levels of caveolin-1. EGF treatment (10 ng/ml) for 0.5, 
1, 3 and 6 hours produced a vast decrease in caveolin-1 expression levels in the 
WHCO1 cell lines of membrane/cytoplasmic cell lysates (see Figure 23). Although 
expression levels of membrane/cytoplasmic caveolin-1 varied, depending on the time 
exposure to EGF, the trend suggested a decrease in caveolin-1 expression levels at the 
membrane/cytoplasm. This is in agreement with previous reports demonstrating a 
similar reduction in caveolin-1 protein, following the addition of EGF in human 
epidermoid carcinoma cells, prostate cells and human non-small cell lung cancer cells, 
as well as rat bladder carcinoma cells (Lu et al., 2003). 
 
Examination of the nuclear levels of caveolin-1 revealed an increase in nuclear 
caveolin-1 concentration (see Figure 24). While this held true for the WHCO1, WHCO5 
and SNO cell lines, nuclear caveolin-1 concentration in WHCO3 cells was reduced. It 
appears that EGF results in caveolin-1 downregulation in this cell line. Furthermore, 
since it is known that WHCO3 cells particularly overexpress the EGF receptor, it could 
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be implied that a constitutive downregulation of caveolin-1 exists in this cell line. While 
the WHCO6 cell line showed a large decrease in membrane/cytoplasmic caveolin-1 
associated cell lysates, surprisingly, no change in nuclear caveolin-1 levels was 
observed. The strong band intensity observed for both untreated and EGF-treated 
lysates is indicative of an extremely large concentration of caveolin-1 protein. It is 
possible that of the 10 µg total protein electrophoresed, a proportion may not have 
transferred across to the nitrocellulose membrane during the Western blotting 
procedure. This would then suggest that the densitometrically determined caveolin-1 
levels are not a true reflection of nuclear caveolin-1 concentration in WHCO6 cells. In 
the WHCO1, WHCO5 and SNO cell lines however, it was demonstrated that EGF 
directly increases caveolin-1 transport into the nuclear region and decreases expression 
at the membrane/cytoplasm. To support this data EGF has been shown previously to 
cause caveolin-1 redistribution to an intracellular localisation in NRK cells (Pol et al., 
2000). 
 
An increase was apparent for the expression levels of nuclear caveolin-1 when exposed 
to EGF for this short time period (on average 1.2 fold higher than untreated cell lysates 
in the WHCO1, WHCO5 and SNO cell lines). Although this increase in expression was 
not nearly as substantial in comparison to the decrease noted in the 
membrane/cytoplasmic fractions, suggests that EGF causes a transfer of caveolin-1 
expression from the membrane/cytoplasmic region to the nucleus. Unfortunately, this 
could not be corroborated by immunofluorescence. An explanation may be that 
caveolin-1 redistribution only occurs when these HOSCCs are exposed to EGF for a 
different time period, which would necessitate a time course analysis. 
 
This study was concerned with explaining the nuclear ILK concentration demonstrated 
in chapter 2. The membrane retention of ILK requires an association with caveolin-1, 
which blocks a putative nls of ILK located near the caveolin-1 binding site (Chun et al., 
2005). While these authors showed that disruption of the ILK/caveolin-1 association 
resulted in increased nuclear ILK, we suggested that translocation of ILK to the nucleus 
can also occur in conjunction with caveolin-1. Since EGF incurred a decrease in the 
membrane/cytoplasmic expression of caveolin-1, followed by an increase in nuclear 
caveolin-1 protein levels (see Figures 23 and 24), it was proposed that EGF would elicit 
a similar response in nuclear ILK protein levels. Cells were exposed to EGF for 0.5 
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hours since during this time period EGF seemed to elicit the most noticeable response in 
membrane/cytoplasmic levels of ILK across all cell lines. In the WHCO5 and WHCO6 
cell lines, an increase in nuclear ILK concentration was observed, while no change in 
expression was noticed in WHCO1 and SNO cells. Surprisingly, the WHCO3 cell line 
experienced a reduction in nuclear ILK following exposure to EGF for 0.5 hours (see 
Figure 25). 
 
It is well established that a close relationship exists between EGF and caveolin-1. For 
instance, caveolin-1 recruitment to the endocytic pathway requires EGF in NRK cells. 
Interactions between caveolin-1 and EGF have also been demonstrated in numerous 
other cell types, including rat bladder carcinoma cells and human epidermoid carcinoma 
cells (Kim et al., 2000; Park et al., 2000; Kim et al., 2002; Lu et al., 2003; Lee et al., 
2005). It is interesting to note that Lee et al., (2005) showed in the human epidermoid 
carcinoma cell line that tyrosine phosphorylated caveolin-1 results in the cell surface 
localisation of caveolin-1. This suggests that tyrosine phosphorylation of caveolin-1 
directly effects its distribution and allows it to act as a signalling molecule (Lee et al., 
2005). At present however, the complete functional significance of caveolin-1 tyrosine 
phosphorylation is not yet known. The present study was focused on better 
understanding the relationship between caveolin-1 and EGF in HOSCCs. 
 
Analysis of caveolin-1 tyrosine phosphorylation revealed that a 25 kDa caveolin-1 
tyrosine phosphorylated product is shown in the WHCO1 and WHCO5 cell lines. This 
molecular weight is supported by a study conducted by Lee et al., (2005) who 
demonstrated an identical molecular weight for phosphorylated caveolin-1. 
Nonphosphorylated caveolin-1 migrates at approximately 22-24 kDa (Lee et al., 2005). 
In order to confer such a dramatic increase in molecular weight suggests that caveolin-1 
undergoes a vast degree of tyrosine phosphorylation. 
 
Although we were able to show that caveolin-1 was tyrosine phosphorylated under 
standard tissue culture conditions (see Figure 26), the effect of growth factors on the 
tyrosine phosphorylation status of caveolin-1 could not be discerned. This was due to 
difficulties in optimising conditions when utilising the phosphospecific tyrosine 
antibody. 
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The observed nuclear ILK concentration in these HOSCCs, suggested an interaction 
between caveolin-1 and ILK. Therefore, the remainder of this chapter was concerned 
with investigating whether a physical relationship existed between caveolin-1 and ILK, 
and if so, whether ILK nuclear entry required caveolin-1 expression. 
 
Caveolin-1 is largely regarded as a membrane-associated protein, but is also thought to 
play a role in cellular signalling and is involved in the shuttling of signalling moieties 
(Park et al., 2000; Wiechen et al., 2001; Upla et al., 2004; Epand et al., 2005). In 
agreement with this, caveolin-1 was identified at a membrane/cytoplasmic level as well 
as being expressed in the nucleus (confirmed via Western blotting). With the addition of 
EGF a dramatic decrease in caveolin-1 membrane/cytoplasmic expression was noted 
with a concomitant increase in nuclear caveolin-1 in the WHCO5 and SNO cell lines, 
which implied a cellular redistribution of caveolin-1. Although WHCO1 cells also 
demonstrated an increase in caveolin-1 nuclear levels (WHCO6 cells demonstrated no 
change in nuclear expression), a similar increase occurred in the expression of caveolin-
1 at the membrane/cytoplasm for both WHCO1 and WHCO6. This implies that in 
WHCO1 and WHCO6 cells, total protein levels of caveolin-1 are increased by EGF as 
opposed to a shuttling of caveolin-1 between cellular compartments. 
 
Not surprisingly, confocal microscopy revealed that caveolin-1 was distributed 
primarily at the membrane in the WHCO1, WHCO3 and WHCO5 cell lines. However, 
variable caveolin-1 staining was also observed in the cytoplasmic and nuclear region of 
the WHCO6 and SNO cell lines (see Figure 27). Since caveolae exist either as 
invaginations in the plasma membrane proper or as vesicles occurring close to the 
membrane (Razani et al., 2005), the cytoplasmic distribution of caveolin-1 in the 
oesophageal cell lines was not totally unexpected. In the presence of EGF however, no 
redistribution of caveolin-1 was visible in any of the cell lines, which is surprising 
considering that caveolin-1 has been reported to internalise into endocytic 
compartments in response to growth factors such as EGF (Pol et al., 2000). Although 
immunofluorescence microscopy revealed no apparent redistribution of caveolin-1 in 
the presence of EGF, the fact that EGF affected caveolin-1 expression at the 
membrane/cytoplasm and nucleus, suggests that EGF is able influence caveolin-1 
distribution, which was not observed utilising indirect immunofluorescence. A possible 
explanation for not being able to demonstrate a noticeable visual change occurring in 
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the distribution of caveolin-1 in the presence of EGF, could be that the indirect 
immunofluorescence could not detect the small changes in caveolin-1 redistribution (see 
Figure 27). 
 
To investigate\ the association between caveolin-1 and ILK, co-immunoprecipitation 
analysis was performed, which established the association between ILK and caveolin-1 
at both membrane/cytoplasm and nuclear levels in the oesophageal carcinoma cell lines 
in question (see Figure 28). Thus it appears from this data that the transport of ILK to 
the nuclear region requires an association with caveolin-1. To investigate this 
possibility, cell lines were treated with a known inhibitor of caveolin-1 function, namely 
methyl-β-cyclodextrin, and nuclear levels of ILK expression examined.  
 
Exposure of the oesophageal carcinoma cell lines to methyl-β-cyclodextrin resulted in a 
vast reduction in the expression levels of ILK; up to 4 fold at both a nuclear and 
cytoplasmic level (see Figures 29 and 30). It is clear that the disruption of caveolin-1 
via methyl-β-cyclodextrin impairs the expression of nuclear ILK. Thus, it could be said 
that not only is a direct/indirect interaction with caveolin-1 required for the retention of 
ILK at the plasma membrane, but the caveolin-1/ILK association is also necessary for 
the transport of ILK into the nuclear region. While the present data has not addressed 
the functional significance of nuclear ILK, it is likely that nuclear ILK plays a role in 
the phosphorylation of nuclear GSK3β, which would in turn effect the stabilisation of 
nuclear β-catenin. Indeed, it has been shown previously that nuclear β-catenin is 
phosphorylated in the nucleus (He, 2006; Oloumi et al., 2006). This may have important 
consequences with regard to transcription processes that ultimately impinge upon 
cellular processes such as the cell cycle and proliferation.  
 
Since disruption of the ILK/caveolin-1 interaction through methyl-β-cyclodextrin 
impairs nuclear ILK protein levels, it is apparent that an intact ILK/caveolin-1 
interaction is required for ILK nuclear transport. EGF is thought to provide the stimulus 
for directing the changes in the expression patterns of both ILK and caveolin-1, which 
subsequently results in a shift from a membranous to a cytoplasmic/nuclear localisation. 
In the case of caveolin-1, we suggest that EGF achieves this via tyrosine 
phosphorylation, although this is yet to be verified.  
 155
While this potentially explains how ILK is translocated to the nucleus, it does not 
provide any insight with regard to the functional significance of nuclear ILK. It would 
be interesting for future studies to examine the role of nuclear ILK in carcinoma of the 
oesophagus, as it is possible that ILK is acting as a potential nuclear transcription factor, 
although this is speculative at present. 
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Chapter 5 
Role of ILK in Substrate Adhesion of Oesophageal SCC Cells 
 
5.1 Introduction 
Cell-ECM interactions are pivotal in the control of cellular proliferation, migration, 
survival, differentiation and tissue formation, thereby directly impacting upon processes 
such as embryogenesis, wound healing, inflammation, and cancer (Jones and Walker, 
1999; Li et al., 1999; Tu et al., 2001; Aplin et al., 2002; Wu, 2004; Takanami, 2005; 
Boulter et al., 2006). Cell-ECM adhesion is especially important during malignant 
processes, since oncogenic transformation routinely induces anchorage independent 
growth in vitro, which is a specific correlate of tumour growth in vivo (Ruoslahti and 
Reed, 1994; Radeva et al., 1997). The integrins are the primary cellular receptors that 
mediate adhesion of cells to the substrate. In this regard, the αβ associations determine 
the ligand binding specificities of the receptor for various ECM proteins such as 
collagen, fibronectin and laminin (Juliano and Haskill, 1993; Ruoslahti, 1996; Kumar, 
1998; Katz et al., 2000; Aplin et al., 2002; Pinkse et al., 2005). 
 
The importance of the integrin receptors in metastatic processes has been widely 
acknowledged. For example, the classic fibronectin receptor, α5β1 is reduced in many 
human tumours, including pancreatic and skin carcinomas; and a reduction of the 
collagen receptor, α2β1 is seen in adenocarcinoma of the breast (Weinel et al., 1992; 
Zutter et al., 1995; Taverna et al., 1998). The importance of integrins is further 
established by the αvβ6 integrin, which is found in almost all squamous cell carcinoma 
(SCC) tumours and plays a critical role in tumour cell migration and invasion (Koivisto 
et al., 2000). Yet another example is the αvβ5 integrin, which is reduced in poorly 
differentiated SCC lesions (Koivisto et al., 2000). Interestingly the β1 integrin subunit is 
reduced in oesophageal SCCs (Miller and Veale, 2001). The consequences of aberrant 
expression of integrins in malignancy are therefore considered as components central to 
metastatic events. 
 
Over the past few years an understanding of the involvement of ILK in adhesion- 
dependent processes of metastatic tumours has slowly emerged. Cell adhesion events 
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play a significant part during metastasis since the invasion of carcinoma cells through 
basement membranes requires tumour cell adhesion to ECM, proteolytic degradation of 
the basement membrane and tumour cell motility (Flug and Kopf-Maier, 1995). Perhaps 
more pertinent is the fact that the development of SCC requires tumour cell interaction 
with the surrounding ECM (Koivisto et al., 2000). The regulatory control that ILK 
exerts over the β integrin subunits suggests that ILK is certainly involved in mediating 
cell-ECM processes (Hannigan et al., 1996; Mulrooney et al., 2000; Stevens et al., 
2004; Pinkse et al., 2005), as well as being involved in ECM assembly (Tu et al., 2001). 
During metastatic events the regulation of β integrin subunits by ILK is almost certainly 
a vital regulatory step (Mulrooney et al., 2000; Ishii et al., 2001; Friedrich et al., 2002; 
Chun et al., 2005), since neoplastic cells possess the ability to overcome the adhesion 
constraints that exist in normal cells (Frisch and Francis, 1994; Novak et al., 1998; 
Attwell et al., 2000). Therefore, changes in the regulatory control that ILK exerts over 
integrins, and hence cell-ECM adhesion is pivotal in the development of the metastatic 
spread of tumours (Novak et al., 1998; Takanami, 2005; Yau et al., 2005). 
 
The present study attempts to elucidate the effect of reduced ILK on cell adhesion to 
collagen and fibronectin. Previously, Miller and Veale (2001) showed that the majority 
of the oesophageal SCC cell lines in question are dependent on collagen and fibronectin 
for cell adhesion. However, the role of ILK was not taken into consideration when this 
study was performed. In Chapters 2 and 4, it was demonstrated that ILK is involved in 
integrin regulation since ILK was capable of phosphorylating an analogue of the β1 
peptide MBP and, that ILK and the β3 integrin subunit interact. The role of ILK activity 
on cell-ECM adhesion was examined from two perspectives. Firstly, a direct approach 
was taken where cells were treated with a specific inhibitor of ILK function, KP-392 (a 
kind gift from S.Dedhar). Secondly, to discern whether PI3K was involved as an 
upstream promoter of ILK-mediated cell adhesion events, which was accomplished by 
treating cells with a potent inhibitor of PI3K function, wortmannin (Powis et al., 1994; 
Schultz et al., 1995; Delcommenne et al., 1998).  
 
It was hoped that an understanding could be provided of the functional role for the 
biochemical link demonstrated earlier. 
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5.2 Methods and Materials 
 
5.2.1 Tissue culture 
Cells were cultured under standard conditions as previously documented in Chapter 2, 
Section 2.2.1. 
 
5.2.2 Cell harvesting and preparation for adhesion assays 
Medium was removed and cells washed twice with pre-warmed PBS (37 °C) (see 
Appendix 1.1.1). Cells were harvested using 0.05 % (w/v) trypsin and 0.01 % (w/v) 
EDTA (see Appendix 1.1.2), which is a concentration that has been shown to preserve 
integrin activity (Gui et al., 1995). The cell suspension was added to DMEM 
supplemented with 0.01 % trypsin inhibitor (Appendix 1.8.1), to inactivate TE activity 
and centrifuged gently (2000 rpm). Cells were resuspended in serum free DMEM 
containing 0.1 % filter sterilised BSA (see Appendix 1.3.4) and counted using a 
haemacytometer. 
 
5.2.3 Extracellular matrix cell adhesion assays 
Nunc™ 24 multiwell tissue culture dishes were precoated with filter sterilised 50 µg/ml 
collagen or 50 µg/ml fibronectin (Sigma, USA) (Appendix 1.8.2) for a period of 24 
hours at 4 °C modified from Sugiyama et al., (1993). Control wells were coated with 
filter sterilised BSA (Merck AR, SA) under the same conditions. Thereafter, cells were 
harvested and prepared for plating as above. 250 000 cells/well in 500 µl serum free 
DMEM were plated in triplicate, per cell line, on ECM coated wells, supplemented with 
or without 150 nm wortmannin (Sigma, USA) (Appendix 1.8.3) or 100 µM KP-392 
(Appendix 1.8.4). Control BSA coated wells were similarly seeded with cells and 
supplemented with or without wortmannin/KP-392. Cells were cultured under standard 
temperature, CO2, and humidity for two hours, which has been shown to be the shortest 
time to maximise adhesion for the five oesophageal SCC cell lines (Miller, 2001). The 
supernatant containing nonadhesive cells was removed. Thereafter, each well was 
rinsed twice in 500 µl PBS and added to the cell suspension containing nonadherent 
cells. The resultant cell suspension (in total 1500 µl) for each cell line and controls was 
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counted. The number of adherent cells per well was ascertained by subtracting the 
number of floating cells from 250 000. The wortmannin cell adhesion assays were 
repeated on three separate occasions. KP-392 adhesion assays were repeated twice due 
to insufficient availability of KP-392. However, it was concluded that since the 
differences between the means of the two repeats were not large, the experiment did not 
warrant a third repeat. 
 
5.2.4 Statistical analysis 
All the data obtained was analysed with Statistica (version 5.5). A one-way analysis of 
variance (ANOVA) was performed since these data were nonparametric and the sample 
size (N) was small. Thereafter a Tukey HSD test was performed. All results are 
represented in Appendix 3. 
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5.3 Results 
 
5.3.1 Cell-Extracellular Matrix Adhesion Assays 
To ensure that cell adhesion was dependent on an ECM substrate, a suitable in vitro 
control substrate was required for this assay. Since cell adhesion has the potential to be 
artificially benefited when using a polystyrene tissue culture dish as a substrate, this 
option could not be considered as a relevant control. Instead, a proteinaceous substrate 
was necessary, in particular one that was not a specific substrate for epithelial cells. 
BSA is one such commonly used protein (Delcommenne et al., 1998), and hence was 
used to precoat control wells. Since the behaviour of neoplastic cells is strongly affected 
by their associations with the surrounding ECM (Parise et al., 2000), experimental wells 
were precoated with the two ECM proteins, collagen and fibronectin, that are especially 
important integrin ligands for epithelial cells. Fibronectin was the obvious choice for 
substrate-dependent epithelial cells such as these. Furthermore, collagen, which is also 
an abundant ECM protein, was considered to be useful for comparative purposes. 
 
The data gathered from these cell binding assays generated large and complex matrices 
that were relatively difficult to analyse statistically (see Appendix 3). The permutations 
were many thus requiring one way analyses of variance (ANOVA) to interpret the data. 
To make these statistics easier to comprehend, comparisons will firstly be made of 
differences in cell adhesion of untreated and treated cells within each cell line, followed 
by comparisons between the five cell lines. Furthermore, it must be noted that, 
following trypsinisation, visually these cells attached with no noticeable difference to 
that observed during typical culturing procedures. 
 
5.3.1.1 Cell Adhesion to Fibronectin Following KP-392 Exposure 
 
Cell Attachment Compared within HOSCCs (BSA Control) 
To elucidate the effect of ILK on cell-ECM adhesion, cell attachment to fibronectin was 
examined in the presence of a specific ILK inhibitor, KP-392, which is known to inhibit 
the catalytic function of ILK (Persad et al., 2000; Troussard et al., 2000; Tan et al., 
2002). Unfortunately, insufficient KP-392 was provided to enable the examination of 
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ILK inhibition on cell adhesion to both fibronectin and collagen. Importantly, ILK has 
been shown to be involved in the regulation of fibronectin matrix assembly. A study by 
Wu et al., (1998) demonstrated that ILK overexpression results in a dramatic increase in 
fibronectin matrix assembly in IEC-18 rat intestinal epithelial cells. Thus, it is for this 
reason that fibronectin was utilised as a substrate when examining the effect of KP-392 
on cell adhesion. Standardly across all the cell adhesion assays, BSA was utilised as a 
control substrate. 
 
A reduction in cell adhesion as a trend was apparent when cells either not exposed to 
KP-392 (untreated), or ILK-inhibited (KP-392-treated), were plated on a BSA substrate. 
However, the difference in cell adhesion between untreated cells and ILK-inhibited 
cells was only significant in the SNO cell line (p ≤ 0.05). Not surprisingly, cell adhesion 
to coated BSA culture dishes was reduced to the greatest extent in the SNO cells line 
(33 %) following KP-392 exposure. KP-392-treated WHCO3 cells demonstrated a 
substantial but nonsignificant reduction of 27 % in cell adhesion to BSA compared to 
untreated WHCO3 cells. Smaller differences were observed in cell lines WHCO1, 
WHCO5 and WHCO6 (up to 15 %) (Figure 31). A comparison of cell attachment will 
now be made between the five cell lines 
 
Cell Attachment Compared between HOSCCs (BSA Control) 
The SNO cell line exhibited the highest number of untreated cells attaching to a BSA 
substrate compared to the other cell lines. Significant differences were noted in 
comparison to the WHCO3 and WHCO5 cell lines, where cell adhesion to BSA of 
untreated SNO cells was 64 and 47 % higher respectively (p ≤ 0.05). Cell attachment to 
BSA in untreated WHCO1 and WHCO6 cells both showed very similar reductions in 
cell adhesion, on average 13 % lower in comparison to untreated SNO cells (p ≥ 0.05) 
(Figure 31).  
 
Across the five HOSCCs, the greatest decrease in cell attachment to BSA was in KP-
392-treated WHCO3 cells. Cell adhesion in this cell line was significantly lower than 
cell adhesion to BSA in ILK-inhibited WHCO1, WHCO5, WHCO6 and SNO cells (p ≤ 
0.05). KP-392 treatment resulted in a 69 % reduction in cell adhesion to BSA in 
WHCO3 cells compared to cell adhesion in WHCO1 cells. Further large reductions 
were observed between cell adhesion to BSA in the WHCO3 cell line and cell adhesion 
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to BSA in the WHCO5, WHCO6 and SNO of 46, 65, and 61 % respectively (p ≤ 0.05). 
The WHCO5 cell line showed a considerable reduction in KP-392-treated cell binding 
to BSA compared to WHCO1 and WHCO6 cells of 42 and 35 % respectively (p ≤ 
0.05). Although cell adhesion to BSA in KP-392-treated WHCO5 cells was 23 % lower 
than cell attachment in KP-392-treated SNO cells, this difference was not statistically 
significant (p ≥ 0.05). Furthermore, nonsignificant differences in cell adhesion of KP-
392-treated cells to coated BSA dishes were noted between the WHCO1, WHCO6 and 
SNO cell lines (up to 21 %) (p ≥ 0.05). 
 
Cell Attachment to Fibronectin Compared within HOSCCs 
With regard to their ability to attach to fibronectin, only WHCO3 cells demonstrated a 
significant increase in attachment when compared to cell adhesion of untreated WHCO3 
cell attachment to BSA (p ≤ 0.05). In these untreated cells a 44 % increase in cell 
attachment to fibronectin was observed in comparison to cell attachment to BSA. In 
untreated WHCO5 cells a 25 % increase was apparent in the binding of cells to 
fibronectin compared to binding to BSA. Both the WHCO1 and WHCO6 cell lines 
displayed similar increases in adhesion of 14 %, whereas attachment of cells to 
fibronectin in the SNO cell line was 11 % higher compared to adhesion to BSA of 
untreated cells (p ≥ 0.05) (Figure 31). 
 
When considering the effect of KP-392 on cell attachment to fibronectin a significant 
difference was only noted in the WHCO5 cell line when compared to fibronectin 
adhesion of untreated WHCO5 cells (p ≤ 0.05). The trend for the remaining cell lines 
however, did suggest a decrease in cell adhesion to fibronectin following the addition of 
KP-392. A 30 % decrease in cell attachment to fibronectin was apparent in the WHCO5 
cell line. The SNO cell line demonstrated a 17 % decrease in the presence of KP-392, 
while the WHCO3, WHCO6 and WHCO1 cell lines showed modest decreases of 15, 11 
and 6 % respectively (p ≥ 0.05) (Figure 31). 
 
Cell Attachment to Fibronectin Compared between HOSCCs 
Comparisons between the five cell lines revealed the SNO cells attached to fibronectin 
to the greatest extent. A significant difference in cell adhesion to fibronectin was 
observed between the SNO and WHCO3 cell lines, as well as between the SNO and 
WHCO5 cell lines (p ≤ 0.05). Indeed, cell attachment of untreated SNO cells was 42 
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and 36 % higher than attachment to fibronectin of untreated WHCO3 and WHCO5 cells 
respectively. Cell adhesion to fibronectin of untreated WHCO1, WHCO6 and SNO cells 
demonstrated comparable attachment (less than 10 %) (p ≥ 0.05). 
 
When comparing the effects of KP-392 treatment across the five cell lines it was 
revealed that the WHCO3 and WHCO5 cell lines exhibited the greatest depression in 
attachment to fibronectin. Conversely, WHCO1 cells exhibited the most stringent 
attachment to fibronectin when treated with KP-392. A significant difference in cell 
adhesion to fibronectin was observed between the ILK-inhibited WHCO1 and WHCO3 
cells. A similar significant difference was also noted between WHCO1 cells and the 
WHCO5 cell line (p ≤ 0.05). KP-392-treated WHCO1, WHCO6 and SNO cells all 
demonstrated comparable levels of attachment to fibronectin whereas both the WHCO3 
and WHCO5 cell lines showed relatively similar levels (10 %) of cell adhesion to 
fibronectin (p ≥ 0.05). In WHCO1 cells, respective increases in cell attachment to 
fibronectin of 42 and 48 % were apparent compared to fibronectin attachment in the 
WHCO5 and WHCO3 cell lines (p ≤ 0.05) (Figure 31).  
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Figure 31: Adhesion to Fibronectin Following KP-392 Exposure in HOSCCs. 
The WHCO1, WHCO6 and SNO cells demonstrated greatest cell adhesion to both 
fibronectin and BSA. KP-392 induced a reduction in cell adhesion to fibronectin in all 
five HOSCCs, which was statistically not significant from untreated cells (p ≥ 0.05). 
Blue bars − the number of cells attached to fibronectin, red bars − the number of cells 
attached to fibronectin in the presence of the ILK inhibitor KP-392, yellow bars − the 
number of cells attaching to BSA and purple bars− the number of cells attached to BSA 
in the presence of KP-392. Bars represent standard deviation. Results represent two 
experiments performed in triplicate. 
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5.3.1.2 Cell Adhesion to Fibronectin Following Exposure to Wortmannin 
 
Cell Attachment Compared within HOSCCs (BSA Control) 
When this data was statistically analysed, a significant difference in cell attachment to 
coated BSA culture dishes was revealed when comparing untreated WHCO5 cells to 
wortmannin-treated WHCO5 cells (p ≤ 0.05). Furthermore, this difference in cell 
binding to BSA was the greatest in WHCO5 cells (47 %). Both the WHCO6 and SNO 
cell lines displayed an increase of 17 %, whereas cell adhesion to BSA of untreated 
WHCO1 and WHCO3 cell lines were similarly increased (by 5 %) compared to cell 
adhesion to BSA of wortmannin treated cells (Figure 32). 
 
Cell Attachment Compared between HOSCCs (BSA Control) 
Examining whether PI3K was involved in ILK-mediated effects on cell attachment to 
fibronectin, cells were exposed to wortmannin and a fibronectin-based cell adhesion 
assay was conducted. As was the case with the KP-392 fibronectin assay and the 
wortmannin collagen adhesion assay, BSA was used as a control protein substrate for 
the wortmannin fibronectin adhesion assay. Cell adhesion of untreated cells to BSA was 
highest in the WHCO1 cell line and, in addition, was shown to be significantly different 
from cell adhesion to BSA in the other untreated cell lines (p ≤ 0.05). This increase in 
cell adhesion demonstrated by WHCO1 was 68 % higher in comparison to the SNO cell 
line and, 53 % and 30 % higher over cell binding to BSA of untreated cells in cell lines 
WHCO3 and WHCO5 respectively. Furthermore, cell adhesion to BSA of untreated 
WHCO1 cells was 15 % higher than cell adhesion of the WHCO6 cell line (Figure 32). 
The data obtained thus showed that wortmannin treatment produced a reduction in cell 
adhesion to BSA compared to BSA cell adhesion in the absence of wortmannin. 
 
Distinguishing between the levels of cell adhesion to BSA of wortmannin-treated cells 
across the five cell lines revealed that attachment of the SNO cell line was 67 % lower 
in comparison to cell adhesion of treated WHCO1 cells. Further, exposure to 
wortmannin resulted in a 54 % reduction in cell adhesion to BSA in WHCO6 cells 
compared to treated SNO cells. No significant differences were noted between cell lines 
WHCO3, WHCO5 and SNO, which all showed similar, cell adhesion to BSA following 
wortmannin treatment (up to a 23 % difference) (p ≥ 0.05). Additionally, cell adhesion 
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to BSA of wortmannin-treated WHCO3, WHCO5 and SNO cells lines was significant 
from treated WHCO1 and WHCO6 cell lines (p ≤ 0.05, Appendix 3, Figure 32). 
 
Therefore, wortmannin reduced cell adhesion to BSA to the greatest extent in the 
WHCO3, WHCO5 and SNO cell lines in comparison to the effect of wortmannin 
treatment in the WHCO1 and WHCO6 cell lines. The differences between the WHCO3, 
WHCO5 and SNO cell lines were not significant (p ≥ 0.05). However, cell adhesion of 
the wortmannin-treated BSA controls in these cell lines was significantly different from 
the wortmannin treated WHCO1 and WHCO6 BSA controls (p ≤ 0.05). Furthermore, a 
significant difference in cell adhesion to BSA, following wortmannin treatment was 
shown between the WHCO1 and the WHCO6 cell lines (p ≤ 0.05). 
 
Cell Attachment to Fibronectin Compared within HOSCCs 
Similar to the collagen adhesion assay, cell adhesion to fibronectin was considerably 
higher for the five cell lines in comparison to the attachment of cells to BSA not treated 
with wortmannin. Of the five SCC cell lines tested, untreated SNO cells demonstrated 
greatest cell adhesion to fibronectin in comparison to adhesion to BSA (66 %) (Figure 
33). This is in concurrence with Miller and Veale, (2001). The WHCO1 cell line 
showed the lowest number of cells attached to fibronectin compared to WHCO1 cells 
bound to BSA (31 %). Statistically, all five cell lines showed a significant increase in 
the number of cells attached to fibronectin compared to untreated cells attaching to BSA 
(p ≤ 0.05), implying a preference for fibronectin as a substrate.  
 
Compared to untreated cells, wortmannin treatment reduced the number of cells 
attached to fibronectin in four of the five cell lines, and although quite noticeable, 
statistically these differences in cell adherence were not significant (p ≥ 0.05). As was 
the case with cell adhesion to collagen, it implies that over the two hour incubation 
period, wortmannin reduction of ILK did not disrupt the cellular interaction with 
fibronectin. However, as with the collagen adhesion assay, there is a trend indicating a 
reduction in cell adhesion to fibronectin following wortmannin treatment. This trend 
was apparent since significance was obtained at a p-value of 0.1. The SNO cell line 
demonstrated the greatest reduction in cell adhesion to fibronectin following 
wortmannin treatment (12 %) in comparison to untreated SNO cells exposed to culture 
dishes coated with fibronectin. Both treated WHCO3 and WHCO1 cell lines showed 
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decreased cell adhesion to fibronectin, 9 % and 3 % respectively, in contrast to 
untreated cells of the same cell lines. The number of untreated cells attached to 
fibronectin for WHCO5 was comparable to the number of adherent cells following 
wortmannin treatment (Figure 32). 
 
WHCO6 was the only cell line that did not follow the trend in reduction in cell 
adhesion. Here cell adhesion to fibronectin was increased following wortmannin 
treatment by 7 %. Statistics revealed however, that this was not a significant difference 
(p ≥ 0.05) (Appendix 3). Even though this difference was shown to be statistically 
nonsignificant, it suggests that the Wortmannin-induced PI3K/ILK reduction, resulted 
in stabilisation of the αβ integrin heterodimer-ECM ligand complex, thus increasing 
cell-ECM adhesion in this cell line. 
 
Cell Attachment to Fibronectin Compared between HOSCCs 
Comparisons across the cell lines showed that the WHCO1 cell line had the greatest 
number of cells attached to fibronectin, just over 4 % higher in comparison to the 
WHCO3 and WHCO6 cell lines (Figure 32). However, the number of cells attached to 
fibronectin for these three cell lines were not significantly different from each other (p ≥ 
0.05). In its ability to adhere to fibronectin, untreated WHCO1 cells differed 
significantly from untreated WHCO5 and SNO cell lines. Untreated WHCO3 and 
WHCO6 cells showed no significant increase in the number of cells binding to the 
fibronectin substrate when compared to cell attachment of the WHCO5 cell line. 
Furthermore, statistically the WHCO5 and SNO lines were not significantly different 
from one another, indicative of equal levels of binding to fibronectin for these cell lines 
as well as for the WHCO3 and WHCO6 cell lines (p ≥ 0.05) (Figure 32). 
 
Wortmannin caused the greatest reduction in cell adhesion to fibronectin in the SNO 
cell line compared to the other oesophageal SCCs. Analysed statistically, this difference 
was shown to be significantly different from wortmannin-treated WHCO1, WHCO3, 
and WHCO6 cells (p ≤ 0.05), but not from wortmannin-treated WHCO5 cells. The 
smallest decrease in cell adhesion to fibronectin following wortmannin treatment was in 
wortmannin-treated WHCO1 and WHCO6 cells, and the numbers of cells adhering in 
these cell lines were similar. Furthermore, cell adhesion to fibronectin of treated 
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WHCO3 cells was not significantly different from attachment of wortmannin-treated 
WHCO5 cells (p ≥ 0.05) (Figure 32). 
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Figure 32: Adhesion to Fibronectin Following Wortmannin Exposure in 
HOSCCs.  
The WHCO1 demonstrated greatest cell adhesion to fibronectin followed closely by 
WHCO3. Wortmannin (W) induced a reduction in cell adhesion in WHCO1, WHCO3, 
WHCO5 and SNO but not WHCO6. The differences in cell attachment between 
wortmannin-treated and untreated cells were not significant (p ≥ 0.05). Blue bars − the 
number of cells attached to fibronectin, red bars − the number of cells attached to 
fibronectin in the presence of the PI3K inhibitor wortmannin, yellow bars − the number 
of cells attaching to BSA and purple bars − the number of cells attached to BSA in the 
presence of wortmannin. Bars represent standard deviation. Results represent two 
experiments performed in triplicate. 
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5.3.1.3 Cell Adhesion to Collagen Following Exposure to Wortmannin 
 
BSA Cell Attachment Compared within HOSCCs 
When considering cell adhesion to the control BSA substrate a slight reduction in 
adhesion in response to wortmannin treatment was noted, in contrast to cell adhesion to 
BSA of untreated cells in all human oesophageal SCC cell lines tested. However, this 
difference was statistically nonsignificant (p ≥ 0.05, Appendix 3). The trend, however, 
suggests a reduction in cell adhesion in the wortmannin-treated BSA control in 
comparison to cell adhesion of untreated cells to BSA (Figure 32). Wortmannin 
treatment reduced cell adhesion to BSA to the greatest extent in the WHCO3 and SNO 
cell lines (37 %) and decreased cell adhesion in the WHCO6 and WHCO5 cell lines by 
28 % and 21 % respectively. The smallest reduction in cell adhesion to BSA following 
wortmannin treatment was by the WHCO1 cell line (12 %). 
 
Cell Attachment Compared between HOSCCs (BSA Control) 
WHCO1 cells that were not wortmannin-treated exhibited increased cell adhesion to 
BSA in contrast to that shown by the other four untreated cell lines to the same 
substrate. This difference was shown to be significant from the WHCO3, WHCO6 and 
SNO cell lines (p ≤ 0.05), but not from WHCO5 (p ≥ 0.05). The difference in cell 
adhesion between WHCO1 and WHCO5 was only 21 %. Furthermore, cell adhesion to 
BSA in untreated WHCO1 was 41 % higher compared to the SNO cell line and, 45 % 
and 42 % higher than untreated WHCO3 and WHCO6 cell lines respectively (Figure 
32).  
 
Cell adhesion to BSA by wortmannin-treated WHCO3 and SNO cells was reduced 60 
% and 58 % respectively, in comparison to WHCO1, which demonstrated the highest 
adhesion to BSA following wortmannin treatment. Furthermore, adhesion to BSA of 
wortmannin-treated WHCO6 cells was 53 % less than treated WHCO1 cells, whereas 
the WHCO5 cell line was reduced 28 % in comparison. Statistically, cell adhesion of 
the wortmannin-treated WHCO3, WHCO5, WHCO6 and SNO cell lines to BSA was 
not significantly different from one another (p ≥ 0.05). Interestingly, a significant 
difference was apparent between BSA adhesion of wortmannin-treated WHCO1 cells 
compared to BSA adhesion of wortmannin-treated WHCO3, WHCO6 and SNO cell 
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lines (p ≤ 0.05). No significant difference was apparent between wortmannin-treated 
WHCO1 and WHCO5 (p ≥ 0.05) (Figure 32, Appendix 3).  
 
Cell Attachment to Collagen Compared within HOSCCs 
Not surprisingly, the number of untreated cells that attached to the collagen substrate 
was greater than attachment to BSA for all human oesophageal SCC cell lines. In 
addition, statistical analysis (Appendix 3) showed that the number of untreated cells 
attached to collagen in comparison to cell attachment to coated BSA culture dishes was 
significantly different (p ≤ 0.05). The untreated WHCO3 and SNO cell lines showed the 
greatest increase in cell adhesion to collagen compared to BSA (up to 62 %). Similarly, 
the WHCO6 cell line demonstrated a 58 % increase, whereas the lowest adhesion to 
collagen in comparison to binding to the BSA substrate, were by the WHCO1 and 
WHCO5 cell lines (Figure 33). 
 
The number of wortmannin-treated cells that attached to collagen increased in 
comparison to the number of wortmannin treated cells that attached to BSA in all 
oesophageal SCCs. However, when this data was analysed statistically, it was revealed 
that four of the cell lines (WHCO1, WHCO3, WHCO6 and SNO) were significantly 
different from cell adhesion to BSA of wortmannin-treated cells (p ≤ 0.05). The 
wortmannin-treated SNO and WHCO3 cell lines exhibited greatest cell adhesion to 
collagen, up to 71 % higher than wortmannin-treated cell attachment to BSA. Cell 
adhesion to collagen was reduced to the lowest extent in the WHCO1 and WHCO5 cell 
lines (27 %), following wortmannin treatment, while cell adhesion to collagen of 
wortmannin-treated cells in the WHCO6 cell line was 56 % higher than treated cells 
plated on a BSA substrate (Figure 33).  
 
A comparison of the differences is now required between cell adhesion of untreated 
cells to that of wortmannin-treated cells to collagen. Not surprisingly, wortmannin 
reduced cell adhesion to collagen in the five oesophageal SCC cell lines. However, the 
effect of wortmannin treatment on cell adhesion to collagen was not significantly 
different compared to collagen cell adhesion of untreated cells (p ≥ 0.05) (Figure 33). 
The WHCO5 cell line exhibited the greatest reduction in cell adhesion following 
wortmannin treatment of 21 %, followed by WHCO1, WHCO3, WHCO6 and SNO, 
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which were all reduced by just over 1 %. This trend of reduced adhesion will be 
elaborated upon in the discussion. 
 
Cell Attachment to Collagen Compared between HOSCCs 
In the ability to bind collagen, it was untreated WHCO1 cells, which displayed the most 
rigorous attachment to collagen compared to the other four cell lines. This difference 
was 26 % higher than collagen adhesion of untreated WHCO6 cells and 19 % higher 
than the WHCO5 cell line. Cell attachment of untreated WHCO1 cells to collagen was 
only slightly higher than cell adhesion of untreated WHCO3 and SNO cells to collagen 
(just over 1 %). Statistically, a significant difference was noted only between the 
WHCO1 and WHCO6 cell lines (p ≤ 0.05) (Figure 33). 
 
The number of wortmannin-treated WHCO5 and WHCO6 cells attached to collagen 
was notably reduced in comparison to treated WHCO1, WHCO3 and SNO cells. 
Moreover, these differences were shown to be significant (p ≤ 0.05). The WHCO5 cell 
line showed a 36 % reduction compared to WHCO1 and was decreased by 25 % and 32 
% in comparison to cell adhesion of treated WHCO3 and SNO cells to collagen 
respectively. The levels of cell adhesion in treated WHCO6 cells were similar to that of 
the WHCO5 cell line (differing by just over 1 %) (Figure 33). 
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Figure 33: Adhesion to Collagen Following Wortmannin Exposure in HOSCCs.  
The WHCO1, WHCO3 and SNO cell lines attached more readily to collagen. 
Attachment to BSA was highest in the WHCO1 and WHCO5 cell lines. Wortmannin 
treatment reduced adhesion of cells to collagen, but this was statistically not significant 
(p ≥ 0.05) from untreated cells. Blue bars − the number of cells attached to fibronectin, 
red bars − the number of cells attached to fibronectin in the presence of the PI3K 
inhibitor wortmannin, yellow bars − the number of cells attaching to BSA and purple 
bars − the number of cells attached to BSA in the presence of wortmannin. Bars 
represent standard deviation. Results represent two experiments performed in triplicate. 
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5.3.1.4 A Comparison between Wortmannin and KP-392 Exposure on 
Cell Adhesion 
Comparisons will now be made between cell adhesion of wortmannin-treated cells and 
cell adhesion of KP-392-treated cells. It is important to note that in both wortmannin 
and KP-392 fibronectin assays the differences in attachment of untreated cells to 
fibronectin were nonsignificant in the majority of cell lines examined (p ≥ 0.05). In 
untreated WHCO3 cells however, a significant difference was observed between 
fibronectin cell binding of the respective fibronectin assays (p ≤ 0.05). A large reduction 
in cell adhesion of 32 % was shown in WHCO3 cells between the fibronectin assays. 
SNO cells also showed a large difference of 28 % while in the WHCO1, WHCO5 and 
WHCO6 cell lines these differences were considerably less (up to 13 %). 
 
When comparing the differences between wortmannin and KP-392 on the attachment of 
cells to fibronectin the following was apparent. The trend following treatment of cells 
with both wortmannin and KP-392 was a reduction in cell adhesion across all five 
HOSCCs. However, unlike the wortmannin treatment, which exhibited no significant 
differences between cell attachments of untreated cells to that of treated cells, a 
significant difference was noted in KP-392-treated WHCO5 cell line compared to 
untreated WHCO5 cells (p ≤ 0.05) (Figures 31 and 32).  
 
5.3.1.5 A Comparison between Collagen and Fibronectin as Substrates 
for Cell Adhesion Following Wortmannin Exposure 
Finally, when comparing the effect of wortmannin on collagen adhesion to that of 
fibronectin adhesion (at the p ≤ 0.05 level), the following similarities and distinctions 
were apparent. Wortmannin caused a reduction in cell adhesion, although 
nonsignificant, to collagen compared to cells that plated in the absence of wortmannin 
in all the cell lines. Similarly, in the fibronectin adhesion assay, wortmannin caused a 
reduction in cell adhesion but again not significant (p ≥ 0.05). However, this was the 
case for only four of the cell lines. When plated on fibronectin, the WHCO6 cell line 
demonstrated an increase in cell adhesion following wortmannin treatment. Cell 
adhesion to collagen of wortmannin-treated WHCO6 cells did not demonstrate this 
increased attachment. This further corroborates the notion that the WHCO6 cell line 
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expresses different integrin receptors when binding to either collagen or fibronectin. 
Thus the wortmannin-mediated PI3K/ILK reduction may affect distinct signalling 
pathways in the WHCO6 cell line in the presence of differing ECM ligands. Although 
this increase in WHCO6 cell adhesion to fibronectin following wortmannin treatment 
was not significant from cell adhesion in the absence of wortmannin, it was the only cell 
line that exhibited increased cell attachment subsequent to wortmannin treatment. 
 
It appears that these oesophageal SCC cell lines adhere to fibronectin more readily than 
collagen. Cell adhesion between collagen and fibronectin was statistically shown as not 
significant in the WHCO1, WHCO3 and SNO cell lines (p ≥ 0.05). Nevertheless, a 
trend exists that suggests an increase in cell adhesion to fibronectin in these cell lines 
when compared to collagen adhesion. A significant difference was noted between 
collagen and fibronectin cell adhesion for untreated/wortmannin treated WHCO6 cells 
as well as for wortmannin treated WHCO5 cells (p ≤ 0.05) (Figures 32 and 33). 
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5.4 Discussion 
Integrins have long been recognised as the dominant family of cell adhesion receptors 
that mediate attachment to the ECM (Puddefoot et al., 1997; Koivisto et al., 2000; 
Reyes-Reyes et al., 2002). Integrin ligation to the ECM activates the PI3K signalling 
pathway, which leads to the activation of an integrin-mediated moiety, namely ILK 
(Somasiri et al., 2000). ILK is thought to play an essential role during the assembly and 
functioning of the cell-matrix adhesion structures (Zhang et al., 2002). Two lines of 
evidence support this notion. Firstly, ILK activity is stimulated by extracellular matrix 
attachment (Delcommenne et al., 1998; Duxbury et al., 2005) and secondly, ILK is 
capable influencing the process of cell adhesion to the ECM (Ishii et al., 2001). In light 
of this role of ILK, it was of interest to elucidate the effect that inhibiting ILK has on 
cell-ECM adhesion in HOSCC.  
 
Inhibition of ILK was exercised through the use of KP-392. KP-392 is a small molecule 
ATP-analog, which has previously been shown to inhibit ILK activity in a highly 
selective, dose-dependent manner (D’Amico et al., 2000; Persad et al., 2001; 
Yoganathan et al., 2002; Attwell et al., 2003; Troussard et al., 2006). In order to 
ascertain whether PI3K was mediating the ILK-induced effects on cell-ECM adhesion, 
cell adhesion assays were also conducted in the presence of an inhibitor of PI3K 
activity, wortmannin. 
 
The biochemical function of wortmannin on ILK has been demonstrated by 
Delcommenne et al., (1998). These authors showed that in rat intestinal epithelial cells 
(IEC-18), ILK activity depended on PI3K, and furthermore, that PI3K was functioning 
upstream of ILK. This experiment was accomplished by measuring ILK activity at 
various time intervals following plating on fibronectin and wortmannin treatment 
(Delcommenne et al., 1998). ILK activity is stimulated upon attachment to ECM 
components. However, this stimulation is only transient, peaking at approximately 30-
45 minutes and declining rapidly so that at 60 minutes it is almost diminished 
(Delcommenne et al., 1998; Dedhar et al., 1999). Since this is the only known study to 
consider the effects of Wortmannin on ILK it was assumed that, in these oesophageal 
SCCs, wortmannin would induce a similar effect on the PI3K/ILK signalling sequence 
in HOSCCs. 
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To establish the effects of wortmannin and KP-392 exposure, on the ability of the 
oesophageal carcinoma cells to adhere to fibronectin, it was shown that both 
wortmannin and KP-392 resulted in a reduction in cell attachment to fibronectin. In the 
case of wortmannin exposure, these differences were not statistically significant in any 
of the cell lines. However, KP-392-treated WHCO5 cells exhibited a significant 
reduction in cell attachment to fibronectin (p ≥ 0.05). Furthermore, the decreases in cell 
adhesion to fibronectin that were observed in KP-392-treated cells of the remaining 
oesophageal lines were more substantial than that of wortmannin-treated cells (12-30 % 
reduction in adhesion). This implies that ILK is indeed involved in directing cell-ECM 
adhesion in HOSCCs. Furthermore, it is proposed that the inhibition of cell-fibronectin 
adhesion is not mediated by PI3K, which is especially apparent in the WHCO5 cell line. 
It is possible that another protein moiety such as PTEN may be more directly involved 
during ILK-mediated cell-ECM adhesion events. 
 
In support of the data which showed a trend in reduced cell adhesion in the presence of 
KP-392, Attwell et al., (2003) demonstrated that treatment of PC3 cells with KP-392 
resulted in reduction in cell attachment to fibronectin. It was suggested that the decrease 
in cell adhesion associated with decreased ILK activity could be due to the role of ILK 
in focal adhesion formation and actin organisation (Attwell et al., 2003). In addition to 
the known substrates of ILK, which include CH-ILKBP, paxillin and vinculin, these 
authors propose that currently unidentified substrates of ILK are not phosphorylated, 
which in turn prevents proper focal adhesion formation and integrin malfunction 
integrin (Attwell et al., 2003).  
 
When considering the effects of both wortmannin and KP-392, the cell adhesion assays, 
performed above, established that all the oesophageal SCCs tested depended on the 
presence of either collagen or fibronectin for cell adhesion, since significant differences 
were noted between cell adhesion to collagen/fibronectin and the BSA controls (see 
Figures 31, 32 and 33). Attachment to ECM substrates by stratified epithelial squamous 
cells in vivo requires adhesion to collagen and fibronectin. Since this study 
demonstrated that cell attachment to either collagen or fibronectin was greater than 
adhesion to BSA, it implies that the behaviour of cultured cells in vitro is similar to that 
of cells in vivo. 
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In the presence of wortmannin, the collagen-based adhesion assay showed that WHCO5 
and WHCO6 cell adhesion to collagen was reduced in comparison to the other cell 
lines. Interestingly, when cells were exposed to either wortmannin or KP-392 in the 
fibronectin-based adhesion assay, it was the WHCO5 and SNO cell lines, which showed 
greatest reduction in adhesion. However, in the instance of wortmannin treatment, the 
WHCO6 cell line exhibited increased binding to fibronectin, which was not exhibited 
by KP-392-treated WHCO6 cells (see Figures 31 and 32). Furthermore, fibronectin 
adhesion of wortmannin-treated WHCO6 cells was much higher compared to collagen 
adhesion of wortmannin-treated WHCO6, where this difference was shown to be 
statistically significant (p ≤ 0.05). A possible explanation for this apparent increase in 
cell adhesion could be that integrin expression levels are increased in the WHCO6 cell 
line. Indeed, differential integrin expression could account for the noted differences in 
cell attachment to the ECM substrates between the five cell lines. However, the process 
of establishing which integrin is expressed when this cell line attaches to ECM 
substrates is not trivial and remains of interest for future work. 
 
It has been discovered that the β1 integrin requires a period in excess of two hours for 
biological maturation (Heino et al., 1989). Thus adhesion of oesophageal SCCs to the 
various ECM proteins can be considered to be a consequence of the integrins already 
embedded in the cell membrane and not due to de novo integrin synthesis (Miller, 
2001), since the adhesion assays were performed over a time period of two hours. 
Furthermore, the increase in cell adhesion on the ECM proteins in comparison to BSA 
controls is indicative of integrin engagement via “inside-out signalling”. As a reminder 
to the reader that “inside-out signalling” refers to the ability of intracellular signals to 
modulate integrin affinity towards ECM proteins (Holly et al., 2000). Due to ILK 
involvement in integrin signalling, ILK may well be mediating this activation process. 
 
The number of cells attaching to either collagen or fibronectin treated with wortmannin 
or KP-392 exhibited no significant difference in comparison to attachment of untreated 
cells (p ≥ 0.05). This cell adhesion assay was modified from an established protocol 
from Sugiyama et al. (1993), and it is feasible that this assay technique lacks sensitivity. 
However, there was a reduction in the number of cells attaching to both collagen and 
fibronectin following wortmannin treatment (besides WHCO6) and a decrease in cell 
attachment to fibronectin following KP-392 treatment (see Figures 31, 32 and 33). 
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Interestingly, WHCO6 was the only cell line to exhibit an increase in cell adhesion to 
fibronectin following wortmannin treatment. Although the increase was nonsignificant, 
adhesion in the WHCO6 cell line was different to the rest of the cell lines, which 
requires some sort of explanation. Speculating on the reason for this result is difficult 
since this particular outcome was observed in only one cell line. This result does 
suggest however, that the reduction of PI3K in WHCO6 via wortmannin leads to 
activation of integrin and increased binding towards ECM ligand. Alternatively, it is 
possible that deficient β integrin subunit phosphorylation, due to inhibited ILK, 
prevents the removal of the integrin heterodimer from the cell-matrix adhesion site. In 
support of this, Mulrooney et al. (2000) have shown that, in migrating parietal 
endoderm cells, ILK is capable of phosphorylating the β1 integrin subunit, resulting in a 
subsequent release of β1 from the cytoskeleton and removal of cell-matrix adhesion. 
 
Besides the WHCO6 cell line, the other four cell lines displayed a reduction in cell 
adhesion to either collagen or fibronectin after wortmannin treatment, in comparison to 
untreated cells (see Figures 32 and 33). KP-392 induced a similar reduction on cell 
attachment, which was apparent for all five HOSCCs. Although this decline in cell 
adhesion to collagen/fibronectin for wortmannin- and KP-392-treated cells was not 
significant (p ≤ 0.05) the trend cannot be ignored. Since ANOVA is a robust statistical 
test and the sample size (N) of this study was low; it is feasible that choosing another 
arbitrary p-value ≥ 0.05, would substantially increase the probability of significance for 
wortmannin and KP-392 effects on cell adhesion. For example, if a p-value of 0.1 was 
chosen, it was apparent that wortmannin and KP-392 induced a significant reduction in 
cell adhesion in all the cell lines. This would then imply that ILK inhibition via KP-392 
is sufficient to disrupt the structure of the αβ integrin heterodimer-ECM ligand 
interaction and, is influenced by the upstream effects of PI3K. A consequence of this 
would be reduced cell adhesion to collagen and fibronectin ECM substrates. 
 
The increased adhesion to fibronectin in the wortmannin treated WHCO6 cell line was 
unexpected but can be explained by previous studies which have indicated that ILK 
overexpression, and not inhibition, reduces cell adhesion. For example, overexpression 
of ILK in IEC-18 induces a less adhesive phenotype (Hannigan et al., 1996; Radeva et 
al. 1997). Furthermore, Attwell et al. (2000) showed that ILK overexpression in mouse 
mammary epithelial cells (SCP2) inhibits anoikis, a form of apoptosis, which occurs 
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when cell-ECM interactions are disrupted. Taking these data into consideration, one 
would expect ILK inhibition to correlate with stabilisation of the αβ integrin 
heterodimer, a consequence being increased cell adhesion to ECM.  
 
Another possible explanation for the observed effects of wortmannin on the increased 
cell adhesion noted in the WHCO6 cell line is due to reduced wortmannin activity over 
the 2 hour incubation period utilised during the cell adhesion assay. While 
Delcommenne et al., (1998) demonstrated that 20 minutes was sufficient time for 
wortmannin to reduce PI3K and subsequently ILK activity, the authors make no 
mention of the feasible possibility that wortmannin activity peaks at 20 minutes, and 
subsequently becomes reduced over prolonged periods. If this were indeed the case then 
the 2 hour incubation period in the present study would be indicative of diminished 
wortmannin activity and hence, elevation of PI3K and subsequent ILK activity levels. 
This would result in the stabilisation of the αβ integrin heterodimer complex.  
 
To our knowledge this was the first investigation to consider the effects of inhibited 
ILK on cell-ECM adhesion in oesophageal SCCs. In fact, this is the first study to 
examine cell adhesion in SCCs in general. Previous studies have examined ILK 
activity-based adhesion in other cell types, including IEC-18 intestinal epithelial cells 
and Scp2 mammary epithelial cells (Delcommenne et al., 1998; Persad et al., 2000). 
These differences in tissue types may require different integrins for ECM specificity, 
hence accounting for the differences in cell adhesion to fibronectin. 
 
Interpreted in conjunction with the ILK activity levels elucidated in Chapter 3, there 
does not seem to be a similarity between the patterns of basal ILK activity and the effect 
of reduced ILK activity on cell adhesion. Recalling that KP-392 and wortmannin 
specifically inhibits ILK and PI3K respectively, ascertaining the time period for optimal 
inhibition of ILK and PI3K, would require a time course experiment for both these 
inhibitors. Subsequently, the length of time that the cells are exposed to either KP392 or 
wortmannin during the course of the cell adhesion assay can be altered accordingly. 
Only then would it be possible to further understand the behaviourial change on cell 
adhesion as a consequence of KP392-induced ILK inhibition. The surprising high 
binding capacity to BSA that was observed in the cell adhesion was surprising. It 
suggested that impurties may have been present in the BSA which allowed for binding 
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to certain proteins and accounted for the successful binding to BSA in this study (see 
Figures 31, 32 and 33). 
 
A complex reciprocal interaction exists between ILK and the integrin receptors where, 
integrins modulate ILK activity and, ILK regulates integrin activity via phosphorylation 
of the β integrin subunit (Hannigan et al., 1996; Mulrooney et al., 2000; Janji et al., 
2000; Somasiri et al., 2000). From a statistical standpoint, this investigation implies that 
ILK alone is not involved in adhesion events in oesophageal carcinoma over the time 
period analysed but certainly plays a key role. However, due to the obvious trend 
showing a reduction in cell adhesion in ILK-inhibited cells to both collagen and 
fibronectin observed in all five HOSCCs and the demonstration of an interaction 
between ILK and the β integrin subunit (see Chapter 2), the involvement of ILK in cell-
ECM processes in HOSCCs cannot be ignored. These results may also have been 
affected by differences in collagen and fibronectin receptor numbers which would have 
required different analyses to resolve. Furthermore, in the instances of the WHCO1, 
WHCO3 and SNO cell lines, ILK regulation of cell attachment is almost certainly 
mediated by PI3K. However, the WHCO5 and WHCO6 cells did not follow the trend of 
reduced cell adhesion. PI3K inhibition via wortmannin treatment understandably had 
less of an affect on cell adhesion since this approach indirectly influenced ILK activity. 
However, direct ILK inhibition via KP-392 treatment resulted in a more substantial 
effect on cell attachment. This is evidence for a definite role for ILK in cell adhesion in 
HOSCCs. 
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Chapter 6 
General Discussion and Conclusion 
 
6.1 The Importance of ILK in Human Oesophageal Squamous Cell 
Carcinomas 
At present, it is widely accepted that the signalling cascades existing within cells are a 
tightly regulated phenomena (Persad et al., 2000; Yoganathan et al., 2000; Brakebusch 
and Fässler, 2003; Mould and Humphries, 2004). This regulation occurs primarily 
through the ability of numerous protein kinases and phosphatases to either 
phosphorylate or dephosphorylate protein substrates (Yoganathan et al., 2000). ILK is a 
serine/threonine protein kinase that is capable of influencing cell proliferation, 
migration, differentiation and survival (Novak et al., 1998; Dedhar et al., 1999; 
Yoganathan et al., 2000; Wu and Dedhar, 2001; Pasquet et al., 2002). ILK influences 
these signalling processes by regulating intermediate molecules such as GSK3β, PKB, 
and PINCH, as well as the integrin class of adhesion receptors (Tan et al., 2001; Yamaji 
et al., 2002; Cordes and van Beuningen, 2003; Gary et al., 2003; Obara et al., 2004; 
Pinkse et al., 2005; Yau et al., 2005). 
 
The way in which ILK accomplishes this regulation is through its kinase domain, which 
serves to phosphorylate specific residues present on target proteins. For example, in 
response to phosphorylation by ILK, PKB elicits a response that promotes cell survival 
whereas phosphorylation of GSK3β initiates a signalling response that leads to 
differentiation and proliferation in cells (Dedhar et al., 1999; Attwell et al., 2000; 
Yoganathan et al., 2000; Dai et al., 2003).  
 
From a tumour biology perspective, ILK is vital to the control of these aforementioned 
processes in order to maintain cellular functioning within normal limits. Disturbances in 
this system are seen in cancers, good examples being colon, prostate, breast and brain. 
What makes the present study particularly exciting is that ILK has not previously been 
described in any SCC and, due to the importance of oesophageal SCCs in South Africa, 
it has become critical to investigate the role of ILK in oesophageal carcinoma cells. 
 183
It is well established that alterations in ILK impinge upon essential signalling pathways 
that ultimately impact upon cell behaviourial traits (Walsh and Dedhar, 2002; Dai et al., 
2003; Stevens et al., 2004; Vouret-Craviari et al., 2004; Wu, 2004; Watanabe et al., 
2005; Boulter et al., 2006). For example, overexpressed ILK alters the phenotype of 
cells by inducing an epithelial to mesenchymal transformation (Novak et al., 1998; 
Somasiri et al., 2000), as well as resulting in increased anchorage-independent growth, 
cell cycle progression and invasiveness (Radeva et al., 1997; Dedhar, 2000; Dai et al., 
2003; Ito et al., 2003). Conversely, inhibition of ILK has been shown to reduce tumour 
growth in pancreatic cancer (Yau et al., 2005). Current literature suggests that ILK is 
directly associated with another aspect of cell behaviour, that is, cell-ECM adhesion 
(Hannigan et al., 1996; Mulrooney et al., 2000; Attwell et al., 2003). Cell adhesion is 
important as it is directly linked to the ability of tumour cells to leave their original site 
and metastasise. Due to the fact that ILK has not been previously considered in 
carcinoma of the oesophagus, a biochemical description of ILK was first required, 
before an understanding of the significance of ILK in cell adhesion events could be 
achieved. 
 
6.2 ILK and Integrin Signalling Pathways are Closely Associated 
Typically, ILK distribution has been shown to occur along focal adhesion plaques in the 
majority of cell types examined, implicating this protein kinase in integrin-mediated 
adhesion events (Zervas et al., 2001; Dai et al., 2003; Aoyagi et al., 2005; Cho et al., 
2005). ILK localisation requires the adaptor protein, PINCH, which binds, through its 
LIM domain to the ankyrin (ANK)-repeat domain of ILK (Wu, 2004). The ANK repeats 
are necessary but not sufficient for ILK localisation to focal adhesions as demonstrated 
by Li et al. (1999). Briefly, these authors showed that an ILK mutant lacking the C-
terminal binding site, but containing the ANK repeats, failed to localise to focal 
adhesions in Chinese hamster ovary cells (CHO). Furthermore, they showed that ILK 
was not recruited to epithelial cell-cell adhesion sites (Li et al., 1999). This interaction 
has been found in both mammalian cells as well as in vitro (Wu, 1999). The observation 
that ILK is a focal adhesion constituent, strongly suggests that ILK could function as 
one of the major kinases responsible for phosphorylation in focal adhesions during 
integrin-mediated signal transduction (Li et al., 1999). Examination of the localisation 
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of ILK would hence allow for the functional role/s of ILK in carcinoma of the 
oesophagus to be gauged, by identifying the site/s of ILK functioning in the cell. 
 
It was shown that ILK and the β3 integrin were interacting, as demonstrated by co-
immunoprecipitation analysis (see Figure 9). Miller and Veale (2001) previously 
showed that the β1 integrin subunit followed a membranal distribution, which suggests 
similar distributions between ILK and this subunit. Co-localisation between ILK and the 
β3 integrin was demonstrated in these oesophageal carcinoma cell lines. ILK is able to 
associate with the majority of β integrin subunits including β1, β2 and β3 (Hannigan et 
al., 1996; Dedhar et al., 1999; Somasiri et al., 2000). 
 
Indirect immunofluorescence showed that ILK displayed prominent and distinctive 
cytoplasmic localisation. Unexpectedly prominent nuclear localisation was also 
demonstrated, with variable amounts of ILK distributed at the plasma membrane (see 
Figure 10a-e). The demonstration of ILK nuclear localisation was somewhat surprising, 
especially since ILK is largely regarded as a focal adhesion protein. Subsequent 
Western analysis however confirmed that ILK was prominently present in nuclear 
extracts of all five HOSCCs (see Figure 11). Interestingly, Chun et al. (2005) 
demonstrated recently that for cytoplasmic retention of ILK an association with a 
cholesterol-dependent molecule, caveolin-1 is required. When this interaction was 
disrupted it resulted in subsequent ILK nuclear localisation. Since it is likely that ILK 
nuclear localisation could be explained by mechanism/s involving caveolin-1, this 
molecule was considered important with regards to ILK distribution in HOSCCs. ILK 
nuclear localisation and caveolin-1 will be discussed at a later stage in this chapter. 
 
At present, it is generally thought that the complete elucidation of the functional 
significance of ILK activity would aide in providing novel research approaches to the 
development of specific treatments in malignancies (Yoganathan et al., 2000). The 
activity of ILK is PI3K-dependent and is stimulated by numerous signalling molecules 
including growth factors and ECM (Dedhar et al., 1999; Troussard et al., 2000; Dai et 
al., 2003; Barker et al., 2005). In support of this, it has been shown that the interaction 
of ILK with the cytoplasmic tail of the β1 integrin subunit activates ILK when epithelial 
cells adhere to the ECM in a β1 integrin-dependent manner (Hannigan et al., 1996; 
Somasiri et al., 2000). 
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Integrin activation is also directly affected by the kinase activity of ILK. The interaction 
of integrin receptors to specific ECM ligands results in the activation of PI3K 
signalling, which in turn activates ILK (Somasiri et al., 2000; Attwell et al., 2003; 
Grashoff et al., 2004; Khyrul et al., 2004). It has long been known that ILK interacts 
with the integrin class of receptors and, in doing so, is able to phosphorylate the 
cytoplasmic domain of the β integrin subunit (Hannigan et al., 1996; Janji et al., 2000; 
Mulrooney et al., 2000). Since the β integrin subunits do not possess any catalytic 
activity, this phosphorylation by ILK is thought to regulate integrin activity (Hannigan 
et al., 1996; Attwell et al., 2000; Mulrooney et al., 2000). Furthermore, this interaction 
is reciprocal since the integrins are also able to regulate ILK activity (Pinkse et al., 
2005). In confirmation of this, it has been shown that the interaction of ILK with the 
cytoplasmic tail of β1 integrin subunit activates ILK when epithelial cells adhere to the 
ECM in a β1 integrin-dependent manner (Hannigan et al., 1996; Delcommenne et al., 
1998; Somasiri et al., 2000).  
 
From the identification of an integrin β3-ILK association in it would appear that 
integrin-mediated signalling events are regulated by ILK in oesophageal carcinoma. 
Since this interaction is not compromised in HOSCCs suggests that integrin signalling 
pathways depend on ILK functionality. In this particular instance, it implies that 
HOSCCs behave similarly to other tissue types, in which integrin activation relies 
heavily on ILK activity (Hannigan et al., 1996; Mulrooney et al., 2000; Boulter et al., 
2006). Thus, it appears that ILK and the integrin receptors are closely intertwined. 
Integrins however, are not the only molecules responsible for ILK activation. 
Stimulation of ILK activity is also mediated by signalling molecules, including growth 
factors and the ECM (Hannigan et al., 1996; Dedhar et al., 1999). 
 
Perhaps it is important at this point to clarify that while PINCH is necessary for focal 
adhesion localisation of ILK to occur, caveolin-1 is required for cytoplasmic retention. 
Thus, the association currently shown between ILK and β3 integrin further indicates that 
a stable complex exists between the ANK repeats of ILK and the LIM domains of 
PINCH in oesophageal SCCs, although this has not been validated in these HOSCCs. 
Nonetheless, the present investigation still corroborates previous evidence of ILK 
functioning in integrin-mediated signalling pathways. 
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The growth factor receptor link to the integrin receptors is well established (Miyamoto 
et al., 1996; Lai et al., 2000; Pouliot et al., 2000; Yu et al., 2000; Mariotti et al., 2001), 
and the above data point towards an involvement of ILK in integrin receptor signalling. 
The following section elaborates upon the findings which clearly demonstrate that ILK 
is intricately involved in growth factor signalling pathways.  
 
6.3 Functional ILK Activity in Relation to ILK Protein Expression 
The first step in understanding ILK in carcinoma of the oesophagus required the 
confirmation that the ILK gene in oesophageal SCCs was undergoing active 
transcriptional and translational processes. This was verified by the expression of a 
59kDa ILK protein band, and the RT-PCR amplification of a 1360bp ILK fragment. 
ILK has been identified in a variety of tissues that include those of the pancreas, 
stomach, liver, thymus, brain, prostate, and intestine and is found to be abundantly 
expressed in skeletal and heart muscle (Hannigan et al., 1996; Janji et al., 2000; 
Friedrich et al., 2002). Furthermore, its overexpression has been demonstrated in certain 
malignancies that include prostate and colon carcinoma, medullablastoma, melanoma 
and gastric carcinoma (Chung et al., 1998; Persad et al., 2000; Dai et al., 2003; Ito et 
al., 2003). The current study is the first demonstration of ILK expression in not only 
SCC tumour cell lines but furthermore, the first identification in oesophagus. 
 
The signalling pathways of ILK are known to interdigitate with both the integrin and 
growth factor receptors, allowing for crosstalk between these two classes of receptors 
(Delcommenne et al., 1998; Janji et al., 2000; Mulrooney et al., 2000; Nikolopoulos 
and Turner, 2002; Barker et al., 2005; Boulter et al., 2006; Shafiei and Rockey, 2006). 
To establish if growth factor receptor signalling and ILK were associated, the effect of 
growth factors on ILK expression and activity was examined. Analysis revealed that the 
EGF and TGFβ1 growth factor upregulated ILK protein expression in all five 
oesophageal carcinoma cell lines, implying that within a certain class of oesophageal 
SCC cell lines, similar regulatory mechanisms for ILK signalling exist. With regards to 
EGF the increased expression of ILK following EGF exposure in these cell lines was 
not unexpected, considering that these HOSCCs overexpress EGFR (Veale and 
Thornley, 1989). Thus it is apparent that EGF-stimulated ILK could have further 
consequences with regards to the tumourigenicity of oesophageal carcinoma. In 
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addition, it suggests that growth factor and ILK signalling pathways are closely 
associated and that crossmodulation exists between these signalling molecules (see 
Chapter 2, Figures 12 and 13).  
 
The only other data considering growth factor effects on ILK clearly demonstrated an 
increase in ILK regulation following growth factor exposure (Delcommenne et al., 
1998; Janji et al., 2000; Cho et al., 2005). These authors similarly showed that ILK2 
expression was increased following EGF- and TGFβ1-stimulation in human melanoma 
cell lines, while a separate study revealed that insulin was capable of stimulating ILK 
activity in intestinal epithelial cells (Delcommenne et al., 1998; Janji et al., 2000). The 
current data provide the first evidence that ILK is expressed and stimulated in response 
to growth factor treatment in SCC tumour cell lines of oesophagus. These data 
corroborated the above evidence from Janji et al. (2000) which was the only basis of 
comparison for the effects of the EGF and TGFβ1 growth factors on ILK expression. 
 
Lynch et al. (1999) have expressed their doubt as to whether ILK behaves as a bona fide 
protein kinase. These authors suggested that ILK regulates PKB phosphorylation 
indirectly rather than directly. This speculation is based on their observation that a 
mutation of a specific serine residue present in PKB, a recognised autophosphorylation 
site, rendered PKB active. They created an ILK dominant negative mutant and showed 
that this mutant could still phosphorylate PKB (Lynch et al., 1999 cited in Yoganathan 
et al., 2000), indicating that ILK activity is not required for PKB phosphorylation. 
However, more recently it was shown that, in a dominant negative form of ILK, ILK 
activity is severely decreased and inhibits PI3K-dependent phosphorylation of PKB in a 
dominant negative manner. This suggests that ILK activity is required for PKB 
phosphorylation (Yoganathan et al., 2000; Walsh and Dedhar, 2001). There is thus 
conflicting evidence regarding the kinase activity of ILK. The kinase activity of ILK is 
the primary way in which ILK regulates cell survival, but as mentioned at the beginning 
of this discussion, there are numerous cellular processes that are regulated by ILK. One 
such behaviourial event is that of cell-ECM adhesion. Thus it was necessary, and of 
extreme importance to ascertain the functionality of the ILK kinase domain. 
 
The kinase domain of ILK was shown to be active following MBP-based kinase assays. 
Since MBP is a β integrin subunit analogue, this result highlighted the possibility of an 
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interaction between ILK and integrin mediated pathways in oesophageal SCCs. This 
association will be considered further on but presently, the effect of growth factors on 
ILK activity will be discussed, to ascertain if growth factors affect ILK activity in a 
similar fashion to ILK protein expression. Due to the noted increase in ILK protein 
expression following growth factor treatment, a similar increase in ILK kinase activity 
was expected in the presence of growth factors in these oesophageal SCC cell lines. 
Furthermore, our suggestion is supported by Delcommenne et al. (1998) who 
demonstrated increased ILK activity in response to insulin and PDGF growth factors in 
IEC-18 intestinal epithelial cells. 
 
Growth factors are tightly linked to cell proliferation in epithelial cells (Ozanne et al., 
1986). Since ILK is involved in cell cycle progression via PKB-independent pathways 
involving GSK3β, β-catenin, or AP-1 transcription factor (Radeva et al., 1997; Persad 
et al., 2000; Troussard et al., 2000; Pinkse et al., 2005), it was thought that growth 
factors would stimulate ILK activity. While EGF increased ILK protein expression 
across all cell lines it is noteworthy that EGF and TGFβ1 resulted in both 
increases/decreases in ILK activity in the WHCO3 and WHCO5 with a decrease in ILK 
activity in the remaining cell lines. Thus subsequent to growth factor treatment, there 
was an inclination towards a reduction in ILK activity, opposed to the increase noted in 
ILK expression. This is linked to the capacity of TGFβ1 to be either stimulatory at one 
concentration or inhibitory at another concentration (Fujimoto et al., 2001; Hu and 
Zuckerman, 2001). The growth factor-induced upregulation of ILK protein expression 
in these HOSCCs implicated ILK in the progression of oesophageal carcinoma. The 
demonstration that growth factors both stimulated and inhibited ILK activity further 
implied that ILK is more intimately involved in oesophageal carcinoma development 
than originally suggested. Indeed, growth factor-mediated changes in ILK activity could 
possibly lead to the dysregulation of both integrin-mediated cell adhesion and integrin 
signalling cascades, resulting in aberrant expression of critical protein kinases such as 
FAK and MAPK. 
 
This reduction in ILK activity was unexpected considering that these oesophageal 
carcinoma cell lines overexpress EGFR (Veale and Thornley, 1989). In squamous 
carcinoma cells, EGFR has been found to be responsible for the activation of the 
Ras/Raf/ERK signalling pathway as well as the PI3K signalling pathway as a direct 
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result of increased EGF signalling (Mariotti et al., 2001). This identifies a route by 
which cellular events such as cell adhesion may be regulated, since PI3K activation may 
affect ILK/integrin-mediated cell attachment to ECM substrates. This route may occur 
through PI3K-mediated regulation of FAK. However, since HOSCCs demonstrated 
increased ILK protein expression following both EGF and TGFβ1 treatment, and 
decreased ILK activity following treatment with the same growth factors, it suggests 
that PI3K levels are not similarly stimulated by growth factors.  
 
An alternate signalling pathway may be activated by EGF in HOSCCs instead of PI3K. 
This may include stimulation of an ILK inhibitor, PTEN. Therefore, PTEN expression 
levels were monitored in the presence of growth factors. To ensure proper tissue 
homeostasis, epithelial cell growth and survival need to be tightly regulated. Thus ILK, 
which is positively regulated by PI3K, requires a negative regulator. From the above 
hypothesis of unchanged activity levels of PI3K following growth factor treatment, the 
PTEN lipid, which is a protein phosphatase, serves as such a negative regulator of ILK. 
PTEN was the obvious protein phosphatase to consider when explaining the effects of 
growth factors on ILK. Since it has been estimated that 60 % of all solid tumours 
contain inactivating mutations of PTEN (Persad et al., 2000), it is evident that this 
protein phosphatase is crucial during the maintenance of ILK activity. Persad et al. 
(2000) demonstrated that ILK activity is anchorage independent in PTEN-null prostate 
carcinoma cells and, anchorage dependent in cells expressing PTEN.  
 
The EGF-induced effects on ILK activity are mediated by PTEN in the WHCO1, 
WHCO3 and WHCO5 cell lines, since PTEN expression in these cells correlated with 
ILK activity levels (see Figure 17b). In the case of WHCO6 and SNO cells, PTEN 
could not be considered to be regulating the growth factor-mediated responses in ILK 
activity. Instead, it is proposed that another growth factor signalling moiety such as 
ILKAP is regulated by EGF in WHCO6 and SNO cells subsequently resulting in a 
reduction of ILK activity (see Figure 17b). Evidence has suggested that TGFβ1 causes a 
reduction in PTEN in keratinocytes (Janji et al., 2000). Thus, ILKAP may also play a 
role in mediating ILK activity in TGFβ1-treated WHCO3 cells (see Figure 18a and b). 
In support of this notion, ILK was shown to be negatively regulated when physically 
associated with ILKAP in transformed human embryonic kidney (HEK293) cells 
(Leung-Hagesteijn et al., 2001). 
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The effect of growth factors on PTEN expression implies that PTEN has a greater role 
to play in growth factor-mediated effects of ILK activity. Furthermore, although 
interactions between growth factor receptors and PI3K signalling have been shown in 
other malignancies, including ovarian and prostate carcinomas (Ellerbroek et al., 2001; 
Bancroft et al., 2002), this interaction has not been demonstrated in carcinoma of the 
oesophagus. Determining this interaction thus remains an area of focus for future 
studies. However, the demonstration of PTEN levels in response to growth factors in 
these cell lines has provided insight into the mechanism of growth-factor modulation of 
ILK activity in carcinoma of the oesophagus. 
 
From the above data it seems likely that ILK is intricately involved in growth factor and 
integrin signalling processes of oesophageal carcinoma cell lines. To our knowledge 
this is the first investigation regarding ILK in oesophageal SCCs. These differences in 
ILK activity in response to growth factor exposure imply that ILK regulation within 
these HOSCCs is highly complex. Furthermore, these noted differences in ILK activity 
were somewhat surprising since these cell lines are similarly pathologically graded. 
 
Although these data provide a basis for the kinase activity of ILK in HOSCCs the 
adaptor-type role of ILK cannot be discounted. Complexes between ILK, PINCH and 
parvin would also modulate some of the ILK activity described (Nikolopoulos and 
Turner, 2001). Besides these complexes, ILK binding to paxillin and affixin can also 
significantly regulate ILK acitivty (Wu and Dedhar, 2001). 
 
6.4 Significance of the ILK and PTEN Interaction 
It is well established that ILK is an effector of PI3K signalling, which upon 
dephosphorylation of PI3K via PTEN, leads to inhibition of ILK activity (Attwell et al., 
2003; Grashoff et al., 2004; Obara et al., 2004). It stands to reason that in order for 
these regulatory processes to be performed efficiently, PI3K, PTEN and ILK need to be 
in close proximity. The above data clearly suggested that PTEN mediates the growth 
factor effects of ILK activity. Thus, it is obvious that PTEN plays an important role with 
regard to the regulation of ILK signalling in HOSCCs.  
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It was surprising that initial co-immunoprecipitation analysis did not reveal PTEN in 
ILK-precipitated lysates (see Figure 19a). However, when co-immunoprecipitation was 
performed on PTEN-immunoprecipitated lysates, ILK was identified at a molecular 
weight of 59 kDa (see Figure 19b). The surprising result of no PTEN band being 
present in ILK immunoprecipitated lysates was possibly due to ILK not associating with 
PTEN in a 1:1 molar ratio. Another explanation was that the binding epitopes of PTEN 
were masked, preventing antibody recognition and binding. However, subsequent 
analysis of PTEN localisation revealed a very similar pattern of distribution to that 
noted for ILK (see Figure 20), which corroborates the data from the successful co-
immunoprecipitation analysis. 
 
It is proposed that the ILK/PTEN interaction serves an important regulatory function. 
Since our data confirmed an interaction between ILK and PTEN in HOSCCs, it is 
suggested that ILK may also be capable of modulating PTEN activity through 
phosphorylation (see Figure 21). PTEN phosphorylation is speculated to serve a 
regulatory role in PTEN function, although evidence to confirm this has remained 
elusive (Vazquez et al., 2000). Recent evidence however, suggests that PTEN 
phosphorylation serves to maintain PTEN in a conformation that prevents membrane 
association (Das et al., 2003; Leslie and Downes, 2004). Although originally thought to 
involve CKII, it has now come to light that GSK3β is also capable of directly 
phosphorylating PTEN (Al-Khouri et al., 2005; Gericke et al., 2006). Although not 
demonstrated, it is possible that the identified interaction between ILK and PTEN serves 
to provide a similar regulatory function for PTEN. 
 
6.5 Caveolin-1 Regulates ILK Subcellular Localisation 
Experiments reported on in chapter 2 clearly demonstrated the prominent nuclear 
localisation of ILK in HOSCCs. While this distribution of ILK is not unheard of, it is 
not the typical distribution pattern normally exhibited by ILK. Obviously, it was 
therefore of interest to ascertain the mechanism in which ILK achieved this nuclear 
distribution. Previously it was demonstrated in COS-1 cells that ILK dissociation from 
caveolin-1 unblocks a nuclear localisation signal within ILK, thus allowing ILK to 
translocate to the nucleus (Chun et al., 2005). It is therefore apparent that caveolin-1 
had to be considered when examining the nuclear localisation of ILK in HOSCCs.  
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Throughout this study, growth factors have been shown to influence various cellular 
aspects of ILK function (see Chapters 2 and 3). EGF is particularly relevant to the 
HOSCCs in question due to the noted upregulation of EGFR. Previous studies 
investigating caveolin-1 signalling have also implicated EGF as playing a pivotal role in 
caveolin-1 regulation (Pol et al., 2000; Kim et al., 2002). This is highlighted by the fact 
that in cell types including human epidermoid carcinoma cells, prostate cells and non-
small lung cancer cells, EGF was shown to downregulate caveolin-1 expression (Lu et 
al., 2003). Other studies have shown that the relationship between caveolin-1 and EGF 
is reciprocal where the upregulation of caveolin-1 attenuated EGF signalling in rat 
brain, spleen and lung cells (Park et al., 2000). Furthermore, EGFR has been found to 
interact directly with caveolin-1 (Couet et al., 1997). In this study it was revealed that 
the binding of caveolin-1 to EGFR resulted in a downregulation of the 
autophosphorylation activity of EGFR in Chinese hamster ovary cells. Therefore, it is 
highly probable that EGF is almost certainly a key player in ILK and caveolin-1 
interactions in HOSCCs. 
 
Due to caveolin-1 displaying dissimilar expression across different malignancies, it was 
necessary to determine caveolin-1 expression in HOSCCs. Caveolin-1 expression has 
been shown to be reduced in human mammary carcinoma cells as well as ovarian 
carcinoma (Wiechen et al., 2001). Paradoxically however, caveolin-1 expression has 
previously been demonstrated to be increased in prostate cancer and oesophageal 
cancer, which suggests a positive role of tumour development (Li et al., 2001; Kato et 
al., 2002; Mouraviev et al., 2002). Furthermore, re-expression of caveolin-1 in human 
breast cancer cells inhibits cell growth, which directly implicates caveolin-1 in the 
regulation of cell proliferation (Lee et al., 1998; Kim et al., 2000). In the majority of 
HOSCC cell lines examined here relatively uniform caveolin-1 expression levels were 
demonstrated (see Figure 22). It is important to realise that the comparative changes in 
caveolin-1 expression in the malignancies discussed above were made with respect to 
normal tissue. Even though in the present study comparisons could not be drawn to 
normal oesophagus, it still suggests that within this class of moderately differentiated 
HOSCC, caveolin-1 does not display altered regulation and is more than likely not 
involved in the tumourigenicity of HOSCCs. 
 
 193
Analysis of EGF exposure over a 6 hour time course revealed that caveolin-1 was 
reduced in all five cell lines, implying a redistribution of caveolin-1 in the presence of 
EGF (see Figure 23). Indeed, examination of nuclear caveolin-1 levels in the presence 
of EGF revealed an increased trend in expression levels in the majority of cell lines (see 
Figure 24a and b). This supports previous data which demonstrate an internalisation of 
caveolin-1 when treated with the EGF growth factor (Pol et al., 2000). WHCO3 cells 
proved the exception as a reduction in nuclear caveolin-1 was observed in this cell line 
following EGF treatment. Thus, in the WHCO1, WHCO5, WHCO6 and SNO cell lines 
these results confirmed that EGF induced a redistribution of caveolin-1 to a nuclear 
region. In the instance of WHCO3 cells, it implied a constitutive downregulation of 
caveolin-1 expression at both a membrane/cytoplasmic and nuclear level. 
 
In addition to a cytoplasmic ILK distribution, ILK also displayed prominent nuclear 
localisation (see Figures 9 and 10 in Chapter 2). Since EGF increased nuclear caveolin-
1 concentration, we next tested whether EGF induced a similar response in nuclear ILK 
concentration. Indeed, Western analysis showed that nuclear ILK protein levels were 
increased following EGF treatment in WHCO1, WHCO5, WHCO6 and SNO cells. As 
was noticed for caveolin-1 expression, EGF-treated WHCO3 cells exhibited a reduction 
in nuclear ILK concentration. However, unlike membrane/cytoplasmic caveolin-1 
expression, an increased level of ILK expression was displayed in EGF-treated WHCO3 
cells (Figure 25). It is apparent that in the WHCO3 cell line, different mechanisms exist 
for the regulatory control of both caveolin-1 and ILK in comparison to the remaining 
HOSCCs. 
 
Upon ligand binding the activated EGF receptor mediates a number of crucial biological 
responses, including the stimulation of cell proliferation, migration and differentiation 
(Ullrich and Schlessinger, 1990; Boonstra et al., 1995, Wells et al., 1998; Andl et al., 
2003; Normanno et al., 2006). These processes usually involve receptor tyrosine 
kinases, which when bound to their cognate ligand activates their intrinsic kinase 
activity. What ensues is the recruitment and activation of signal transduction machinery 
which ultimately leads to a cascade of events (Puri et al., 2005). An example of this 
includes the ErbB receptor tyrosine kinases of which EGFR is a member. This 
signalling pathway has the potential to signal very potently through tyrosine 
phosphorylation of either the ras/raf/MAPK pathway for cell proliferation, and through 
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the PI3K/Akt pathway for cell survival (Normanno et al., 2006). Tyrosine 
phosphorylated signalling cascades are thus central to the coordination of the biological 
functioning of cells. 
 
With this in mind, it has recently been revealed that EGF is capable of tyrosine 
phosphorylating caveolin-1, suggesting that caveolin-1 may act as a signalling molecule 
(Kim et al., 2000; Labrecque et al., 2004; Lee et al., 2005). Although this tyrosine 
phosphorylation is thought to have important consequences with regards to caveolin-1, 
at present the complete functional significance is not known. In the present study it is 
proposed that caveolin-1 tyrosine phosphorylation via EGF induced the noted 
redistribution of caveolin-1. Utilising a phospho-specific tyrosine antibody, it was 
confirmed that caveolin-1 was tyrosine phosphorylated in the WHCO1; WHCO5 and 
WHCO6 cell lines (see Figure 26). The inability to demonstrate tyrosine 
phosphorylation in the WHCO3 and SNO cell lines is most likely as a result of a low 
level of tyrosine phosphorylated levels, which remained undetected. Unfortunately, 
levels of caveolin-1 tyrosine phosphorylation could not be detected following EGF 
treatment. Although inconsistent, these data suggest that caveoloin-1 tyrosine 
phosphorylation in HOSCCs is mediated by EGF, which has crucial consequences with 
regards to caveolin-1 function, specifically localisation.  
 
Having established that EGF altered caveolin-1 expression levels with a subsequent 
increase in nuclear caveolin-1 concentration, confirmation of this redistribution was 
sought. Surprisingly, no visual detection of this redistribution was observed in the 
distribution patterns of caveolin-1 when treated with EGF (see Figure 27). Even though 
0.5 hours was more than sufficient to elicit changes in both membrane/cytoplasmic and 
nuclear caveolin-1 concentration levels, it could be that this period of time does not 
result in a noticeable visual redistribution or that there is no significant relocalisation. 
 
Due to the similarities noted for expression of both caveolin-1 and ILK in the WHCO1, 
WHCO5, WHCO6 and SNO cell lines when exposed to EGF, this suggested that ILK 
translocation to the nucleus involved an association with caveolin-1. The finding that 
ILK is associated with caveolin-1 in nuclear lysates is indicative of ILK translocation 
requiring an interaction with caveolin-1 (see Figure 28). Although this is in 
disagreement with the study by Chun et al. (2005), who demonstrated that the 
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disruption of the ILK/caveolin-1 interaction allows for ILK nuclear localisation, the 
present data cannot be ignored. It appears that both these mechanisms are plausible. 
Perhaps these differences can be explained by differences in cell type. As mentioned 
earlier, the noted overexpression of EGFR in HOSCCs may have an influence. It has 
been clearly demonstrated that EGF exposure results in a more intracellular distribution 
of caveolin-1 (Pol et al., 2000). This strengthens the suggestion made here that ILK 
nuclear translocation occurs when bound to caveolin-1 in HOSCCs. It is further 
proposed that this redistribution is mediated by EGF tyrosine phosphorylation of 
caveolin-1. 
 
Methyl-β-cyclodextrin sequesters cholesterol, which is required for caveolae function 
(Ilangumaran et al., 1998). To confirm the data from the present study that ILK does 
indeed require an interaction with caveolin-1 for nuclear translocation, then 
downregulating caveolin-1 with methyl-β-cyclodextrin should produce a concomitant 
reduction in nuclear ILK protein levels. The decrease in ILK expression at both 
cytoplasmic and nuclear levels in cells treated with methyl-β-cyclodextrin substantiates 
the above claim (see Figures 29 and 30). To our knowledge this is the first 
demonstration that an association between ILK and caveolin-1 is necessary in order to 
allow for ILK translocation to a nuclear region. Unfortunately, the role of nuclear ILK 
is uncertain at present but it is possible that it is directly involved in the phosphorylation 
of nuclear β-catenin as well as GSK3β. This would have consequences with regards to 
transcription of genes such as cyclin D1, which is involved in cell cycle control.  
 
For ultimate proof that ILK and caveolin-1 do indeed associate in these cell lines, 
double label immunofluorescence could be performed which would indicate visually the 
co-localisation between ILK and caveolin-1. Pull down assays would indicate 
biochemically that this association does indeed occur.  
 
Thus far, this study has provided groundbreaking evidence in that it has identified ILK 
in oesophageal SCCs for the first time and, implicated ILK in integrin and growth factor 
receptor signalling pathways. Furthermore, it has established that a unique ILK nuclear 
localisation mechanism exists in HOSCCs that involves caveolin-1. Even though the 
biochemistry of ILK was an important aspect, it primarily served to complete the 
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understanding of the significance of ILK in cell-ECM adhesion events, which formed 
the main thrust of this study. 
 
6.6 ILK Function in Cell-ECM Interactions 
The ability of malignant cells to metastasise entails the detachment of cells from the 
primary tumour mass, migration on ECM and, adhesion in the new environment once 
the cell has circulated to a secondary site (von Schlippe et al., 2000; Stewart et al., 
2004). The majority of cancer deaths are a result of the invasion of cells into 
surrounding tissues and widespread metastasis to vital organs (Qian et al., 1994; Cooper 
et al., 2003). This metastatic phenotype is dependent on an altered behaviour at various 
cellular levels (Kurschat and Mauch, 2000). An example of such a behaviourial change 
is differences in expression of certain adhesion molecules (Zutter et al., 1998; 
Christofori, 2003). 
 
In recent years the understanding of cell-cell and cell-matrix interactions that are 
involved in tumour invasion and metastasis on a molecular and cellular level has 
improved greatly. The best characterized of the molecules that mediate these 
associations are the integrin class of receptors, which exhibit altered expression in 
certain malignancies. For instance, altered integrin expression is noted in a host of 
malignancies, including breast, lung, prostate, ovary and oesophagus (Giancotti and 
Ruoslahti, 1990; Zutter et al., 1995; Taverna et al., 1998; Koivisto et al., 2000; Felding-
Habermann et al., 2001; Miller and Veale, 2001). Furthermore, the integrins are of 
relevance because they play a central role in anchorage dependent growth, apoptosis, 
differentiation, migration processes and it is these processes that are characteristically 
dysregulated in malignancy (Humphries et al., 2004; Stewart et al., 2004; Brockbank et 
al., 2005; Ginsberg et al., 2005; Reddig and Juliano, 2005). 
 
A possible way in which integrins induce a metastatic phenotype is through interactions 
with other adhesion pathways (Jones and Walker, 1999; Kurschat and Mauch, 2000; 
Tan et al., 2001; Vespa et al., 2005). An example of this includes FAK and paxillin 
which regulate integrin-mediated adhesion and migration and positively modulate cell-
cell adhesion mediated by N-cadherin in HeLa cells (Yano et al., 2004). ILK binds to 
the cytoplasmic domains of β1 and β3 integrins, and is activated by integrin-ligand 
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interactions (Wu and Dedhar, 2001; Vouret-Craviari et al., 2004). ILK is also capable of 
mediating cell-cell interactions. For example, ILK overexpression results in reduced 
expression of the invasive suppressor, E-cadherin, and the acquisition of an invasive 
phenotype (Novak et al., 1998; Jones and Walker, 1999). Conversely, inhibition of ILK 
has been shown to result in increased E-cadherin expression (Tan et al., 2001). Thus it 
is obvious that ILK is able to mediate both cell-cell and cell-ECM processes by 
regulating either cadherin or integrin molecules. 
 
The fact that ILK follows a pattern of distribution similar to that of β integrins and was 
able to associate with β integrins was indicative of a role for ILK in cell-ECM adhesion 
events in carcinoma of the oesophagus. While previous studies placed more emphasis 
on the effects of ILK overexpression on ECM attachment, this study took a different 
approach and examined the effect of reducing ILK on cell-ECM adhesion. Since it has 
been shown that selective inhibition of ILK activity, with KP-392 treatment results in 
decreased adhesiveness to ECM in cell types that include intestinal epithelial cells 
(Attwell et al., 2003), a similar occurrence was expected in the HOSCCs under 
investigation. Following KP-392 treatment a decrease (albeit nonsignificant) in cell 
adhesion to fibronectin was apparent (see Figure 31). Since this trend of reduction was 
observed in all the cell lines, it indicated that ILK inhibition resulted in destabilisation 
of the αβ integrin heterodimer complex and subsequent reduced cell adhesion to the 
ECM. 
 
Examination of cell adhesion to collagen and fibronectin in the presence of the PI3K 
inhibitor, wortmannin revealed a trend of reduced cell attachment to these ECM 
substrates. The exception was the WHCO6 cell line, which exhibited increased 
attachment to fibronectin when treated with wortmannin. A possible explanation for this 
is that the inhibition of PI3K in wortmannin- treated WHCO6 cells results in stimulation 
of integrin receptors such as α5β1, and αvβ6, which are specific for fibronectin (Watt, 
2002). Interestingly, the αvβ6 integrin is often expressed in squamous cell carcinomas 
(Jones et al., 1997) and for this reason may have further relevance to these HOSCCs. 
However, the trend across the cell lines suggests that PI3K is an upstream mediator of 
the ILK-induced effects on cell-ECM in HOSCCs 
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It would appear from the present study that, had ILK not been forcefully inhibited, αβ 
integrin heterodimer stabilisation would have occurred with a subsequent increase in the 
adhesion of cells to ECM proteins. This is contrary to Mulrooney et al. (2000), who 
showed that ILK expression results in β integrin subunit removal from focal adhesions, 
with a subsequent loss in adhesion. Furthermore, with the knowledge that ILK activity 
is transiently increased when cells bind to fibronectin (Hannigan et al., 1996; 
Delcommenne et al., 1998), these recent results suggest that reduced cell adhesion as a 
consequence of reduced ILK may be specific for oesophageal carcinoma. However, 
until the details of these interactions are unraveled in other SCCs, further comparisons 
cannot be made. 
 
6.7 Conclusion 
Understandably to date the literature surrounding ILK has been primarily biochemical. 
As a consequence of these biochemical signals elicited by ILK, various critical 
behaviourial aspects of cellular functions are regulated. ILK accomplishes this role by 
mediating a multitude of integrin and growth factor signalling pathways. Ultimately, 
cellular events such as cell proliferation, cell migration and cell spreading are affected, 
which all play an essential role in the metastatic spread of tumours. Cell adhesion is yet 
another important cellular event, which involves ILK. Surprisingly, although the 
influences of ILK on cell adhesion have been examined to a large extent in many other 
tumours and tissue types, the role of ILK on cell adhesion in oesophageal SCCs has 
been largely overlooked. Oesophageal carcinoma is an aggressive metastatic 
malignancy, which relies on the dysregulation of signalling pathways that allow for 
tumour establishment at distant tissue sites. The present study has clearly demonstrated 
the requirement of ILK in both integrin and growth factor signalling cascades in 
HOSCCs. Therefore, ILK may be a prime candidate for the regulation of the signalling 
cascades involved in the metastatic spread of HOSCC.  
 
Interestingly, throughout this discourse, variation in results has been shown between 
cell lines in certain instances. This is surprising, since histopathogically all five cell 
lines have been graded in the moderately differentiated class of HOSCCs. This implies 
that the current system for the pathological grading of oesophageal tumours is 
inconsistent and that it requires re-evaluation. As biochemical techniques become more 
 199
sophisticated, molecular descriptors need to be developed for more accurate and 
consistent grading of oesophageal malignancies. 
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Appendix 1 
 
1.1 Tissue culture 
 
1.1.1 Phosphate Buffered Saline (PBS) 
136.9 mM Sodium Chloride 
2.63 mM Potassium Chloride 
10.1 mM Disodium hydrogen orthophosphate (anhydrous) 
1.76 mM Potassium dihydrogen orthophosphate 
Make up with distilled water (dH2O) 
Adjusted pH to 7.2-7.3 
Sterilise and store at 4 °C 
 
1.1.2 TE – Trypsin in Ethylenediamine-tretraacetic acid (EDTA) 
0.02 % EDTA in 500 ml PBS 
0.1 % Trypsin in 1 litre PBS 
Mix EDTA:Trypsin (1:1) 
Final: 0.01 % EDTA/0.05 % Trypsin 
 
1.1.3 Trypan Blue (counting viable cells) 
0.4 % Trypan Blue 
Make up in PBS 
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1.2 RNA Extractions 
 
1.2.1 Phenol/Chloroform solution 
25:24:1 mixture of phenol:chloroform:isopropyl alcohol 
Store at 4 °C 
 
1.2.2 Sodium Acetate 
3 M NaAc 
pH adjusted to 5.2 using glacial acetic acid 
Make up with dH2O 
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1.3 Triton X-100 Extraction 
 
1.3.1 Phenyl-methyl-sulphonyl fluoride (PMSF) stock solution 
20 mM PMSF powder (Merck, SA) 
Make up with Methanol 
Store at 4 °C 
 
1.3.2 PMSF/Aprotinin stock solution 
0.5 % PMSF stock solution (see Appendix 1.3.1) 
1 % Aprotinin (Trasylol® Bayer, SA) 
Make up in PBS 
Store at 4 °C 
 
1.3.3 Triton X-100 Extraction Buffer 
0.5 % Triton X-100 
50 mM Tris 
150 mM NaCl 
1 mN CaCl2 
1 mM MgCl2
0.01 % Aprotinin 
Make up to volume with dH2O 
 
1.3.4 Bovine Serum Albumin (BSA) solution 
0.1 % BSA (Merck, SA) 
In a 0.1 % Sodium dodecyl sulphate (SDS) in 20 mM Tris.HCl (pH 7.4) solution 
Store at 4 °C 
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1.3.5 Trichloroacetic Acid 
7.5 % TCA 
Make up to volume with dH2O 
 
1.3.6 Coomassie Blue Stain 
0.25 % Coomassie blue powder 
50 % Methanol 
10 % Acetic acid 
Make up to volume with dH2O 
Store at room temperature 
 
1.3.7 Elution Solution 
67 % Methanol 
32 % dH2O 
1 % concentrated Ammonia 
Store at room temperature 
Made up to 50 ml with dH2O 
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1.4 Western Blotting 
 
1.4.1 Blocking Buffer (BLOTTO) 
0.606 % Tris.HCL (pH 7.8) 
0.0294 % Calcium Chloride (dihydrate) 
5 %  Non-fat milk powder 
0.01 %  Antifoam (1 drop) 
0.05 %  Triton X-100 
Make up with dH2O 
Store at 4 °C 
 
1.4.2 Working Solution 
Mix equal volumes of: 
 Luminol (Supersignal® West Pico Chemiluminescent kit, Pierce, USA) 
 Peroxide (Supersignal® West Pico Chemiluminescent kit, Pierce, USA) 
Note: the total volume is dependent on the size of the nitrocellulose being treated 
 
1.4.3 Developer: D19B 
2.2 g Metol 
72 g Sodium sulphite 
8.8 g Hydroquinone (quinol) 
48 g Sodium Carbonate 
4 g Potassium Bromide 
Make up to 1000 ml with warm dH2O 
 
1.4.4 Fixer 
200 g Sodium thiosulphate 
40 g Sodium or potassium metasulphite 
Make up to 1000 ml with warm dH2O 
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1.4.5 Transfer Buffer 
0.3 % Tris 
1.41 % Glycine 
20 % Methanol 
Dissolve in dH2O 
Adjust to pH 8.3 with HCl 
Store at 4 °C 
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1.5 Electrophoresis 
 
1.5.1 Agarose Gel (2 %) 
0.6 g Agarose 
Make up to 30 ml with TAE buffer (1×) 
Heat until agarose dissolves 
Pour gel and add 
1.5 µl EtBr 
Allow gel to set for approximately 40 minutes 
 
1.5.2 TAE Buffer (20×) 
1.6 M Tris 
0.8 M NaAc.3H2O 
40 M EDTA Na2.2H2O 
Adjust pH to 7.2. 
Make up to 1000 ml with dH2O 
 
1.5.3 TAE Buffer (1×) 
To 950 ml of dH2O 
Add 50 ml TAE buffer (20×) 
 
1.5.4 SDS Polyacrylamide gel 
Separating gel: 
8 % Acrylamide 
25 % of a 1.5 M Tris.HCl (pH 8.8) separating buffer 
4 % of a 0.17 M SDS solution 
4 % of a 0.16 M NN’-Methylenebisacrylamide solution 
Make up to 10 ml with dH2O 
Just prior to pouring add:  
1.8 % of a 0.05 M ammonium persulphate (APS) solution 
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0.25 %l N,N,N’,N’-tetramethylene-diamine (TEMED) 
Allow to set for approximately 20-30 minutes 
 
Stacking gel: 
5 % Acrylamide 
25 % of a 0.5 M Tris.HCl (pH 6.8) stacking buffer 
4 % of a 0.17 M SDS solution 
4 % of a 0.16 M NN’-Methylenebisacrylamide solution 
Make up to 10 ml with dH2O 
Just prior to pouring add: 
1.8 %  of a 0.05 M APS 
0.2 %  TEMED 
Allow to set for approximately 15 minutes 
 
1.5.5 Electrophoresis Running Buffer for SDS-PAGE 
3.5 M SDS (Dissolve into dH2O) 
0.2 M Glycine 
25 mM Tris 
Make up Glycine and Tris solutions separately in dH2O 
Mix SDS and Glycine/Tris solutions together 
Adjust pH to 8.3 with HCl 
Store at room temperature 
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1.5.6 Sample buffer (single lysis) 
1.5 % Tris.HCl (pH 6.8) 
2 % SDS 
10 % Glycerol 
5 % β-mercaptoethanol 
Make up to 100 ml with dH2O 
Store at 4 °C 
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1.6 Indirect Immunofluorescence 
 
1.6.1 Paraformaldehyde Solution (4 %) 
Solution 1: 
166 ml of a 0.14 M sodium dihydrogen orthophosphate (anhydrous)  
34 ml of a 0.63 M sodium hydroxide solution 
 
Solution 2: 
4 % Paraformaldehyde 
Dissolve in Solution 1 
Heat solution to 80 °C and stir until solution is clear 
Allow solution to cool and adjust pH to between 7.2-7.4 
Filter and store solution at 2 °C 
 
1.6.2 Triton X-100 (0.25 %) 
In 10 ml 1× PBS add: 
0.025 ml Triton X100 
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1.6.3 Elvanol mounting agent 
7.5 g Glycerol 
With continual but slow stirring add: 
3 g Polyvinyl Alcohol (grade 51-05) 
Mix well 
Add slowly down the side of the tube to avoid clumping of the polyvinyl alcohol 
7.5 ml dH2O 
Stir for 24 hours at room temperature 
Add: 
15 ml 0.1 M Tris.HCl (pH 8.5) 
Continue stirring in a 50 °C water bath for 48 hours 
Clear by centrifugation (3000 rpm) for 30 minutes at room temperature 
Separate supernatant into aliquots, seal and store at 4 °C 
 
1.6.4 Double lysis buffer 
Use same weights/volumes as for single lysis buffer (Appendix 1.5.6) 
Make up to 50 ml with dH2O 
Store at 4 °C 
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1.7 Kinase Assay 
 
1.7.1 Tris buffer 
10 mM Tris 
Adjust pH 8.8 
Store at room temperature 
 
1.7.2 Kinase buffer 
50 mM Hepes 
10 mM MnCl2 
10 mM MgCl2
Adjust pH 7 
Add 10 µCi of [γ-32P]ATP 
Store at 4 °C 
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1.8 Cell Adhesion Assay 
 
1.8.1 Trypsin Inhibitor 
0.01 % Aprotinin 
Make up to 100 ml with serum free DMEM 
Store at 4 °C 
 
1.8.2 Extracellular matrix proteins 
Collagen: 50 µg/ml 
 Make up in 10 nM acetic acid 
Fibronectin: 50 µg/ml 
  Make up in sterile PBS 
 
1.8.3 Wortmannin Stock 
150 nM Wortmannin 
Make up with serum free DMEM 
Store in the dark at 4 °C 
 
1.8.4 KP-392 Stock 
100 µM KP-392 
Make up with DMSO 
Store at 4 °C 
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The absorbencies (595 nm) of 1, 3, 6, 9, 12, and 15 µg BSA were used to construct a 
standard curve for protein estimation of the Triton X-100 extracts. The concentrations 
of the total protein of the extracts were calculated from this BSA standard curve 
(y=0.0635x−0.01. R2=0.9639). 
Figure A: BSA standard curve for protein estimation.  
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Appendix 3 
 
3.1 Statistical Results of Fibronectin Cell Adhesion Assay 
 
Table 1: Analysis of Variance of the Number of Cells Attached to Fibronectin (Fn).  
Indicates significant difference (p ≤ 0.05). 
 
 
 
 
 
 
Effect df effect MS effect df error MS error F P 
Cell Line 4     25882500E3 40 161620832 160.1433 0.000000
Treatment 3     10614493E3 40 161620832 65.6753 0.000000
Cell line & 
Treatment 12      687027776 40 161620832 4.2509 0.000259
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Table 2: Tukey HSD Test for Fibronectin (Fn) Adhesion Assay Following KP-392 Exposure. 
 Marked effects are significant at p ≤ 0.05 
 
WHCO1 Fn WHCO1 Fn (KP) 
WHCO1 
BSA 
WHCO1 
BSA (KP) WHCO3 Fn 
WHCO3 Fn 
(KP) 
WHCO3 
BSA 
WHCO3 
BSA (KP) WHCO5 Fn 
WHCO5 Fn 
(KP) 
WHCO1 Fn           0.999646 0.321162 0.163602 0.000180 0.000179 0.000179 0.000179 0.002759 0.000179
WHCO1 Fn 
(KP) 0.999646          0.956846 0.828039 0.000217 0.000179 0.000179 0.000179 0.002759 0.000179
WHCO1 
BSA 0.321162          0.956846 1 0.010759 0.000179 0.000179 0.000179 0.002759 0.000179
WHCO1 
BSA(KP) 0.163602          0.828039 1 0.028060 0.000245 0.000179 0.000179 0.085652 0.000180
WHCO3 Fn 0.000180          0.000217 0.010759 0.028060 0.900075 0.000313 0.000179 0.630994 0.247690
WHCO3 
Fn(KP) 0.000179         0.000179 0.000198 0.000245 0.900075 0.046107 0.000313 0.009840 0.999802 
WHCO3 
BSA 0.000179        0.000179 0.000179 0.000179 0.000313 0.046107 0.900075 0.000179 0.446797 
WHCO3 
BSA(KP) 0.000179          0.000179 0.000179 0.000179 0.000179 0.000313 0.900075 0.000179 0.004551
WHCO5 Fn 0.002759 0.063379         0.911775 0.985652 0.630994 0.009840 0.000179 0.000179 0.000513
WHCO5 
Fn(KP) 0.000179         0.000179 0.000180 0.000180 0.247690 0.999802 0.446797 0.004551 0.000513  
WHCO5 
BSA 0.000179         0.000179 0.000184 0.000198 0.715862 1 0.107550 0.000608 0.003624 0.999999 
WHCO5 
BSA(KP) 0.000179         0.000179 0.000179 0.000180 0.199276 0.999275 0.521567 0.006269 0.000404 1 
WHCO6 Fn 1          0.996605 0.212335 0.099980 0.000179 0.000179 0.000179 0.000179 0.001479 0.000179
WHCO6 Fn 
(KP) 0.873928        0.999995 0.999991 0.998987 0.000893 0.000180 0.000179 0.000179 0.376545 0.000179 
WHCO6 
BSA 0.521567        0.994261 1 1 0.004348 0.000185 0.000179 0.000179 0.755796 0.000179 
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WHCO6 
BSA (KP) 0.000825        0.019933 0.674070 0.873928 0.887463 0.033204 0.000179 0.000179 1 0.001544 
SNO Fn 0.844196          0.174869 0.001765 0.000709 0.000179 0.000179 0.000179 0.000179 0.000181 0.000179
SNO Fn 
(KP) 0.978581        1 0.998596 0.978581 0.000382 0.000179 0.000179 0.000179 0.186727 0.000179 
SNO BSA 1          0.999995 0.499940 0.286913 0.000181 0.000179 0.000179 0.000179 0.006269 0.000179
SNO BSA 
(KP) 0.000182          0.000362 0.036076 0.086123 1 0.652653 0.000206 0.000179 0.887463 0.096367
 
 
 WHCO5 BSA 
WHCO5 
BSA (KP) WHCO6 Fn 
WHCO6 Fn 
(KP) 
WHCO6 
BSA 
WHCO6 
BSA (KP) SNO Fn 
SNO Fn 
(KP) SNO BSA 
SNO BSA 
(KP) 
WHCO1 Fn 0.000179         0.000179 1 0.873928 0.521567 0.000825 0.844196 0.978581 1 0.000182 
WHCO1 Fn 
(KP) 0.000179        0.000179 0.996605 0.999995 0.994261 0.019933 0.174869 1 0.999995 0.000362 
WHCO1 
BSA 0.000179        0.000179 0.212335 0.999991 1 0.674070 0.001765 0.998596 0.499940 0.036076 
WHCO1 
BSA (KP) 0.000198         0.000180 0.099980 0.998987 1 0.873928 0.000709 0.978581 0.286913 0.086123
WHCO3 Fn 0.715862        0.199276 0.000179 0.000893 0.004348 0.887463 0.000179 0.000382 0.000181 1 
WHCO3 Fn 
(KP) 0.999999         1 0.000179 0.000180 0.000185 0.033204 0.000179 0.000179 0.000179 0.652653 
WHCO3 
BSA 0.107550          0.521567 0.000179 0.000179 0.000179 0.000179 0.000179 0.000179 0.000179 0.000206
WHCO3 
BSA (KP) 0.000608          0.006269 0.000179 0.000179 0.000179 0.000179 0.000179 0.000179 0.000179 0.000179
WHCO5 Fn 0.003624      0.000404 0.001479 0.376545 0.755796 1 0.000181 0.186727 0.006269 0.887463 
WHCO5 Fn 
(KP) 0.999999         1 0.000179 0.000179 0.000179 0.001544 0.000179 0.000179 0.000179 0.096367 
WHCO5 
BSA         0.999995 0.000179 0.000179 0.000181 0.012852 0.000179 0.000179 0.000179 0.416036 
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WHCO5 
BSA (KP) 0.999995         0.000179 0.000179 0.000179 0.001147 0.000179 0.000179 0.000179 0.073994 
WHCO6 Fn 0.000179        0.000179 0.755796 0.376545 0.000497 0.932432 0.932432 1 0.000181 
WHCO6 Fn 
(KP) 0.000179        0.000179 0.755796 1 0.163602 0.021726 1 0.963358 0.003020 
WHCO6 
BSA 0.000181        0.000179 0.376545 1 0.457240 0.004348 0.999974 0.715862 0.015333 
WHCO6 
BSA (KP) 0.012852      0.001147 0.000497 0.163602 0.457240 0.000180 0.068507 0.001765 0.988414 
SNO Fn 0.000179        0.000179 0.932432 0.021726 0.004348 0.000180 0.058591 0.674070 0.000179 
SNO Fn 
(KP) 0.000179         0.000179 0.932432 1 0.999974 0.068507 0.058591 0.997437 0.001056 
SNO BSA 0.000179        0.000179 1 0.963358 0.715862 0.001765 0.674070 0.997437 0.000187 
SNO BSA 
(KP) 0.416036        0.073994 0.000181 0.003020 0.015333 0.988414 0.000179 0.001056 0.000187  
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3.2 Statistical Results of Collagen Cell Adhesion Assay 
 
Table 3: Analysis of Variance of the Number of Cells Attached to Collagen.  
Indicates significant difference (p ≤ 0.05). 
 
Effect df effect MS effect df error MS error F P 
Cell line 4 966730E4 100 405195E3 23.8584 0.000000 
Treatment 3 631596E5 100 405195E3 155.8744  0.000000
Cell line & 
Treatment 12 259739E4 100 405195E3 6.4102 0.000000 
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Table 4: Tukey HSD Test for Collagen Adhesion Assay Following Wortmannin Exposure. 
Marked effects are significant at p ≤ 0.05. 
 
 WHCO1 
Coll 
WHCO1 
Coll (W) 
WHCO1 
BSA 
WHCO1 
BSA (W) 
WHCO3 
Coll 
WHCO3 
Coll (W) 
WHCO3 
BSA 
WHCO3 
BSA (W) 
WHCO5 
Coll 
WHCO5 
Coll (W) 
WHCO1 
Coll         0.913879 0.003765 0.000169 0.99996 0.590239 0.000164 0.000164 0.157006 0.000166 
WHCO1 
Coll (W) 0.913879       0.600847 0.014932 0.999994 1 0.000164 0.000164 0.157006 0.000166 
WHCO1 
BSA 0.003765 0.600847       0.990895 0.098184 0.918936 0.000196 0.000164 0.9993 0.008787 
WHCO1 
BSA (W) 0.000169          0.014932 0.990895 0.000655 0.077916 0.01565 0.000164 0.999563 0.974425
WHCO3 
Coll 0.99996         0.999994 0.098184 0.000655 0.995312 0.000164 0.000165 0.393406 1
WHCO3 
Coll (W) 0.590239        1 0.918936 0.077916 0.995312 0.000164 0.000164 0.805288 0.000424 
WHCO3 
BSA 0.000164     0.000164 0.000196 0.01565 0.000164 0.000164  0.000164 1 0.049818 
WHCO3 
BSA (W) 0.000164          0.000164 0.000164 0.000165 0.000164 0.000164 0.558323 0.000164 0.02596
WHCO5 
Collagen 0.157006        0.9993 0.999563 0.393406 0.805288 1 0.000164 0.558323 0.000165
WHCO5 
Coll (W) 0.000166          0.008787 0.974425 1 0.000424 0.049818 0.02596 0.000164 0.000164
WHCO5 
BSA 0.000164        0.000534 0.558323 0.999979 0.00017 0.003237 0.239288 0.000165 0.294009 0.294009
WHCO5 
BSA (W) 0.000164       0.000164 0.002046 0.224997 0.000164 0.000165 0.999987 0.000196 0.03539 0.999999 
WHCO6 
Coll 0.003765 0.600847       1 0.990895 0.098184 0.918936 0.000196 0.074905 0.000174 0.310913 
WHCO6 
Coll (W) 0.000323 0.136589        0.999999 1 0.008787 0.42304 0.001131 0.000164 0.999563 0.974425
WHCO6 
BSA 0.000164          0.000164 0.000298 0.040294 0.000164 0.000164 1 0.000164 0.891587 0.999994
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WHCO6 
BSA (W) 0.000164        0.000164 0.000164 0.000179 0.000164 0.000164 0.974425 0.346338 0.000165 0.063831 
SNO Coll 1        0.998314 0.028393 0.000238 1 0.932912 0.000164 0.999999 0.000164 0.000196
SNO Coll 
(W) 0.9994      1 0.168059 0.001308 1 0.9994 0.000164 0.000164 0.50533 0.0002 
SNO BSA 0.000164     0.000164 0.000534 0.081027 0.000164 0.000164 1 0.000164 0.908615 0.00078 
SNO BSA 
(W) 0.000164          0.000164 0.000164 0.000166 0.000164 0.000164 0.77057 1 0.000164 0.000167
 
 
 WHCO5 BSA 
WHCO5 
BSA (W) 
WHCO6 
Coll 
WHCO6 
Coll (W) 
 
WHCO6 
BSA 
WHCO6 
BSA (W) SNO Coll 
SNO Coll 
(W) SNO BSA 
SNO BSA 
(W) 
WHCO1 
Coll 0.000164          0.000164 0.003765 0.000323 0.000164 0.000164 1 0.9994 0.000164 0.000164
WHCO1 
Coll (W) 0.000164          0.000164 0.003765 0.000323 0.000164 0.000164 0.998314 1 0.000164 0.000164
WHCO1 
BSA 0.000534         0.000164 0.600847 0.136589 0.000298 0.000164 0.028393 0.168059 0.000534 0.000164
WHCO1 
BSA (W) 0.558323 0.002046 1      0.999999 0.040294 0.000179 0.000238 0.001308 0.081027 0.000166 
WHCO3 
Coll 0.999979          0.224997 0.990895 1 0.000164 0.000164 1 1 0.000164 0.000164
WHCO3 
Coll (W) 0.00017         0.000164 0.098184 0.008787 0.000164 0.000164 0.932912 0.9994 0.000164 0.000164
WHCO3 
BSA 0.003237          0.000165 0.918936 0.42304 1 0.974425 0.000164 0.000164 1 0.77057
WHCO3 
BSA (W) 0.239288          0.999987 0.000196 0.001131 0.346338 0.999999 0.000164 0.000164 0.211306 1
WHCO5 
Collagen 0.000196 0.074905 0.000164        0.000164 0.000165 0.000164 0.50533 0.908615 0.000166 0.000164
WHCO5 
Coll (W) 0.03539        0.000174 0.999563 0.891587 0.063831 0.000196 0.0002 0.00078 0.122609 0.000167 
WHCO5 
BSA          0.310913 0.974425 0.999994 0.42304 0.001308 0.000165 0.000179 0.600847 0.000298 
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WHCO5 
BSA (W) 0.999999         0.558323 0.967325 1 0.463639 0.000164 0.000164 1 0.162465
WHCO6 
Coll 0.866006          0.866006 0.029683 0.000298 0.000164 0.028393 0.168059 0.000534 0.000164
WHCO6 
Coll (W) 0.558323 0.002046         0.002046 0.003237 0.000165 0.001946 0.018004 0.007584 0.000164
WHCO6 
BSA 0.967325 0.029683 0.999999        0.999999 0.891587 0.000164 0.000164 1 0.558323
WHCO6 
BSA (W) 0.42304          1 0.000298 0.003237 0.891587 0.000164 0.000164 0.761492 1
SNO  
Collagen 0.001308 0.463639 0.000164        0.000165 0.000164 0.000164 1 0.000164 0.000164
SNO  Coll 
(W) 0.000165          0.000164 0.028393 0.001946 0.000164 0.000164 1 0.000164 0.000164
SNO  BSA 0.000179        0.000164 0.168059 0.018004 1 0.761492 0.000164 0.000164 0.38376
SNO  BSA 
(W) 0.000298 0.162465 0.000164        0.000164 0.558323 1 0.000164 0.000164 0.38376
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3.3 Statistical Results of Fibronectin Cell Adhesion Assay 
 
Table 5: Analysis of Variance of the Number of Cells Attached to Fibronectin (Fn).  
Indicates significant difference (p ≤ 0.05). 
 
Effect df effect MS effect df error MS error F P 
Cell Line 4 179171E5 100 325847E3 54.9864 0.000000 
Treatment 3  838100E5 100 325847E3 257.2068 0.000000 
Cell line & 
Treatment 12 175173E4 100 325847E3 5.3759  0.000000
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Table 6: Tukey HSD Test for Fibronectin (Fn) Adhesion Assay Following Wortmannin Exposure. 
Marked effects are significant at p ≤ 0.05. 
 
 WHCO1 Fn 
WHCO1 
Fn (W) 
WHCO1 
BSA 
WHCO1 
BSA (W) 
WHCO3 
Fn 
WHCO3 
Fn (W) 
WHCO3 
BSA 
WHCO3 
BSA (W) WHCO5 Fn 
WHCO5 Fn 
(W) 
WHCO1 Fn  0.00024       0.000167 0.999999 0.951909 0.000164  0.000164 0.042791 0.000164
WHCO1 Fn 
(W) 1         0.001051 0.00021 1 0.999402 0.000164 0.000164 0.195346 0.162321
WHCO1 BSA 0.00024        0.001051 1 0.002403 0.064978 0.000164 0.000164 0.978289 0.98702
WHCO1 BSA 
(W) 0.000167          0.00021 1 0.000307 0.007396 0.000164 0.000164 0.683677 0.738503
WHCO3 Fn 0.999999          1 0.002403 0.000307 0.999972 0.000164 0.000164 0.321992 0.275281
WHCO3 Fn 
(W)          0.999402 0.064978 0.007396 0.999972 0.000164 0.000164 0.939362 0.913643
WHCO3 BSA 0.000164          0.000164 0.000164 0.000164 0.000164 0.000164 1 0.000164 0.000164
WHCO3 BSA 
(W) 0.000164          0.000164 0.000164 0.000164 0.000164 0.000164 1 0.000164 0.000164
WHCO5 Fn 0.042791 0.195346         0.978289 0.683677 0.321992 0.939362 0.000164 0.000164 1
WHCO5 Fn 
(W) 0.033625 0.162321         0.98702 0.738503 0.275281 0.913643 0.000164 0.000164 1
WHCO5 BSA 0.000164         0.000164 0.007396 0.064978 0.000164 0.000164 0.113719 0.018381 0.00017 0.000173
WHCO5 BSA 
(W) 0.000164         0.000164 0.000164 0.000164 0.000164 0.000164 0.997479 1 0.000164 0.000164
WHCO6 Fn 0.998619          1 0.014159 0.001303 1 1 0.000164 0.000164 0.683677 0.626029
WHCO6 Fn 
(W) 1          1 0.001234 0.000221 1 0.99965 0.000164 0.000164 0.217359 0.181593
WHCO6 BSA 0.000164          0.000164 0.808135 0.994292 0.000164 0.000179 0.000229 0.000168 0.026257 0.033625
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WHCO6 BSA 
(W) 0.000164        0.000164 0.004008 0.038888 0.000164 0.000164 0.17499 0.032019 0.000167 0.000168
SNO Fn 
0.042791 
0.195346         0.978289 0.683677 0.321992 0.939362 0.000164 0.000164 1 1
SNO Fn (W) 
0.000198 
0.000607 1        1 0.001303 0.038888 0.000164 0.000164 0.943774 0.962471
SNO BSA 
0.000164 
0.000164         0.000164 0.000164 0.000164 0.000164 0.99929 1 0.000164 0.000164
SNO BSA (W) 0.000164          0.000164 0.000164 0.000164 0.000164 0.000164 0.779466 0.98702 0.000164 0.000164
 
 
 WHCO5 BSA 
WHCO5 
BSA (W) 
WHCO6 
Fn 
WHCO6 
Fn (W) 
WHCO6 
BSA 
WHCO6 
BSA (W) SNO Fn 
SNO 
Fn (W) SNO BSA 
SNO 
BSA (W) 
WHCO1 Fn 0.000164          0.000164 0.998619 1 0.000164 0.000164 0.042791 0.000198 0.000164 0.000164
WHCO1 Fn 
(W) 0.000164         0.000164 1 1 0.000164 0.000164 0.195346 0.000607 0.000164 0.000164
WHCO1 
BSA 0.007396          0.000164 0.014159 0.001234 0.808135 0.004008 0.978289 1 0.000164 0.000164
WHCO1 
BSA (W) 0.064978          0.000164 0.001303 0.000221 0.994292 0.038888 0.683677 1 0.000164 0.000164
WHCO3 Fn 0.000164         0.000164 1 1 0.000164 0.000164 0.321992 0.001303 0.000164 0.000164
WHCO3 Fn 
(W) 0.000164         0.000164 1 0.99965 0.000179 0.000164 0.939362 0.038888 0.000164 0.000164
WHCO3 
BSA 0.113719         0.997479 0.000164 0.000164 0.000164 0.000164 0.321992 0.001303 0.000164 0.000164
WHCO3 
BSA (W) 0.018381 1 0.000164       0.000164 0.000179 0.000164 0.939362 0.038888 0.000164 0.000164
WHCO5 Fn 0.00017        0.000164 0.683677 0.217359 0.000229 0.17499 0.000164 0.000164 0.99929 0.779466
WHCO5 Fn 
(W) 0.000173          0.000164 0.626029 0.181593 0.000168 0.032019 0.000164 0.000164 1 0.98702
WHCO5 
BSA  0.001303         0.000164 0.000164 0.026257 0.000167 1 0.943774 0.000164 0.000164
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WHCO5 
BSA (W) 0.001303  0.000164        0.000164 0.033625 0.000168 1 0.962471 0.000164 0.000164
WHCO6 Fn 0.000164          0.000164 1 0.867013 1 0.00017 0.013433 0.00203 0.000196
WHCO6 Fn 
(W) 0.000164          0.000164 1 0.000164 0.002403 0.000164 0.000164 1 0.999999
WHCO6 
BSA 0.867013 0.000164        0.000166 0.000164 0.000164 0.683677 0.007816 0.000164 0.000164
WHCO6 
BSA (W) 1 0.002403        0.000164 0.000164 0.000166 0.217359 0.000699 0.000164 0.000164
SNO Fn 0.00017       0.000164 0.683677 0.217359 0.000164 0.000164  0.895194 0.000164 0.000164
SNO Fn (W) 0.013433          0.000164 0.007816 0.000699 0.769505 0.769505 0.026257 0.003785 0.000234
SNO BSA 0.00203 1 0.000164      0.000164 0.026257 0.000167 0.000167 0.007396 0.000164
SNO BSA 
(W) 0.000196 0.999999 0.000164      0.000164 0.895194 0.007396 0.943774 0.943774 0.000164
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3.4 Number of Cells Attaching to Fibronectin and Collagen 
 
Table 7: Cell Counts of Untreated and Wortmannin-Treated Cells Attaching to Fibronectin (Fn) and BSA. 
 
 fibronectin 
fibronectin 
(W) 
fibronectin 
fibronectin 
(W) 
BSA    BSA (W) BSA BSA (W)
 205000       205000 199000 193000 169000 145000 142000 108000 
WHCO1 217000       220000 193000 196000 175000 103000 154000 205000 
 211000       202000 211000 184000 121000 121000 139000 175000 
 178000       181000 211000 190000 61000 46000 80000 109000 
WHCO3 190000       190000 208000 196000 67000 52000 73000 70000 
 187000       181000 211000 184000 75000 34000 70000 76000 
 160000       170000 184000 166000 106000 82000 90000 64000 
WHCO5 178000       160000 172000 169000 100000 28000 130000 70000 
 163000       184000 148000 151000 103000 61000 106000 34000 
 199000       217000 190000 202000 127000 118000 135000 118000 
WHCO6 175000       202000 148000 187000 133000 163000 124000 94000 
 205000       184000 199000 205000 106000 88000 139000 43000 
 175000       155000 172000 163000 63000 49000 60000 55000 
SNO 169000       157000 163000 142000 55000 37000 66000 45000 
 166000       148000 160000 124000 46000 58000 57000 43000 
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Table 8: Cell Counts of Untreated and Wortmannin-Treated Cells Attaching to Collagen and BSA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Collagen 
collagen 
(W) 
collagen 
collagen 
(W) 
BSA    BSA (W) BSA BSA (W)
 205000        166000 199000 190000 145000 139000 142000 145000
WHCO1 187000        181000 172000 157000 151000 142000 154000 103000
 208000        178000 202000 165000 133000 106000 139000 121000
 175000        166000 199000 166000 76000 46000 83000 50000
WHCO3 163000        169000 187000 175000 79000 55000 76000 53000
 187000        160000 190000 163000 82000 49000 80000 46000
 151000        124000 187000 133000 85000 52000 169000 120000
WHCO5 169000        112000 151000 128000 67000 74000 175000 130000
 155000        130000 136000 118000 70000 61000 121000 106000
 133000        135000 142000 127000 82000 97000 86000 60000
WHCO6 154000        145000 139000 130000 58000 40000 95000 50000
 151000        139000 145000 133000 103000 58000 73000 52000
 199000        208000 196000 172000 91000 88000 127000 55000
SNO 184000        202000 181000 139000 43000 22000 82000 67000
         214000 196000 157000 169000 61000 28000 110000 60000
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Table 9: Cell Counts of Untreated and KP-392-Treated Cells Attaching to Fibronectin and BSA. 
 
 
 
 Fibronectin 
fibronectin 
(KP-392) 
fibronectin 
fibronectin 
(KP-392) 
BSA 
BSA (KP-
392) 
BSA 
BSA (KP-
392) 
 217000        199000 210000 204000 174000 178000 180000 185000
WHCO1 208000        199000 214000 197000 188000 187000 183000 176000
 208000        199000 210000 193000 180000 166000 180000 179000
 148000        136000 132000 120000 98000 46000 77000 60000
WHCO3 136000        97000 137000 125000 56000 61000 73000 63000
 122000        112000 136000 101000 72000 58000 75000 49000
 154000        85000 160000 107000 98000 99000 105000 110000
WHCO5 168000        110500 157000 102000 124000 102000 100000 99000
 160000        115000 164000 100000 112000 106000 109000 106000
 222000        210000 217000 188000 190000 145000 180000 195000
WHCO6 214000        174000 210000 195000 172000 163000 193000 177000
 204000        186000 212000 187000 190000 160000 178000 182000
 238000        208000 233000 200000 217000 121000 213000 211000
SNO 238000        190000 225000 190000 214000 163000 205000 210000
         222000 184000 231000 192000 193000 136000 207000 206000
